BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Phase 3 readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 3 and phase 2/3 readouts across every tracked d
 rug\, the next 18 months\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06389136-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic
  Dermatitis and Inadequate Response to Dupilumab\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 upadacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06389136
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662383-118@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:retatrutide: Phase 3 readout est. (NCT06662383)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesit
 y\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06662383
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202509-401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT05202509)
DESCRIPTION:Obicetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapi
 b in Patients With Cardiovascular Disease\nEstimated primary completion: N
 ovember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obicetr
 apib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05202509
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389136-1356@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: A S
 tudy of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic 
 Dermatitis and Inadequate Response to Dupilumab\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 upilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06389136
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448312-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06448312)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Pembro
 lizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lun
 g Cancer\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06448312
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118333-2044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06118333)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy 
 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NP
 C01)\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06118333
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118333-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06118333)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: A Study Comparing BL-B0
 1D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or 
 Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06118333
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118333-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06118333)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study Comparing BL-B01D1 With
  Physician's Choice of Chemotherapy in Patients With Recurrent or Metastat
 ic Nasopharyngeal Carcinoma(PANKU-NPC01)\nEstimated primary completion: No
 vember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecita
 bine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06118333
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05134441-9637@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:vidofludimus calcium: Phase 3 readout est. (NCT05134441)
DESCRIPTION:vidofludimus calcium\, phase 3\, Multiple Sclerosis.\nStudy: St
 udy to Evaluate the Efficacy\, Safety\, and Tolerability of IMU-838 in Pat
 ients With Relapsing Multiple Sclerosis\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vidofludi
 mus-calcium#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05134441
URL:https://assetmemo.bio/drug/vidofludimus-calcium#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201638-9637@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:vidofludimus calcium: Phase 3 readout est. (NCT05201638)
DESCRIPTION:vidofludimus calcium\, phase 3\, Multiple Sclerosis.\nStudy: St
 udy to Evaluate the Efficacy\, Safety and Tolerability of IMU-838 in Patie
 nts With Relapsing Multiple Sclerosis\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vidofludimu
 s-calcium#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05201638
URL:https://assetmemo.bio/drug/vidofludimus-calcium#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914895-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06914895)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabet
 es and Obesity or Overweight\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 14895
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962280-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06962280)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Long-Term
  Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesi
 ty or Overweight\nEstimated primary completion: November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06962280
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704620-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06704620)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Re
 ceptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small
  Cell Lung Cancer\nEstimated primary completion: November 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06704620
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704620-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06704620)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Tislelizumab and Platinum-based Chemotherapy Combination Wit
 h H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic No
 n-Small Cell Lung Cancer\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06704620
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428488-96@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT05428488)
DESCRIPTION:Orencia (Abatacept)\, phase 3\, Rheumatoid Arthritis.\nStudy: E
 fficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428488
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05532813-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05532813)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Evaluation of the Eff
 icacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's
  Disease)\nEstimated primary completion: November 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05532813
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05206955-518@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Adcirca (Tadalafil): Phase 3 readout est. (NCT05206955)
DESCRIPTION:Adcirca (Tadalafil)\, phase 3.\nStudy: Study of Tadalafil vs. P
 lacebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Phys
 iology\nEstimated primary completion: November 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05206955
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07237568-1413@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zemprocitinib: Phase 3 readout est. (NCT07237568)
DESCRIPTION:Zemprocitinib\, phase 3.\nStudy: A Study to Evaluate Efficacy a
 nd Safety of LNK01001 in Adults With Ankylosing Spondylitis\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zemprocitinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07237568
URL:https://assetmemo.bio/drug/zemprocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341335-1994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06341335)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Study of AK104/Placebo Plus AK
 109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenoca
 rcinoma\nEstimated primary completion: November 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06341335
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239311-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 3 readout est. (NCT06239311)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Efficacy and Safety of Methotre
 xate Versus Placebo in Adults With Atopic Dermatitis.\nEstimated primary c
 ompletion: November 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06239311
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04221035-8999@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Temozolomide: Phase 3 readout est. (NCT04221035)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: High-Risk Neuroblastoma Study 2
  of SIOP-Europa-Neuroblastoma (SIOPEN)\nEstimated primary completion: Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4221035
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229651-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:Glucophage (metformin): Phase 2/3 readout est. (NCT07229651)
DESCRIPTION:Glucophage (metformin)\, phase 2/3.\nStudy: Metformin in Parkin
 son Disease\nEstimated primary completion: 20 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07229651
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04634877-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04634877)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Study of 
 Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or 
 Without Radiotherapy in Participants With Newly Diagnosed Endometrial Canc
 er After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-e
 n11 / GOG-3053)\nEstimated primary completion: 20 November 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04634877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06231758-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT06231758)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Metformin Safety and 
 Efficacy in Osteoarthritis.\nEstimated primary completion: 20 November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06231758
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03815643-2017@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Avelumab: Phase 3 readout est. (NCT03815643)
DESCRIPTION:Avelumab\, phase 3.\nStudy: Avelumab Program Rollover Study\nEs
 timated primary completion: 24 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03815643
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585787-712@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 585787)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate KarXT as a Treatment for Psychosis As
 sociated With Alzheimer's Disease (ADEPT-4)\nEstimated primary completion:
  24 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/xa
 nomeline-trospium-chloride#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06585787
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216079-1477@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07216079)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Rilz
 abrutinib for the Adult Participants With Chronic ITP Who Have Completed P
 hase 3 Study in Japan\nEstimated primary completion: 25 November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07216079
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775860-1392@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Soficitinib (ICP-332): Phase 3 readout est. (NCT06775860)
DESCRIPTION:Soficitinib (ICP-332)\, phase 3\, Atopic Dermatitis.\nStudy: IC
 P-332 in Subjects With Moderate to Severe Atopic Dermatitis\nEstimated pri
 mary completion: 25 November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/soficitinib-icp-332#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06775860
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Niraparib: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Niraparib\, phase 3.\nStudy: A Study to Evaluate Dostarlimab Pl
 us Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Pa
 rticipants With Recurrent or Primary Advanced Endometrial Cancer\nEstimate
 d primary completion: 26 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2162@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: A Study to 
 Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carbo
 platin-paclitaxel in Participants With Recurrent or Primary Advanced Endom
 etrial Cancer\nEstimated primary completion: 26 November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122401-897@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:MT1013: Phase 3 readout est. (NCT07122401)
DESCRIPTION:MT1013\, phase 3\, Chronic Kidney Disease.\nStudy: Study of MT1
 013 for the Treatment of Patients With Secondary Hyperparathyroidism\nEsti
 mated primary completion: 26 November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mt1013#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07122401
URL:https://assetmemo.bio/drug/mt1013#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06641466-10363@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06641466)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Women When Used for 
 Intermittent Prevention of Menstrual Migraine\nEstimated primary completio
 n: 29 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06641466
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06111443-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT06111
 443)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3.\nStudy: Effect o
 f Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Un
 dergoing Catheter Ablation of Atrial Fibrillation\nEstimated primary compl
 etion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06111443
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06030843-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Jardiance (Empagliflozin): Phase 2/3 readout est. (NCT06030843)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2/3.\nStudy: The Treatment Ef
 fects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1\nE
 stimated primary completion: 30 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06030843
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03148418-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03148418)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Participants Previou
 sly Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Ate
 zolizumab Study (IMbrella A)\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03148418
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429463-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT05429463)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectabl
 e Squamous Cell NSCLC（neoSCORE Ⅱ）\nEstimated primary completion: 30 
 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05429463
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429463-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05429463)
DESCRIPTION:Sintilimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Sq
 uamous Cell NSCLC（neoSCORE Ⅱ）\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 29463
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03020030-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03020030)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and 
 Adolescents\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03020030
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03020030-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03020030)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Treatment of Newly Diagnosed A
 cute Lymphoblastic Leukemia in Children and Adolescents\nEstimated primary
  completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03020030
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226169-590@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 3 readout est
 . (NCT05226169)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 3.\nStud
 y: Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced 
 Gastric Cancer(EFFECT-AGC)\nEstimated primary completion: 30 November 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ferric-carboxymalto
 se#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5226169
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892654-960@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT04892654)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: Efficacy of Dora
 virine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therap
 y Switch\nEstimated primary completion: 30 November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/doravirine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04892654
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892654-1031@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT04892654)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Efficacy of Doravirine + Dolutegravir Dual Therap
 y in the Context of Antiretroviral Therapy Switch\nEstimated primary compl
 etion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dolutegravir#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04892654
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672561-1865@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:WD-890: Phase 3 readout est. (NCT07672561)
DESCRIPTION:WD-890\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomize
 d\, Double-Blind\, Placebo-Controlled Phase Ⅲ Study to Evaluate the Effi
 cacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe 
 Plaque Psoriasis\nEstimated primary completion: 30 November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/wd-890#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07672561
URL:https://assetmemo.bio/drug/wd-890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06156514-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06156514)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Evaluation of Concomitant Chemo-
 radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouter
 ine Cancer\nEstimated primary completion: 30 November 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06156514
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954961-9088@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taragarestrant: Phase 3 readout est. (NCT06954961)
DESCRIPTION:Taragarestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Adva
 nced or Metastatic Breast Cancer\nEstimated primary completion: 30 Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/taragarestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 954961
URL:https://assetmemo.bio/drug/taragarestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721871-1030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mytesi (Crofelemer): Phase 2/3 readout est. (NCT06721871)
DESCRIPTION:Mytesi (Crofelemer)\, phase 2/3.\nStudy: Ascending Doses of Cro
 felemer Powder for Oral Solution in Pediatric Microvillus Inclusion Diseas
 e (MVID)\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/crofelemer#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06721871
URL:https://assetmemo.bio/drug/crofelemer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208347-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT04208347)
DESCRIPTION:Camrelizumab\, phase 2/3\, Gastric Cancer.\nStudy: Perioperativ
 e Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagoga
 stric Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04208347
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208347-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT04208347)
DESCRIPTION:Apatinib\, phase 2/3.\nStudy: Perioperative Treatment of Combin
 ed SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04208347
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-2266@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Selinexor\, phase 2/3.\nStudy: A Study of Rituximab-Gemcitabine
 -Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With
  Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04442022
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) 
 With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Lar
 ge B-cell Lymphoma\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04442022
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04704921-5173@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Surabgene lomparvovec: Phase 2/3 readout est. (NCT04704921)
DESCRIPTION:Surabgene lomparvovec\, phase 2/3\, Age-Related Macular Degener
 ation.\nStudy: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gen
 e Therapy Administered Via Subretinal Delivery One Time in Participants Wi
 th nAMD\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04704921
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: A Study of Rituximab-Gemcita
 bine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients 
 With Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04442022
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132893-8940@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Opakalim: Phase 2/3 readout est. (NCT06132893)
DESCRIPTION:Opakalim\, phase 2/3\, Epilepsy.\nStudy: A Study to Determine i
 f BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epi
 lepsy\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/opakalim#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06132893
URL:https://assetmemo.bio/drug/opakalim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05427084-307@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Invokana (Canagliflozin): Phase 2/3 readout est. (NCT05427084)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2/3\, Type 2 Diabetes.\nStudy:
  Canagliflozin Targeting Vascular Inflammation\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 nagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05427084
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05065216-903@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvecalinase alfa: Phase 2/3 readout est. (NCT05065216)
DESCRIPTION:Rinvecalinase alfa\, phase 2/3\, Acute Ischemic Stroke.\nStudy:
  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rinvecalinase-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05065216
URL:https://assetmemo.bio/drug/rinvecalinase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05778188-1538@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pegtarazimod: Phase 2/3 readout est. (NCT05778188)
DESCRIPTION:Pegtarazimod\, phase 2/3.\nStudy: A Study to Evaluate the Safet
 y\, Tolerability\, Pharmacokinetics\, and Efficacy of RLS-0071 in Newborns
  With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therap
 eutic Hypothermia\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pegtarazimod#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05778188
URL:https://assetmemo.bio/drug/pegtarazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221748-1994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Cadonilimab\, phase 2/3.\nStudy: DV Combined With Cadonilimab i
 n Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Juncti
 on Adenocarcinoma After Progression on First-line Therapy\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221748-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, Gastric Cancer.\nStudy: DV Comb
 ined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and 
 Gastroesophageal Junction Adenocarcinoma After Progression on First-line T
 herapy\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03258320-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT03258320)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Prostate Cancer.\nStudy: A R
 andomised Trial of Cabazitaxel\, Docetaxel\, Mitoxantrone or Satraplatin (
 CDMS) Plus Surgery for Prostate Cancer Patients\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ocetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03258320
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06468228-103@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:lutikizumab: Phase 3 readout est. (NCT06468228)
DESCRIPTION:lutikizumab\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole
 scent Participants With Moderate to Severe Hidradenitis Suppurativa\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06468228
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994650-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ribupatide: Phase 3 readout est. (NCT06994650)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Multicenter\, Randomi
 zed\, Double-blind\, Placebo-controlled Phase III Clinical Study to Evalua
 te the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructi
 ve Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Venti
 lation (PAP) Therapy\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06994650
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05397639-701@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Masupirdine: Phase 3 readout est. (NCT05397639)
DESCRIPTION:Masupirdine\, phase 3\, Alzheimer's Disease.\nStudy: Masupirdin
 e for the Treatment of Agitation in Dementia of the Alzheimer's Type\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/masupirdine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05397639
URL:https://assetmemo.bio/drug/masupirdine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05500222-1161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT05500222)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pati
 ents With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05500222
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688772-1489@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07688772)
DESCRIPTION:SHR-1819\, phase 3.\nStudy: A Clinical Study Evaluating the Eff
 icacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic 
 Rhinitis\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/shr-1819#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07688772
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04116047-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04116047)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: CompARE: Escalating Treatment of 
 Intermediate and High-risk Oropharyngeal Cancer (OPC)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04116047
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-1965@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: Identification and Treatment Of Mi
 crometastatic Disease in Stage III Colon Cancer\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03803553
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in 
 Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative 
 Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell L
 ung Cancer\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Identification and Treatment Of Mi
 crometastatic Disease in Stage III Colon Cancer\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03803553
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Chemot
 herapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1
  Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04639986-1992@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04639986)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2
 - Metastatic Breast Cancer (MBC)\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04639986
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04344158-1993@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Penpulimab: Phase 3 readout est. (NCT04344158)
DESCRIPTION:Penpulimab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Phas
 e III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochlor
 ide Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Car
 cinoma (HCC)\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/penpulimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04344158
URL:https://assetmemo.bio/drug/penpulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-1996@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Binimetinib: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Binimetinib\, phase 3.\nStudy: Identification and Treatment Of 
 Micrometastatic Disease in Stage III Colon Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /binimetinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03803553
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-2044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06382129)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unrese
 ctable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung C
 ancer(PANKU-Lung02)\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500026-2044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06500026)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study Comparing BL
 -B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PA
 NKU-Lung03)\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06500026
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671379-2181@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT06671379)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-muta
 ted\, Advanced or Metastatic NSCLC\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06671379
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-2219@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Encorafenib: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Encorafenib\, phase 3.\nStudy: Identification and Treatment Of 
 Micrometastatic Disease in Stage III Colon Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /encorafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03803553
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: Identification and Treatment Of M
 icrometastatic Disease in Stage III Colon Cancer\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03803553
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-8457@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05780567)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Clinica
 l Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Com
 pared With Placebo Combined With Endocrine Therapy in Patients With Breast
  Cancer\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-8888@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Clinical Study on Adjuvant Thera
 py of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combin
 ed With Endocrine Therapy in Patients With Breast Cancer\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/anastrozole#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010471-8983@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relutrigine: Phase 3 readout est. (NCT07010471)
DESCRIPTION:Relutrigine\, phase 3\, Epilepsy.\nStudy: A Clinical Trial for 
 Participants With DEE to Assess Efficacy\, Safety\, Tolerability\, and PK 
 of Relutrigine\nEstimated primary completion: December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/relutrigine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07010471
URL:https://assetmemo.bio/drug/relutrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06382129)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresecta
 ble Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Canc
 er(PANKU-Lung02)\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03820830-9034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT03820830)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Palbociclib for HR Positive / HER2-negative Isolated Locore
 gional Recurrence of Breast Cancer\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT038208
 30
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Clinical Study on Adjuvant Therapy
  of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined
  With Endocrine Therapy in Patients With Breast Cancer\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05780567
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05948475-9067@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tinengotinib: Phase 3 readout est. (NCT05948475)
DESCRIPTION:Tinengotinib\, phase 3\, Cholangiocarcinoma.\nStudy: Study of T
 inengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-alter
 ed in Cholangiocarcinoma\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tinengotinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05948475
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-9077@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Culmerciclib: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Culmerciclib\, phase 3.\nStudy: Clinical Study on Adjuvant Ther
 apy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combi
 ned With Endocrine Therapy in Patients With Breast Cancer\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477576-9190@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 3 readout est. (NCT05477576)
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 3.\nStudy: Study of RYZ1
 01 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET
  That Has Progressed Following 177Lu-SSA Therapy\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 actinium-225ac-oxodotreotide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05477576
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128550-9829@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tobevibart (VIR-3434): Phase 3 readout est. (NCT07128550)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 3\, Chronic Hepatitis Delta.\nStu
 dy: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic 
 HDV Infection Not Virologically Suppressed With Bulevirtide\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tobevibart-vir-3434#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07128550
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05392114-10797@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT05392114)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in
  the Prophylactic Treatment of Hereditary Angioedema (HAE)\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05392114
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02736656-10826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT02736656)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: Open-label Study to Evaluate Long-term Safety and Effi
 cacy of SPN-812 (Viloxazine Extended-release Capsule)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/viloxazine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02736656
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03683186-524@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ralinepag: Phase 3 readout est. (NCT03683186)
DESCRIPTION:Ralinepag\, phase 3\, Pulmonary Arterial Hypertension.\nStudy: 
 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subje
 cts With PAH Via an Open-Label Extension\nEstimated primary completion: De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ralinepa
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 683186
URL:https://assetmemo.bio/drug/ralinepag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173478-1444@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07173478)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam
  to the Vehicle in Adult Patients With Atopic Dermatitis\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/difamilast#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07173478
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928272-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06928272)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3.\nStudy: Long Covid (LC)-REVITA
 LIZE - A Long Covid Repurposed Drug Study\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadaci
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06928272
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04227314-95@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04227314)
DESCRIPTION:Otezla (apremilast)\, phase 3.\nStudy: Randomized Double Blind 
 Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Pl
 acebo in Severe Forms of Recurrent Aphthous Stomatitis\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apremilast#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04227314
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059377-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07059377)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Sema
 glutide for Smoking Cessation in Patients With Diabetes\nEstimated primary
  completion: December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07059377
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974851-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ribupatide: Phase 3 readout est. (NCT06974851)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Phase III Study Evalu
 ating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstru
 ctive Sleep Apnea (OSA) and Obesity\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069748
 51
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Glucophage (metformin)\, phase 3\, Type 2 Diabetes.\nStudy: Eff
 icacy and Safety of Add-On Therapy With Empagliflozin in Patients With Typ
 e 2 Diabetes on a Background of Alogliptin and Metformin\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07093476
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-299@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nesina (Alogliptin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Nesina (Alogliptin)\, phase 3\, Type 2 Diabetes.\nStudy: Effica
 cy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2
  Diabetes on a Background of Alogliptin and Metformin\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/alogliptin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07093476
URL:https://assetmemo.bio/drug/alogliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: 
 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With 
 Type 2 Diabetes on a Background of Alogliptin and Metformin\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07093476
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06274801-535@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Seralutinib: Phase 3 readout est. (NCT06274801)
DESCRIPTION:Seralutinib\, phase 3\, Pulmonary Arterial Hypertension.\nStudy
 : Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PR
 OSERA-EXT)\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/seralutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06274801
URL:https://assetmemo.bio/drug/seralutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413433-866@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT06413433)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3.\nStudy: Elucidating TAAR-1\, D
 opamine\, and Norepinephrine in Binge Eating Disorder Using Solriamfetol\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/solriamfetol#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06413433
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568367-866@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT06568367)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3.\nStudy: Studying Solriamfetol 
 Modulation of TAAR-1\, Dopamine\, and Norepinephrine in Shift Work Disorde
 r (SUSTAIN)\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/solriamfetol#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06568367
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06482554-872@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06482554)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Lumat
 eperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lumateperone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06482554
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747507-1031@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT06747507)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Ndovu RCT: Investing the Optimal Management of Do
 lutegravir Resistance\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06747507
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678931-1335@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:stapokibart: Phase 3 readout est. (NCT07678931)
DESCRIPTION:stapokibart\, phase 3.\nStudy: Study on the Treatment of Adoles
 cent Patients With Seasonal Allergic Rhinitis\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sta
 pokibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07678931
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04585490)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive ctDNA-Based Personalization of Treatment During Consolidation Therapy
  in NSCLC\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04853342-1983@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT04853342)
DESCRIPTION:Furmonertinib\, phase 3.\nStudy: To Assess the Efficacy and Saf
 ety of Furmonertinib Versus Placebo\, in Patients With Epidermal Growth Fa
 ctor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinom
 a\, Following Complete Tumour Resection With or Without Adjuvant Chemother
 apy\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04853342
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05918094-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05918094)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Comparing Modified XELOX Plus Sin
 tilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HE
 R2-negative Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05918094
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05281471-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05281471)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Efficacy & Safe
 ty of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's 
 Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ov
 arian Cancer (PRROC) (OnPrime\, GOG-3076)\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05281471
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05654454-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05654454)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 afety and Efficacy Study of Bevacizumab\, Paclitaxel\, Carboplatin Compare
 d to Avastin® in Non-Small Cell Lung Cancer\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05654454
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177301-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06177301)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06177301
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-2015@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT04585490)
DESCRIPTION:Tremelimumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 aptive ctDNA-Based Personalization of Treatment During Consolidation Thera
 py in NSCLC\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05340491-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05340491)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Chemo
 radiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter\, Open-label\, 
 Randomised\, Controlled\, Phase III Trial\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05340491
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767527-2023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767527)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: AK112 or Placebo Plus Nab-Paclit
 axel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Tr
 iple-negative Breast Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06767527
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-2052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Niraparib: Phase 3 readout est. (NCT03903835)
DESCRIPTION:Niraparib\, phase 3.\nStudy: ProBio: A Biomarker Driven Study i
 n Patients With Metastatic Prostate Cancer\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nirapa
 rib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03903835
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04585490)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Adaptive ctDNA-Based Personalization of Treatment During Consolidatio
 n Therapy in NSCLC\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754644-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06754644)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate Efficacy\, and Safety of QL2107 Plus Chemo and Co
 mpare With Keytruda in Participants With IV nqNSCLC\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06754644
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05281471-2654@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olvimulogene nanivacirepvec: Phase 3 readout est. (NCT05281471)
DESCRIPTION:Olvimulogene nanivacirepvec\, phase 3\, Ovarian Cancer.\nStudy:
  Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared
  to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resista
 nt/Refractory Ovarian Cancer (PRROC) (OnPrime\, GOG-3076)\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olvimulogene-nanivacirepvec#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05281471
URL:https://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03593759-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03593759)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Cardiac Sarcoidosis Randomized 
 Trial\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03593759
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928272-6205@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pirfenidone (Esbriet): Phase 3 readout est. (NCT06928272)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 3.\nStudy: Long Covid (LC)-REVITA
 LIZE - A Long Covid Repurposed Drug Study\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirfeni
 done-esbriet#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06928272
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-7646@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capivasertib: Phase 3 readout est. (NCT03903835)
DESCRIPTION:Capivasertib\, phase 3\, Prostate Cancer.\nStudy: ProBio: A Bio
 marker Driven Study in Patients With Metastatic Prostate Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/capivasertib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019922-8868@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elsunersen: Phase 3 readout est. (NCT07019922)
DESCRIPTION:Elsunersen\, phase 3\, Epilepsy.\nStudy: A Clinical Trial of El
 sunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/elsunersen#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07019922
URL:https://assetmemo.bio/drug/elsunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03903835)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: ProBio: A Biomarker Driven Study in Patients Wi
 th Metastatic Prostate Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04290793-2207@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pyrotinib: Phase 2/3 readout est. (NCT04290793)
DESCRIPTION:Pyrotinib\, phase 2/3.\nStudy: Neoadjuvant Chemotherapy With Py
 rotinib\, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzu
 mab for HER-2+ Breast Cancer\nEstimated primary completion: 1 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04290793
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04290793-9113@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Epirubicin: Phase 2/3 readout est. (NCT04290793)
DESCRIPTION:Epirubicin\, phase 2/3\, Breast Cancer.\nStudy: Neoadjuvant Che
 motherapy With Pyrotinib\, Epirubicin and Cyclophosphamide Followed by Tax
 anes and Trastuzumab for HER-2+ Breast Cancer\nEstimated primary completio
 n: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pirubicin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04290793
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974084-967@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2/3 readout est. (NCT06974
 084)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2/3.\nStudy: A Multi-
 Center\, Individually-Randomized\, Double-Blind\, Placebo-Controlled\, Par
 allel-Group\, Superiority Trial to Evaluate the Efficacy of the Combinatio
 n of Maraviroc and Atorvastatin for the Treatment of Subjects With Long CO
 VID\nEstimated primary completion: 1 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/maraviroc#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06974084
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312982-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT06312982)
DESCRIPTION:Tislelizumab\, phase 2/3.\nStudy: A Series of Neoadjuvant Chemo
 radiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cance
 r\nEstimated primary completion: 1 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06312982
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05860465-9055@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SPH4336: Phase 2/3 readout est. (NCT05860465)
DESCRIPTION:SPH4336\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in
  the Treatment of Locally Advanced or Metastatic Breast Cancer\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sph4336#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05860465
URL:https://assetmemo.bio/drug/sph4336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06685757-3402@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06685757)
DESCRIPTION:Felzartamab\, phase 3.\nStudy: A Study to Learn More About the 
 Effects and Safety of Felzartamab Infusions in Adults With Kidney Transpla
 nts Who Have Antibody-Mediated Rejection (AMR)\nEstimated primary completi
 on: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 felzartamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06685757
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139535-198@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139535)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ray1225#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07139535
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139548-198@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139548)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Partic
 ipants With Type 2 Diabetes\nEstimated primary completion: 1 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ray1225#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07139548
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446439-1508@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:tradipitant: Phase 3 readout est. (NCT07446439)
DESCRIPTION:tradipitant\, phase 3.\nStudy: A Study to Evaluate Tradipitant 
 on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tradipitant#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07446439
URL:https://assetmemo.bio/drug/tradipitant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998069-1965@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06998069)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Head and Neck Cancer Study Project in the Geriatric Population\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06998069
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998069-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06998069)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Head and Neck Cancer Study Project in the Geriatric Population\n
 Estimated primary completion: 1 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06998069
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712848-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07712848)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: DEC3-VEN
  vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07712848
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029711-5938@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07029711)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study to Learn About Medicine 
 Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alo
 pecia Areata\nEstimated primary completion: 2 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07029711
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336733-3446@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:Anakinra: Phase 3 readout est. (NCT06336733)
DESCRIPTION:Anakinra\, phase 3.\nStudy: Randomized Controlled Trial in Pati
 ents on Long-term Colchicine With Colchicine-resistant Familial Mediterran
 ean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment f
 or Painful Attacks in Patients Who Refuse Continuous Daily Therapy\nEstima
 ted primary completion: 4 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/anakinra#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06336733
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500506-11283@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:PF-07307405: Phase 3 readout est. (NCT07500506)
DESCRIPTION:PF-07307405\, phase 3\, Lyme Disease.\nStudy: A Study to Learn 
 About the Safety\, Tolerability\, and Immunogenicity of a Fifth Dose of 6-
 Valent OspA-Based Lyme Disease Vaccine\nEstimated primary completion: 4 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-07307
 405#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07500506
URL:https://assetmemo.bio/drug/pf-07307405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716176-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07716176)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomitin
 g Caused by Docetaxel Plus Cyclophosphamide\nEstimated primary completion:
  6 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dex
 amethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07716176
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716189-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07716189)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomitin
 g Caused by Trastuzumab Deruxtecan\nEstimated primary completion: 6 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethason
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 716189
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716228-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07716228)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Auricular Point Stimulation Pl
 us Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomitin
 g Caused by Gemcitabine Combined With Paclitaxel Protein-bound\nEstimated 
 primary completion: 6 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07716228
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06724809-886@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06724809)
DESCRIPTION:Soliris (Eculizumab)\, phase 3.\nStudy: Efficacy\, Safety\, PK\
 , PD\, and ADA of Eculizumab in Chinese Adults With NMOSD\nEstimated prima
 ry completion: 7 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/eculizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06724809
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757869-11184@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:Milvexian: Phase 3 readout est. (NCT05757869)
DESCRIPTION:Milvexian\, phase 3.\nStudy: A Study of Milvexian Versus Apixab
 an in Participants With Atrial Fibrillation\nEstimated primary completion:
  8 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mil
 vexian#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05757869
URL:https://assetmemo.bio/drug/milvexian#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126224-712@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 126224)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Assess Efficacy and Safety of KarXT for the Tr
 eatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)\nEstima
 ted primary completion: 9 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06126224
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151574-2274@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT06151574)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) 
 Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations 
 Compared With Standard Treatment\nEstimated primary completion: 10 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06151
 574
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-1958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT07376382)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimerti
 nib in Patients With Locally Advanced or Metastatic NSCLC\nEstimated prima
 ry completion: 12 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07376382
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-2211@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:CPO301: Phase 3 readout est. (NCT07376382)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients 
 With Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 1
 2 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo3
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7376382
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04957550-29@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:ivarmacitinib: Phase 3 readout est. (NCT04957550)
DESCRIPTION:ivarmacitinib\, phase 3.\nStudy: To Evaluate the Efficacy and S
 afety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis\nEstimat
 ed primary completion: 13 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04957550
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892339-1346@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:Eucrisa (crisaborole): Phase 3 readout est. (NCT07892339)
DESCRIPTION:Eucrisa (crisaborole)\, phase 3.\nStudy: Efficacy of Crisaborol
 e 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertri
 ginous and/or Anogenital Psoriasis.\nEstimated primary completion: 13 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/crisaborol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 892339
URL:https://assetmemo.bio/drug/crisaborole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430866-2085@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Abp 234: Phase 3 readout est. (NCT06430866)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pharmac
 okinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)\nEstima
 ted primary completion: 14 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abp-234#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06430866
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03595592-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03595592)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: Neoadjuvant Treatment of HER2 P
 ositive Early High-risk and Locally Advanced Breast Cancer\nEstimated prim
 ary completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03595592
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nivolumab: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Study of XL
 092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05678673
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03595592-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT03595592)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Neoadjuvant Treat
 ment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer\n
 Estimated primary completion: 15 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03595592
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-2819@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Study o
 f XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic N
 on-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5678673
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03817502-803@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT03817502)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Schizophrenia.\nStudy: Effica
 cy and Safety of Cariprazine in the Treatment of Adolescent Participants (
 13 to 17 Years of Age) With Schizophrenia\nEstimated primary completion: 1
 5 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cari
 prazine-vraylar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03817502
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05796401-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT05796401)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Efficiency of a Composite P
 ersonalised Care on Functional Outcome in Early Psychosis\nEstimated prima
 ry completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05796401
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06269900-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06269900)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone for Treating Sev
 ere Hospital-acquired Pneumonia in Critically Ill Patients With a Proinfla
 mmatory Phenotype\nEstimated primary completion: 15 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06269900
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375563-8999@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Temozolomide: Phase 3 readout est. (NCT07375563)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: Chemoimmunotherapy Combined Wit
 h Autologous NK Cell Therapy for Pediatric Patients With Refractory and Re
 lapsed High-Risk Neuroblastoma and Ganglioneuroblastoma\nEstimated primary
  completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/temozolomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07375563
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607627-11169@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Klygefa (Gefurulimab): Phase 3 readout est. (NCT06607627)
DESCRIPTION:Klygefa (Gefurulimab)\, phase 3\, Generalized Myasthenia Gravis
 .\nStudy: PK\, PD\, Safety\, and Efficacy Study of Gefurulimab in Pediatri
 c Patients With AChR+ Generalized Myasthenia Gravis\nEstimated primary com
 pletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gefurulimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06607627
URL:https://assetmemo.bio/drug/gefurulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747338-2506@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT06747338)
DESCRIPTION:Docetaxel (HB1801)\, phase 3\, HER2-Positive Breast Cancer.\nSt
 udy: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin 
 as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breas
 t Cancer\nEstimated primary completion: 16 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06747338
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730061-1262@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Iqirvo (Elafibranor): Phase 3 readout est. (NCT06730061)
DESCRIPTION:Iqirvo (Elafibranor)\, phase 3\, Primary Biliary Cholangitis.\n
 Study: A Study of Elafibranor in Adult Japanese Participants With Primary 
 Biliary Cholangitis (PBC)\nEstimated primary completion: 17 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elafibranor#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06730061
URL:https://assetmemo.bio/drug/elafibranor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363720-11363@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Orzeyful (Oveporexton): Phase 3 readout est. (NCT07363720)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 3\, Narcolepsy.\nStudy: A Trial 
 of TAK-861 for the Treatment of Narcolepsy With Cataplexy\nEstimated prima
 ry completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/oveporexton#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363720
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853664-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07853664)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Topical Dexamethasone/Diclof
 enac Hydrogel for Postoperative Pain and Swelling in Facial Soft Tissue In
 juries\nEstimated primary completion: 20 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07853664
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921850-92@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06921850)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in C
 hildren and Adolescents With Moderate to Severe Hidradenitis Suppurativa\n
 Estimated primary completion: 21 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06921850
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856577-11228@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Ixoberogene soroparvovec: Phase 3 readout est. (NCT06856577)
DESCRIPTION:Ixoberogene soroparvovec\, phase 3\, Wet Age-Related Macular De
 generation.\nStudy: Efficacy and Safety Study of Ixoberogene Soroparvovec 
 (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneratio
 n\nEstimated primary completion: 22 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06856577
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539623-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07539623)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine-enhanced 
 MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery\nEstima
 ted primary completion: 22 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07539623
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692180-1322@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT05692180)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: A Multicentr
 e\, Randomised\, Double-blind\, Parallel Group\, Placebo-controlled\, Time
 -to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benra
 lizumab in Paediatric Patients With Severe Eosinophilic Asthma\nEstimated 
 primary completion: 23 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05692180
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008119-2273@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Vemurafenib: Phase 3 readout est. (NCT06008119)
DESCRIPTION:Vemurafenib\, phase 3.\nStudy: Efficacy and Safety of Tunlameti
 nib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorec
 tal Cancer\nEstimated primary completion: 24 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vemurafenib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06008119
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073768-305@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:Zafatek (Trelagliptin): Phase 3 readout est. (NCT07073768)
DESCRIPTION:Zafatek (Trelagliptin)\, phase 3\, Type 2 Diabetes.\nStudy: Com
 parison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabet
 ic Patients\nEstimated primary completion: 26 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trelagliptin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07073768
URL:https://assetmemo.bio/drug/trelagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\,
  Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and Dex
 amethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma
  (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\, 
 Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and Dexa
 methasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma 
 (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\
 , Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and De
 xamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myelom
 a (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Carfilzomib\, Lenalidomide\, a
 nd Dexamethasone Versus Bortezomib\, Lenalidomide and Dexamethasone (KRd v
 s. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)\nEstimat
 ed primary completion: 28 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925594-86@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:TH-SC01: Phase 3 readout est. (NCT06925594)
DESCRIPTION:TH-SC01\, phase 3\, Crohn's Disease.\nStudy: Phase 3 Study of H
 uman TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients Wit
 h Crohn's Disease\nEstimated primary completion: 28 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/th-sc01#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06925594
URL:https://assetmemo.bio/drug/th-sc01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633236-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT07633236)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Olanzapine in the Preve
 ntion and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Ne
 oadjuvant/Preoperative Chemotherapy\nEstimated primary completion: 28 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine
 -zyprexa#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07633236
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264010-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07264010)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Sorafe
 nib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML:
  a Prospective\, Single-arm\, Multicenter Clinical Study\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07264010
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355257-5453@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Telitacicept: Phase 2/3 readout est. (NCT07355257)
DESCRIPTION:Telitacicept\, phase 2/3.\nStudy: TELITACICEPT IN INFLAMMATORY 
 MYOPATHIES(TELITACICEPT-IM)\nEstimated primary completion: 30 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/telitacicept#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07355257
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062837-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT05062837)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: He
 patectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC\n
 Estimated primary completion: 30 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05062837
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062837-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT05062837)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Hepate
 ctomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05062837
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388680-6205@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pirfenidone (Esbriet): Phase 2/3 readout est. (NCT07388680)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2/3.\nStudy: Pirfenidone Capsules
  in the Treatment of Radiation-induced Lung Injury With or Without Immune 
 Pneumonia\nEstimated primary completion: 30 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07388680
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Combination With Sintilimab and X
 ELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal C
 ancer\nEstimated primary completion: 30 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Combination 
 With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Me
 tastatic Colorectal Cancer\nEstimated primary completion: 30 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04658862-2285@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT04658862)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in P
 articipants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04658862
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799247-3307@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Descartes-08: Phase 3 readout est. (NCT06799247)
DESCRIPTION:Descartes-08\, phase 3\, Myasthenia Gravis.\nStudy: Investigati
 ng an mRNA CAR T-cell Therapy\, Known as Descartes-08\, as a Potential App
 roach to Treat Myasthenia Gravis\nEstimated primary completion: 30 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/descartes-08#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0679
 9247
URL:https://assetmemo.bio/drug/descartes-08#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letroz
 ole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Combination
  With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant M
 etastatic Colorectal Cancer\nEstimated primary completion: 30 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9103@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Veppanu (Vepdegestrant): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letr
 ozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/vepdegestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238843-11359@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:TAK-921: Phase 3 readout est. (NCT06238843)
DESCRIPTION:TAK-921\, phase 3.\nStudy: A Multicenter\, Phase 3 Study of IBI
 343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With
  Previously Treated\, Claudin (CLDN) 18.2-positive\, HER2-negative\, Gastr
 ic or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tak-921#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06238843
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04772287-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04772287)
DESCRIPTION:Toripalimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Adj
 uvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage I
 I-IIIB(N2) NSCLC (LungMate-008)\nEstimated primary completion: 30 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047722
 87
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751485-9179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Anbenitamab repodatecan: Phase 3 readout est. (NCT06751485)
DESCRIPTION:Anbenitamab repodatecan\, phase 3.\nStudy: JSKN003 in Platinum-
 Resistant\, Relapsed Epithelial Ovarian Cancer\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /anbenitamab-repodatecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06751485
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578078-608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 06578078)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: A Clinical Trial to Define the Best Strategy for the
  Management of Heart Failure in Elderly Patients\nEstimated primary comple
 tion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sodium-zirconium-cyclosilicate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06578078
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559306-802@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Seltorexant: Phase 3 readout est. (NCT06559306)
DESCRIPTION:Seltorexant\, phase 3\, Major Depressive Disorder.\nStudy: Phas
 e 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Pa
 rticipants With Major Depressive Disorder and Insomnia Symptoms\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/seltorexant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06559306
URL:https://assetmemo.bio/drug/seltorexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577519-8692@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sumecigrel: Phase 3 readout est. (NCT06577519)
DESCRIPTION:Sumecigrel\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Efficacy and Safety Study of Vicagrel in Patients With Acute Coron
 ary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sumecigrel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06577519
URL:https://assetmemo.bio/drug/sumecigrel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04093167-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT04093167)
DESCRIPTION:Pembrolizumab\, phase 2/3.\nStudy: Study of CTDNA Response Adap
 tive Immuno-Chemotherapy in Lung Cancer\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04093167
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03859128-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT03859128)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Toripalimab or Placebo as Adju
 vant Therapy in Hepatocellular Carcinoma After Radical Resection\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03859128
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279610-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT07279610)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: N-Acetylcysteine as Thera
 py for Transplantation- Associated Thrombotic Microangiopathy\nEstimated p
 rimary completion: 31 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07279610
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06907602-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06907602)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Esophageal Squamous Cell Carcinoma.
 \nStudy: Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Es
 ophageal Squamous Cell Carcinoma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 07602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280495-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06280495)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Neoadjuvan
 t Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT\, 
 pMMR/MSS CRC Patients\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06280495
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280495-2161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT06280495)
DESCRIPTION:Serplulimab\, phase 2/3.\nStudy: Neoadjuvant Serplulimab & Beva
 cizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT\, pMMR/MSS CRC Patient
 s\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06280495
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884293-183@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:mazdutide: Phase 3 readout est. (NCT06884293)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study Comparing IBI362
  vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfu
 nction-associated Fatty Liver Disease （MAFLD）\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mazdutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06884293
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531824-369@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06531824)
DESCRIPTION:Vicadrostat\, phase 3\, Chronic Kidney Disease.\nStudy: EASi-KI
 DNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combin
 ation With Empagliflozin)\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06531824
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03887455-665@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT03887455)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study to Confirm Safety and Efficacy of Lecanemab in Participants With Ear
 ly Alzheimer's Disease\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03887455
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04020055-912@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT04020055)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and R
 enal Disease\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04020055
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488755-1328@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rademikibart: Phase 3 readout est. (NCT06488755)
DESCRIPTION:Rademikibart\, phase 3\, Asthma.\nStudy: SIM0718 Treatment of A
 sthma Clinical Study\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rademikibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06488755
URL:https://assetmemo.bio/drug/rademikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-1970@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Lorlatinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cont
 inued Access Study for Participants Deriving Benefit in Pfizer-Sponsored A
 velumab Parent Studies That Are Closing\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorlat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05059522
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03712605-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03712605)
DESCRIPTION:Pembrolizumab\, phase 3\, Merkel Cell Carcinoma.\nStudy: Testin
 g Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma 
 After Surgery\, STAMP Trial\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03712605
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162883-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07162883)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 harmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 162883
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04841811-1984@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Almonertinib: Phase 3 readout est. (NCT04841811)
DESCRIPTION:Almonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: MD
 T-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance i
 n EGFRm+ Unresectable Stage III NSCLC (APPROACH)\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04841811
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04170283-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT04170283)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study to Evaluate Long-term S
 afety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Wh
 o Participated in BeiGene Parent Studies of Zanubrutinib\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04170283
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939439-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06939439)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Using ctDNA to
  Guide Treatment Decisions for Stage III Gastric Cancer\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06939439
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2017@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Avelumab\, phase 3\, Urothelial Carcinoma.\nStudy: Continued Ac
 cess Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab 
 Parent Studies That Are Closing\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523493-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04523493)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase III Study of Toripalimab
 （JS001） Combined With Lenvatinib for Advanced HCC\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04523493
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2214@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Axitinib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Axitinib\, phase 3.\nStudy: Continued Access Study for Particip
 ants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are
  Closing\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05059522)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Continued Access Study for Participants Deriving Benefit in Pfizer-Sp
 onsored Avelumab Parent Studies That Are Closing\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05059522
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2243@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Talazoparib\, phase 3.\nStudy: Continued Access Study for Parti
 cipants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That 
 Are Closing\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib or
  Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0186
 3550
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib or 
 Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With 
 Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT018635
 50
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib o
 r Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients Wit
 h Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT01
 863550
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03017326-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT03017326)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Paediatric Hepatic International
  Tumour Trial\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03017326
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660394-8867@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06660394)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Phase 3\, Placebo-C
 ontrolled Study to Investigate LP352 in Children and Adults With Dravet Sy
 ndrome (DS)\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06660394
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Bortezomib or Carfilzomib With
  Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed 
 Multiple Myeloma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT01863550
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00978458-8999@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT00978458)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Radiation Therapy With
  or Without Temozolomide in Treating Patients With Low-Grade Glioma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT00978458
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691804-9052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT04691804)
DESCRIPTION:Fluzoparib\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Multicenter\, Randomized\, Double-Blind\, Placebo-Contr
 olled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and
  Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatme
 nt in Patients With Metastatic Castration-Resistant Prostate Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04691804
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05424835-9096@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT05424835)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Tria
 l of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Po
 sitive\, Unresectable and/or Metastatic Breast Cancer Subjects Previously 
 Treated With Trastuzumab and Taxane\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05424835
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04170283-10908@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT04170283)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3.\nStudy: A Study to Evaluate 
 Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Mali
 gnancies Who Participated in BeiGene Parent Studies of Zanubrutinib\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04170283
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303532-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05303532)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Roll Over StudY for Patients Who 
 Have Completed a Previous Oncology Study With Durvalumab\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05303532
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733245-11078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-9190: Phase 3 readout est. (NCT07733245)
DESCRIPTION:HRS-9190\, phase 3.\nStudy: Efficacy and Safety of HRS-9190 in 
 General Anesthesia\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/hrs-9190#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07733245
URL:https://assetmemo.bio/drug/hrs-9190#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149467-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07149467)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: Uste
 kinumab and Upadacitinib for Induction and Maintenance Therapy in Patients
  With Refractory Crohn's Disease: A Multicenter\, Randomized\, Parallel-Co
 ntrolled Study\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07149467
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486479-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07486479)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Azacitidine\, and Mitoxantrone Hydrochloride Liposome Versus Idarubic
 in and Cytarabine in Newly Diagnosed AML\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07486479
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255795-2286@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06255795)
DESCRIPTION:Chidamide\, phase 3.\nStudy: The Efficacy and Safety of Chidami
 de\, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in th
 e Treatment of Newly Diagnosed\, Stage III to IV Extranodal Natural Killer
 /T-Cell Lymphoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06255795
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486479-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07486479)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax\, Azacitidine\, and Mitoxantrone Hydrochloride Liposome Versus Idarubi
 cin and Cytarabine in Newly Diagnosed AML\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07486479
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06304857-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630485
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treate
 d with AnthrAcycline - PROTECTAA TRIAL\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06304857
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890143-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0689014
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: The Effica
 cy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disea
 se With Proteinuria in Children\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0689
 0143
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05392764-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05392764)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: Ea
 rly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-ris
 k Patients With Acute Heart Failure\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflo
 zin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05392764
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420296-886@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT07420296)
DESCRIPTION:Soliris (Eculizumab)\, phase 3.\nStudy: Modified Zipper Therapy
  for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder\nEstimated p
 rimary completion: 31 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/eculizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07420296
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819826-945@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SC0062: Phase 3 readout est. (NCT06819826)
DESCRIPTION:SC0062\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of S
 C0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sc0062#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06819826
URL:https://assetmemo.bio/drug/sc0062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307586-1026@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:FNC (Azvudine): Phase 3 readout est. (NCT07307586)
DESCRIPTION:FNC (Azvudine)\, phase 3.\nStudy: A Small Sample Prospective Cl
 inical Study of Azvudine Tablets to Promote Clinical Cure in Patients With
  Chronic Hepatitis B\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azvudine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07307586
URL:https://assetmemo.bio/drug/azvudine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06710080-1037@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vascepa (Icosapent Ethyl): Phase 3 readout est. (NCT06710080)
DESCRIPTION:Vascepa (Icosapent Ethyl)\, phase 3.\nStudy: Targeting Vascular
  INflammation in Patients With Community-Acquired Pneumonia\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/icosapent-ethyl#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06710080
URL:https://assetmemo.bio/drug/icosapent-ethyl#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330337-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06330337)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Effect of Electroacupuncture 
 Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of 
 High-grade Glioma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06330337
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226857-1965@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06226857)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: Oth
 er Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided R
 AS-wild Type Metastatic Colorectal Cancer\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06226857
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533384-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06533384)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: PARPi or Capecitabine Combined 
 With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06533384
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06674343-1983@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06674343)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib 160mg as First-line Treatment in Locally Advanced or Metastat
 ic NSCLC With EGFR Classical Mutations\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furmone
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06674343
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081959-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06081959)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of SKB264 for Locally Advanced\, Recurrent or Metas
 tatic HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06081959
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03303495-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT03303495)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of 2
 nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03303495
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05823311-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT05823311)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Lenvatinib\, Tislelizumab Combi
 ned with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Ch
 olangiocarcinoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05823311
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: A Study of RC48-ADC Combined Wit
 h Toripalimab For First-line Treatment of Urothelial Carcinoma\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990321-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06990321)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Effectiv
 eness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation
  Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid 
 Leukemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06990321
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813015-2242@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:S-1: Phase 3 readout est. (NCT05813015)
DESCRIPTION:S-1\, phase 3.\nStudy: Study of Comparing of With and Without S
 equential Therapy of S-1\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05813015
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined With Toripalimab For First-line Treatment of Uro
 thelial Carcinoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345365-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT06345365)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: MA+AZA 
 Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06345365
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06104566-2883@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06104566)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: Global Trial in APG2575 for Pati
 ents With CLL/SLL\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06104566
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681260-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 3 readout est. (NCT05681260)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Capizzi Escalating Methotrexate
  Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lym
 phoblastic Lymphoma (T-LBL)\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05681260
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05058287-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT05058287)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Lumbar Steroid Use in Pat
 ients Undergoing Posterior Lumbar Decompression\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methylprednisolone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05058287
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249632-5453@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07249632)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: A Study of Telitacicept in Pati
 ents With Ocular Myasthenia Gravis (OMG)\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07249632
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05764044-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT05764044)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Adjuvant Chemotherapy in cfHPV-D
 NA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Canc
 er\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05764044
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04638790-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04638790)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: First Line Chemotherapy for Cl
 assical Hodgkin Lymphoma in Russia (HL-Russia-1)\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04638790
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330337-8999@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT06330337)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Effect of Electroacupu
 ncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurre
 nce of High-grade Glioma\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06330337
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813015-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05813015)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Study of Comparing of W
 ith and Without Sequential Therapy of S-1\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doce
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05813015
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533384-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06533384)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: PARPi or Capecitabine Combined 
 With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06533384
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746726-11078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-9190: Phase 3 readout est. (NCT07746726)
DESCRIPTION:HRS-9190\, phase 3.\nStudy: Safety and Efficacy of HRS-9190 Com
 pared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adult
 s\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/hrs-9190#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07746726
URL:https://assetmemo.bio/drug/hrs-9190#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109272-990@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Budigalimab: Phase 2/3 readout est. (NCT06109272)
DESCRIPTION:Budigalimab\, phase 2/3.\nStudy: A Study to Assess the Dose\, A
 dverse Events\, and Change in Disease Activity of Livmoniplimab as an Intr
 avenous (IV) Solution in Combination With Budigalimab as an IV Solution in
  Adult Participants With Hepatocellular Carcinoma (HCC)\nEstimated primary
  completion: January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/budigalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06109272
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981118-1783@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tapinarof: Phase 2/3 readout est. (NCT05981118)
DESCRIPTION:Tapinarof\, phase 2/3\, Psoriasis.\nStudy: Comparison of Post-I
 nflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant
 )\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tapinarof#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05981118
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747130-4366@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Montelukast (Singulair): Phase 2/3 readout est. (NCT06747130)
DESCRIPTION:Montelukast (Singulair)\, phase 2/3.\nStudy: Efficacy of Montel
 ukast in Preventing Transaminase Elevation in Adult Dengue Patients\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/montelukast-singulair#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06747130
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701331-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06701331)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Sa
 fety and Efficacy of Upadacitinib in Combination With Topical Corticostero
 ids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate
  to Severe Atopic Dermatitis\nEstimated primary completion: January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06701331
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06481891-314@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06481891)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Hypertrophic Cardiomyopathy.
 \nStudy: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in S
 ymptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06481891
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922110-819@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azetukalner: Phase 3 readout est. (NCT06922110)
DESCRIPTION:Azetukalner\, phase 3\, Major Depressive Disorder.\nStudy: An O
 pen-Label Study of Azetukalner in Major Depressive Disorder\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azetukalner#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06922110
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533164-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05533164)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab Effect on Decr
 easing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experi
 encing a PMR Relapse\nEstimated primary completion: January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05533164
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505004-8949@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07505004)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Randomized Clinical 
 Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Fo
 cal Seizures\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/vormatrigine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07505004
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636071-10813@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:setrusumab: Phase 3 readout est. (NCT06636071)
DESCRIPTION:setrusumab\, phase 3\, Osteogenesis Imperfecta.\nStudy: Setrusu
 mab in Pediatric Japanese Subjects With Osteogenesis Imperfecta\nEstimated
  primary completion: January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/setrusumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06636071
URL:https://assetmemo.bio/drug/setrusumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162896-1346@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Eucrisa (crisaborole): Phase 3 readout est. (NCT07162896)
DESCRIPTION:Eucrisa (crisaborole)\, phase 3\, Atopic Dermatitis.\nStudy: Cr
 isaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atop
 ic Dermatitis\nEstimated primary completion: January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/crisaborole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07162896
URL:https://assetmemo.bio/drug/crisaborole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543224-1475@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:RSS0393: Phase 3 readout est. (NCT07543224)
DESCRIPTION:RSS0393\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomiz
 ed\, Double-Blind\, Placebo-Controlled Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaqu
 e Psoriasis.\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rss0393#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07543224
URL:https://assetmemo.bio/drug/rss0393#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894784-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06894784)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: A Clinical Trial to Ev
 aluate The Effects of Semaglutide and Empagliflozin Combined to Automated 
 Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
 \nEstimated primary completion: January 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06894784
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297589-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0729758
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Epicardial
  Cardiac Fat-CT (EPIC-CT)\nEstimated primary completion: January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07297589
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894784-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06894784)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: A Clinical Trial t
 o Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automa
 ted Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diab
 etes\nEstimated primary completion: January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06894784
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601335-2023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06601335)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase 3 Study of AK112 Plus AK
 117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous
  Cell Carcinoma (R/M HNSCC)\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06601335
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601335-2833@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ligufalimab: Phase 3 readout est. (NCT06601335)
DESCRIPTION:Ligufalimab\, phase 3.\nStudy: A Phase 3 Study of AK112 Plus AK
 117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous
  Cell Carcinoma (R/M HNSCC)\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ligufalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06601335
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05997693-6104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05997693)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: One-Month DAPT in CABG
  Patients\nEstimated primary completion: January 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05997693
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412132-6316@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vimpat (Lacosamide): Phase 3 readout est. (NCT07412132)
DESCRIPTION:Vimpat (Lacosamide)\, phase 3.\nStudy: Evaluation of the Effica
 cy\, Safety\, and Tolerability of Lacosamide in Major Depressive Episodes 
 of Bipolar Disorder Types I and II.\nEstimated primary completion: January
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lacosamide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0741213
 2
URL:https://assetmemo.bio/drug/lacosamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-5@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tremfya (guselkumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Tremfya (guselkumab)\, phase 2/3.\nStudy: Using a Contact Derma
 titis Model With Biologic Medications to Study Skin Inflammation\nEstimate
 d primary completion: 1 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-6@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Stelara (ustekinumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Stelara (ustekinumab)\, phase 2/3.\nStudy: Using a Contact Derm
 atitis Model With Biologic Medications to Study Skin Inflammation\nEstimat
 ed primary completion: 1 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-8@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Humira (adalimumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Humira (adalimumab)\, phase 2/3.\nStudy: Using a Contact Dermat
 itis Model With Biologic Medications to Study Skin Inflammation\nEstimated
  primary completion: 1 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-1356@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dupixent (dupilumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Dupixent (dupilumab)\, phase 2/3.\nStudy: Using a Contact Derma
 titis Model With Biologic Medications to Study Skin Inflammation\nEstimate
 d primary completion: 1 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-3789@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:fluticasone propionate: Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:fluticasone propionate\, phase 2/3.\nStudy: Using a Contact Der
 matitis Model With Biologic Medications to Study Skin Inflammation\nEstima
 ted primary completion: 1 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/fluticasone-propionate#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/fluticasone-propionate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-5897@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sarilumab: Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Sarilumab\, phase 2/3.\nStudy: Using a Contact Dermatitis Model
  With Biologic Medications to Study Skin Inflammation\nEstimated primary c
 ompletion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05535738
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04971720-528@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2/3 readout est. (NCT0497172
 0)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2/3\, Hypertension.\nSt
 udy: PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP R
 hythm Axis\nEstimated primary completion: 1 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04971720
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369739-2266@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Selinexor: Phase 2/3 readout est. (NCT07369739)
DESCRIPTION:Selinexor\, phase 2/3.\nStudy: Golidocitinib Combined With Seli
 nexor for CAEBVD\nEstimated primary completion: 1 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07369739
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05011266-8925@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Naloxone (Narcan): Phase 2/3 readout est. (NCT05011266)
DESCRIPTION:Naloxone (Narcan)\, phase 2/3.\nStudy: Efficacy of Buprenorphin
 e and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disor
 der\nEstimated primary completion: 1 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05011266
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03244384-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03244384)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Testing
  MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladd
 er Cancer and Locally Advanced Urothelial Cancer\nEstimated primary comple
 tion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03244384
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06641089-104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:sonelokimab: Phase 3 readout est. (NCT06641089)
DESCRIPTION:sonelokimab\, phase 3\, Psoriatic Arthritis.\nStudy: Evaluation
  of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα
  Inadequate Response\nEstimated primary completion: 4 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sonelokimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06641089
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000136-1050@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000136)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With HeFH\nEstimated primary completion: 4 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07000136
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925803-5367@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05925803)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Sclerosis.\nStudy: Determine E
 ffectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)\nEstimated prima
 ry completion: 6 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05925803
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05221840-2157@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Oleclumab: Phase 3 readout est. (NCT05221840)
DESCRIPTION:Oleclumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Glo
 bal Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab
  With Monalizumab Following Concurrent Chemoradiation in Patients With Sta
 ge III Unresectable Non-Small Cell Lung Cancer\nEstimated primary completi
 on: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 leclumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05221840
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05221840-2257@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Monalizumab: Phase 3 readout est. (NCT05221840)
DESCRIPTION:Monalizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A G
 lobal Study to Assess the Effects of Durvalumab With Oleclumab or Durvalum
 ab With Monalizumab Following Concurrent Chemoradiation in Patients With S
 tage III Unresectable Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /monalizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05221840
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06495918-4967@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 6495918)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3\, Age-Related
  Macular Degeneration.\nStudy: Study to Evaluate the Efficacy and Safety o
 f Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age
 - Related Macular Degeneration\nEstimated primary completion: 8 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib-intravit
 real-implant-otx-tki#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06495918
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673029-2244@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:Trastuzumab Emtansine: Phase 3 readout est. (NCT07673029)
DESCRIPTION:Trastuzumab Emtansine\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive 
 Unresectable or Metastatic Breast Cancer\nEstimated primary completion: 9 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-emtansine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07673029
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3025@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Mezigdomide: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Mezigdomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalido
 mide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or
  Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 19085
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eva
 luate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidom
 ide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or 
 Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05519
 085
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate Mezigdomid
 e\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide\, Bortezomib
  and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multi
 ple Myeloma (RRMM)\nEstimated primary completion: 10 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05519085
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000123-1050@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000123)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With Clinical ASCVD or at Risk for a First ASCVD Event\nEstimated p
 rimary completion: 11 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07000123
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-1958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-1980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06417814)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Wi
 thout Osimertinib Compared With Platinum Based Doublet Chemotherapy in Par
 ticipants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 11 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05689879-9@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT05689879)
DESCRIPTION:Remicade (infliximab)\, phase 3.\nStudy: Evaluation of TNF-alph
 a Antagonists (Infliximab) Withdrawal in Sarcoidosis\nEstimated primary co
 mpletion: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/infliximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05689879
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan i
 n Combination With Pembrolizumab for Participants With Metastatic Non-smal
 l Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum
 or Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary completi
 on: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05609968
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1992@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Gov
 itecan in Combination With Pembrolizumab for Participants With Metastatic 
 Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD
 -L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary 
 completion: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05609968
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06573645-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06573645)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Phase III Clinical Tri
 al of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Tr
 eatment of Male Patient With Newly Diagnosed Advanced DLBCL\nEstimated pri
 mary completion: 12 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06573645
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706817-1507@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06706817)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis Wi
 th Nasal Polyposis Initiating Treatment With Tezepelumab\nEstimated primar
 y completion: 13 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06706817
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951503-2023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06951503)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: A
 K112 and Chemotherapy in First-line Metastatic Colorectal Cancer\nEstimate
 d primary completion: 13 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06951503
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261644-1795@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:Amdokitug (Yisaituo): Phase 3 readout est. (NCT07261644)
DESCRIPTION:Amdokitug (Yisaituo)\, phase 3.\nStudy: A Study to Evaluate the
  Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spond
 ylitis(AS)\nEstimated primary completion: 14 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/amdokitug-yisaituo#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07261644
URL:https://assetmemo.bio/drug/amdokitug-yisaituo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987332-1966@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Crizotinib: Phase 2/3 readout est. (NCT05987332)
DESCRIPTION:Crizotinib\, phase 2/3.\nStudy: IDE196 (Darovasertib) in Combin
 ation With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma\n
 Estimated primary completion: 15 January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05987332
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987332-10793@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Darovasertib: Phase 2/3 readout est. (NCT05987332)
DESCRIPTION:Darovasertib\, phase 2/3\, Uveal Melanoma.\nStudy: IDE196 (Daro
 vasertib) in Combination With Crizotinib as First-line Therapy in Metastat
 ic Uveal Melanoma\nEstimated primary completion: 15 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05987332
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-1975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the 
 Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab f
 or Preventing or Delaying Melanoma From Coming Back After it Has Been Remo
 ved With Surgery\nEstimated primary completion: 15 January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-2221@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Fianlimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Fianlimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the C
 ombination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab fo
 r Preventing or Delaying Melanoma From Coming Back After it Has Been Remov
 ed With Surgery\nEstimated primary completion: 15 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102628-1034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT07102628)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Evaluation of Efficacy and Safety of Early in Hospital In
 itiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
 \nEstimated primary completion: 16 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07102628
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2016@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Alecensa (Alectinib): Phase 3 readout est. (NCT05170204)
DESCRIPTION:Alecensa (Alectinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Therapies in 
 Cohorts of Participants With Locally Advanced\, Unresectable\, Stage III N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517020
 4
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2220@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Entrectinib: Phase 3 readout est. (NCT05170204)
DESCRIPTION:Entrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts o
 f Participants With Locally Advanced\, Unresectable\, Stage III Non-Small 
 Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/entrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05170204
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858839-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 39)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 
 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated primary 
 completion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06858839
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858878-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 78)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With
  Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated pr
 imary completion: 21 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06858878
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05877963-6993@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Briumvi (Ublituximab): Phase 3 readout est. (NCT05877963)
DESCRIPTION:Briumvi (Ublituximab)\, phase 3\, Multiple Sclerosis.\nStudy: S
 tudy to Evaluate Safety\, Efficacy and Pharmacokinetics (PK) of a Modified
  Regimen of Ublituximab\nEstimated primary completion: 21 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05877963
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076199-319@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Awiqli (insulin icodec): Phase 3 readout est. (NCT07076199)
DESCRIPTION:Awiqli (insulin icodec)\, phase 3.\nStudy: A Research Study to 
 See How a Weekly Insulin\, Insulin Icodec\, Helps in Reducing the Blood Su
 gar Compared to Daily Insulin Glargine\, Both in Combination With Insulin 
 Aspart\, in Adults With Type 1 Diabetes\nEstimated primary completion: 25 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/insulin
 -icodec#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07076199
URL:https://assetmemo.bio/drug/insulin-icodec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696443-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06696443)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of the Long-term Safety and Effectiveness of 
 Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropa
 thy (DPN)\nEstimated primary completion: 25 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06696443
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757102-4142@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol): Phas
 e 3 readout est. (NCT05757102)
DESCRIPTION:Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)\,
  phase 3\, Asthma.\nStudy: A Study to Compare the Efficacy\, Safety and To
 lerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma\nEstima
 ted primary completion: 26 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/fluticasone-furoate-umeclidinium-vilanterol#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05757102
URL:https://assetmemo.bio/drug/fluticasone-furoate-umeclidinium-vilanterol#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05038735-3247@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT05038735)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulv
 estrant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced 
 Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inh
 ibitor.\nEstimated primary completion: 28 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05038735
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118281-606@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Ziltivekimab: Phase 3 readout est. (NCT06118281)
DESCRIPTION:Ziltivekimab\, phase 3.\nStudy: ARTEMIS - A Research Study to L
 ook at How Ziltivekimab Works Compared to Placebo in People With a Heart A
 ttack\nEstimated primary completion: 29 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ziltivekimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06118281
URL:https://assetmemo.bio/drug/ziltivekimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Disitam
 ab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urot
 helial Cancer Expressing HER2\nEstimated primary completion: 29 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0591129
 5
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated 
 Urothelial Cancer Expressing HER2\nEstimated primary completion: 29 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05911295
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817618-887@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04817618)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Study of Efficacy and S
 afety of Iptacopan in Patients With C3 Glomerulopathy.\nEstimated primary 
 completion: 29 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iptacopan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04817618
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589986-20@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:afimkibart: Phase 3 readout est. (NCT06589986)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for 
 Induction and Maintenance Therapy in Participants With Moderately to Sever
 ely Active Ulcerative Colitis\nEstimated primary completion: 30 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589986
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-8457@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT04906395)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Aceta
 te in Breast Cancer\nEstimated primary completion: 30 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-8888@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Anastrozole: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Bre
 ast Cancer\nEstimated primary completion: 30 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Letrozole: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breas
 t Cancer\nEstimated primary completion: 30 January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-9038@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Exemestane: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Brea
 st Cancer\nEstimated primary completion: 30 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04241185-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04241185)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Efficacy and Safety of Pembrol
 izumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Al
 one in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)\nEs
 timated primary completion: 31 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04241185
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541755-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07541755)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: PD-1 Inhibitors +Venetoclax+CAG R
 egimens in R/R T-ALL\nEstimated primary completion: 31 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07541755
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03267433-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03267433)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab With or Withou
 t Stem Cell Transplant in Treating Patients With Minimal Residual Disease-
 Negative Mantle Cell Lymphoma in First Complete Remission\nEstimated prima
 ry completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03267433
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05047172-6104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05047172)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3.\nStudy: Comparison of Anti-coa
 gulation and Anti-Platelet Therapies for Intracranial Vascular Atherosteno
 sis\nEstimated primary completion: 31 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05047172
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179876-515@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Opsumit (Macitentan): Phase 3 readout est. (NCT05179876)
DESCRIPTION:Opsumit (Macitentan)\, phase 3.\nStudy: A Study Providing Treat
 ment Access in Participants With Pulmonary Hypertension Completing a Paren
 t Study and Having no Other Option\nEstimated primary completion: 31 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/macitentan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05179
 876
URL:https://assetmemo.bio/drug/macitentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179876-518@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Adcirca (Tadalafil): Phase 3 readout est. (NCT05179876)
DESCRIPTION:Adcirca (Tadalafil)\, phase 3.\nStudy: A Study Providing Treatm
 ent Access in Participants With Pulmonary Hypertension Completing a Parent
  Study and Having no Other Option\nEstimated primary completion: 31 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517987
 6
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579573-8851@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Xcopri (Cenobamate): Phase 3 readout est. (NCT06579573)
DESCRIPTION:Xcopri (Cenobamate)\, phase 3\, Epilepsy.\nStudy: ONO-2017 Stud
 y Japanese Patients With Primary Generalized Tonic Clonic Seizures.\nEstim
 ated primary completion: 31 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cenobamate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06579573
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596589-9526@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Remimazolam: Phase 3 readout est. (NCT07596589)
DESCRIPTION:Remimazolam\, phase 3.\nStudy: Effect of Remimazolam Sedation o
 n Outcomes of Mechanically Ventilated Patients in the ICU\nEstimated prima
 ry completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/remimazolam#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07596589
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02377271-514@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tracleer (Bosentan): Phase 3 readout est. (NCT02377271)
DESCRIPTION:Tracleer (Bosentan)\, phase 3.\nStudy: ENDOTHELION Study Group:
  Effect of Bosentan in NAION Patients\nEstimated primary completion: Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bosentan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT023772
 71
URL:https://assetmemo.bio/drug/bosentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Sacit
 uzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Ch
 oice and Pembrolizumab in Patients With Previously Untreated\, Locally Adv
 anced Inoperable or Metastatic Triple-Negative Breast Cancer\nEstimated pr
 imary completion: February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1992@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice and Pembrolizumab in Patients With Previously Untreated\, Loc
 ally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEstimated prima
 ry completion: February 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939595-2443@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P51: Phase 3 readout est. (NCT06939595)
DESCRIPTION:CT-P51\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Prev
 iously Untreated Metastatic Lung Cancer\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p51#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069395
 95
URL:https://assetmemo.bio/drug/ct-p51#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEstimated prim
 ary completion: February 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2842@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106372-1335@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:stapokibart: Phase 3 readout est. (NCT07106372)
DESCRIPTION:stapokibart\, phase 3\, Atopic Dermatitis.\nStudy: A Study of S
 tapokibatrt in Children Subjects With Atopic Dermatitis\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07106372
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184645-1444@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Moizerto / Adquey (difamilast): Phase 3 readout est. (NCT07184645)
DESCRIPTION:Moizerto / Adquey (difamilast)\, phase 3\, Atopic Dermatitis.\n
 Study: A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atop
 ic Dermatitis\nEstimated primary completion: February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/difamilast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07184645
URL:https://assetmemo.bio/drug/difamilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672549-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672549)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Platform
  Trial for Pediatric Participants With Obesity or Overweight (LY900040)\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/orforglipron#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06672549
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060456-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07060456)
DESCRIPTION:ribupatide\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Sa
 fety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal In
 sulin\nEstimated primary completion: February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07060456
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04578652-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04578652)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Fiber and Metformin C
 ombination Therapy in Adolescents With Severe Obesity and Insulin Resistan
 ce\nEstimated primary completion: February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04578652
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464587-1558@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:TQC3721: Phase 3 readout est. (NCT07464587)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate
 -to-Severe Chronic Obstructive Pulmonary Disease\nEstimated primary comple
 tion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tqc3721#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07464587
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996080-5235@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tabirafusp alfa: Phase 3 readout est. (NCT06996080)
DESCRIPTION:Tabirafusp alfa\, phase 3.\nStudy: A Phase 3 Study to Evaluate 
 the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macul
 ar Edema Secondary to Inflammation (MESI) - PINNACLE\nEstimated primary co
 mpletion: February 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tabirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06996080
URL:https://assetmemo.bio/drug/tabirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05906992-7343@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P53: Phase 3 readout est. (NCT05906992)
DESCRIPTION:CT-P53\, phase 3\, Multiple Sclerosis.\nStudy: A Study to Compa
 re Efficacy\, Pharmacokinetics\, Pharmacodynamics and Safety of CT-P53 and
  Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ct-p53#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05906992
URL:https://assetmemo.bio/drug/ct-p53#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05219617-8747@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Carisbamate: Phase 3 readout est. (NCT05219617)
DESCRIPTION:Carisbamate\, phase 3\, Epilepsy.\nStudy: Investigate Efficacy 
 and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated 
 With LGS in Children and Adults\nEstimated primary completion: February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carisbamate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05219617
URL:https://assetmemo.bio/drug/carisbamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645924-10397@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Elismetrep: Phase 3 readout est. (NCT07645924)
DESCRIPTION:Elismetrep\, phase 3\, Migraine.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migr
 aine\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/elismetrep#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07645924
URL:https://assetmemo.bio/drug/elismetrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582458-5607@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Provigil (Modafinil): Phase 2/3 readout est. (NCT07582458)
DESCRIPTION:Provigil (Modafinil)\, phase 2/3.\nStudy: Modafinil for Debilit
 ating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)\nE
 stimated primary completion: 1 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/modafinil#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07582458
URL:https://assetmemo.bio/drug/modafinil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06447623-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Apatinib: Phase 3 readout est. (NCT06447623)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Apatinib Combined With cdk4/6i in F
 irst-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer\nEstimated pr
 imary completion: 1 February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06447623
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06447623-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06447623)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Apatinib Combined With cdk4/6i in First-line Treatment for
  HR+/HER2- SNF4 Subtype Breast Cancer\nEstimated primary completion: 1 Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6447623
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04095364-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Letrozole: Phase 3 readout est. (NCT04095364)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Letrozole With or Without Paclitax
 el and Carboplatin in Treating Patients With Stage II-IV Ovarian\, Fallopi
 an Tube\, or Primary Peritoneal Cancer\nEstimated primary completion: 1 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 095364
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320625-4366@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Montelukast (Singulair): Phase 3 readout est. (NCT07320625)
DESCRIPTION:Montelukast (Singulair)\, phase 3.\nStudy: Efficacy of Monteluk
 ast on STEMl Patients\nEstimated primary completion: 1 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/montelukast-singulair#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0732062
 5
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431595-8583@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:valproate: Phase 2/3 readout est. (NCT05431595)
DESCRIPTION:valproate\, phase 2/3.\nStudy: Managing Agitated Delirium With 
 Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy\nEstima
 ted primary completion: 2 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/valproate#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05431595
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431595-8908@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Haloperidol: Phase 2/3 readout est. (NCT05431595)
DESCRIPTION:Haloperidol\, phase 2/3.\nStudy: Managing Agitated Delirium Wit
 h Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy\nEsti
 mated primary completion: 2 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/haloperidol#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05431595
URL:https://assetmemo.bio/drug/haloperidol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04020263-601@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270203
DTEND;VALUE=DATE:20270204
SUMMARY:Simdax (Levosimendan): Phase 3 readout est. (NCT04020263)
DESCRIPTION:Simdax (Levosimendan)\, phase 3.\nStudy: Effect of Early Use of
  Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope
  Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogen
 ic Shock\nEstimated primary completion: 3 February 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/levosimendan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04020263
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260163-5@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06260163)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Study of Guselkumab in Pediatric Participants With Moderately to Severely 
 Active Ulcerative Colitis\nEstimated primary completion: 10 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06260163
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807424-19@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT06807424)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) 
 in Biologic-experienced and Biologic-naive Participants With Active Psoria
 tic Arthritis\nEstimated primary completion: 10 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06807424
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973304-9608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:teduglutide (Gattex): Phase 3 readout est. (NCT06973304)
DESCRIPTION:teduglutide (Gattex)\, phase 3\, Short Bowel Syndrome.\nStudy: 
 A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome\nEstima
 ted primary completion: 10 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teduglutide-gattex#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06973304
URL:https://assetmemo.bio/drug/teduglutide-gattex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481747-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07481747)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy an
 d Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are
  Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
 \nEstimated primary completion: 14 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07481747
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02972840-3339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT02972840)
DESCRIPTION:Acalabrutinib\, phase 3.\nStudy: A Study of BR Alone Versus in 
 Combination With Acalabrutinib in Subjects With Previously Untreated MCL\n
 Estimated primary completion: 15 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT02972840
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140836-2264@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Repotrectinib: Phase 3 readout est. (NCT06140836)
DESCRIPTION:Repotrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Repotrectinib Versus Crizotinib in Participants With Locally Adv
 anced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive N
 on-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nEstimated primary completio
 n: 16 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 repotrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06140836
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082114-195@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:HDM1002: Phase 3 readout est. (NCT07082114)
DESCRIPTION:HDM1002\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study to
  Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Dia
 betes Mellitus\nEstimated primary completion: 16 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hdm1002#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07082114
URL:https://assetmemo.bio/drug/hdm1002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087835-536@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Zibotentan + Dapagliflozin: Phase 3 readout est. (NCT06087835)
DESCRIPTION:Zibotentan + Dapagliflozin\, phase 3\, Chronic Kidney Disease.\
 nStudy: Study to Investigate Efficacy\, Safety\, and Tolerability of Zibot
 entan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic
  Kidney Disease and High Proteinuria (ZENITH High Proteinuria)\nEstimated 
 primary completion: 18 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06087835
URL:https://assetmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494409-899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:AND017: Phase 3 readout est. (NCT07494409)
DESCRIPTION:AND017\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of A
 ND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney
  Disease (DD-CKD) Patients With Anemia\nEstimated primary completion: 20 F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/and017#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749
 4409
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239727-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06239727)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Reduced-dose Radiotherapy for S
 tage III Nasopharyngeal Carcinoma Based on the Treatment Response\nEstimat
 ed primary completion: 20 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06239727
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015905-11309@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07015905)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee A
 rthroplasty in Adults\nEstimated primary completion: 20 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07015905
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834932-1050@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Laroprovstat: Phase 2/3 readout est. (NCT06834932)
DESCRIPTION:Laroprovstat\, phase 2/3\, Atherosclerotic Cardiovascular Disea
 se.\nStudy: A Study to Evaluate the Efficacy\, Safety\, and Pharmacokineti
 cs of AZD0780 in Participants With Dyslipidaemia\nEstimated primary comple
 tion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/laroprovstat#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06834932
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868212-1415@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06868212)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Ear
 ly Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Co
 ntrolled by Second Generation H1-antihistamines\nEstimated primary complet
 ion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/remibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06868212
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629234-1958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05629234)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3.\nStudy: Roll Over StudY for P
 atients Who Have Completed a Previous Oncology Study With Osimertinib (TAG
 RISSO) (ROSY-T)\nEstimated primary completion: 22 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05629234
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04529772-3339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT04529772)
DESCRIPTION:Acalabrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy
 : A Combination of Acalabrutinib With R-CHOP in Subjects With Previously U
 ntreated Non-GCB DLBCL (ACE-LY-312)\nEstimated primary completion: 22 Febr
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04529772
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138133-5367@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05138133)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: P
 hase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lu
 pus Nephritis\nEstimated primary completion: 23 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05138133
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548385-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07548385)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine for Treat
 ment and Reduction of Intense Discomfort After knEe Replacement PAIN\nEsti
 mated primary completion: 23 February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07548385
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05598723-10441@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270224
DTEND;VALUE=DATE:20270225
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT05598723)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3\, Migraine.\nStudy: BOTO
 X® vs. XEOMIN® for Chronic Migraine\nEstimated primary completion: 24 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/incobotu
 linumtoxina-xeomin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05598723
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341621-2159@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06341621)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Chemo
 therapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes 
 Receiving Extended Adjuvant Abemaciclib\nEstimated primary completion: 25 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemac
 iclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06341621
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208178-3247@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT04208178)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, Breast Cancer.\nStudy: Study of 
 Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maint
 enance Therapy in Patients With HER2-positive Advanced Breast Cancer With 
 a PIK3CA Mutation\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04208178
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02962414-9023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Everolimus: Phase 3 readout est. (NCT02962414)
DESCRIPTION:Everolimus\, phase 3\, Epilepsy.\nStudy: Roll-over Study to Col
 lect and Assess Long-term Safety of Everolimus in Patients With TSC and Re
 fractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and 
 Who Are Benefitting From Continued Treatment\nEstimated primary completion
 : 26 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 verolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02962414
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382167-916@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Tenapanor (Ibsrela): Phase 3 readout est. (NCT07382167)
DESCRIPTION:Tenapanor (Ibsrela)\, phase 3.\nStudy: A 26-Wk Study to Assess 
 Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation 
 in Adults\nEstimated primary completion: 26 February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tenapanor-ibsrela#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07382167
URL:https://assetmemo.bio/drug/tenapanor-ibsrela#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551324-7732@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06551324)
DESCRIPTION:Mevrometostat\, phase 3.\nStudy: A Study to Learn About the Inv
 estigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC
  Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer 
 (MEVPRO-1).\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/mevrometostat#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06551324
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05132439-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05132439)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: MetfOrmin BenefIts Lo
 wer Extremities With Intermittent Claudication\nEstimated primary completi
 on: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05132439
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Atezolizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study o
 f a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpo
 int Blockade for Patients With Metastatic Colorectal Cancer\nEstimated pri
 mary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05141721
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study of
  a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoi
 nt Blockade for Patients With Metastatic Colorectal Cancer\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05141721
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-2009@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Ipilimumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study of 
 a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoin
 t Blockade for Patients With Metastatic Colorectal Cancer\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05141721
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06063967-3@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06063967)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity of Risankizum
 ab Subcutaneous Induction Treatment for Moderately to Severely Active Croh
 n's Disease.\nEstimated primary completion: March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06063967
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843643-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05843643)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Systemic Lupus Erythematosus.
 \nStudy: Program to Assess Adverse Events and Change in Disease Activity o
 f Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic
  Lupus Erythematosus\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05843643
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04870203-98@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04870203)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy
 : Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis\nEstimat
 ed primary completion: March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/baricitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04870203
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285902-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07285902)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Study Comparing the E
 fficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subj
 ects With Obesity\nEstimated primary completion: March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07285902
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681351-1044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05681351)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Severe Hypertriglyceridemia.\
 nStudy: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutan
 eously to Participants With Severe Hypertriglyceridemia (SHTG)\nEstimated 
 primary completion: March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05681351
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04951219-1161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT04951219)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Pat
 ients With Non-alcoholic Fatty Liver Disease (NAFLD)\, MAESTRO-NAFLD-Open-
 Label-Extension (MAESTRO-NAFLD-OLE)\nEstimated primary completion: March 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04951219
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349615-1231@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-1918: Phase 3 readout est. (NCT07349615)
DESCRIPTION:SHR-1918\, phase 3.\nStudy: A Study of SHR-1918 In Participants
  With Hypertriglyceridemia\nEstimated primary completion: March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/shr-1918#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07349615
URL:https://assetmemo.bio/drug/shr-1918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03295383-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03295383)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Randomized Clinical Tria
 l Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophospham
 ide in Severe Forms of Mucous Membrane Pemphigoid\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03295383
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929624-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06929624)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus
  R-GemOx in Diffuse Large B-cell Lymphoma\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0692
 9624
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456580-5453@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Telitacicept: Phase 3 readout est. (NCT06456580)
DESCRIPTION:Telitacicept\, phase 3\, Generalized Myasthenia Gravis.\nStudy:
  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravi
 s (UPSTREAM MG)\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456580
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06872125-9001@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Zorevunersen: Phase 3 readout est. (NCT06872125)
DESCRIPTION:Zorevunersen\, phase 3\, Dravet Syndrome.\nStudy: A Double-blin
 d Study Evaluating the Efficacy\, Safety\, and Tolerability of Zorevunerse
 n in Patients With Dravet Syndrome\nEstimated primary completion: March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zorevunersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06872125
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02455141-9113@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epirubicin: Phase 3 readout est. (NCT02455141)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: Adjuvant Treatmen
 t of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cance
 r\nEstimated primary completion: March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02455141
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018700-10441@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT07018700)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3\, Migraine.\nStudy: A Cl
 inical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Pr
 eventing Episodic Migraine\nEstimated primary completion: March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/incobotulinumtoxina-xeomi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 018700
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018713-10441@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT07018713)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3\, Migraine.\nStudy: A Cl
 inical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Pr
 eventing Chronic Migraine\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/incobotulinumtoxina-xeomin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 18713
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929624-11073@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-A1912: Phase 3 readout est. (NCT06929624)
DESCRIPTION:SHR-A1912\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx i
 n Diffuse Large B-cell Lymphoma\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1912#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06929624
URL:https://assetmemo.bio/drug/shr-a1912#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147946-1558@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TQC3721: Phase 3 readout est. (NCT07147946)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Pati
 ents With Moderate-to-Severe Chronic Obstructive Pulmonary Disease\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tqc3721#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07147946
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04777357-803@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT04777357)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Bipolar Disorder.\nStudy: A S
 tudy to Assess Change in Disease Activity and Adverse Events (AEs) With Ca
 riprazine in the Treatment of Depressive Episodes in Pediatric Participant
 s Participants (10 to 17 Years of Age) With Bipolar I Disorder.\nEstimated
  primary completion: March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cariprazine-vraylar#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04777357
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880276-1468@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:QLM3003: Phase 3 readout est. (NCT06880276)
DESCRIPTION:QLM3003\, phase 3\, Atopic Dermatitis.\nStudy: Efficacy and Saf
 ety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic
  Dermatitis\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/qlm3003#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06880276
URL:https://assetmemo.bio/drug/qlm3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504458-3093@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Arsenic trioxide (QTX-2101): Phase 3 readout est. (NCT07504458)
DESCRIPTION:Arsenic trioxide (QTX-2101)\, phase 3\, Acute Myeloid Leukemia.
 \nStudy: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Pa
 tients With Acute Promyelocytic Leukemia\nEstimated primary completion: Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/arsenic-tri
 oxide-qtx-2101#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07504458
URL:https://assetmemo.bio/drug/arsenic-trioxide-qtx-2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04656184-3446@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Anakinra: Phase 3 readout est. (NCT04656184)
DESCRIPTION:Anakinra\, phase 3.\nStudy: A Trial Comparing the Efficacy and 
 Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment\, 
 in Patients With Kawasaki Disease Who Failed to Respond to Initial Standar
 d IVIG Treatment\nEstimated primary completion: March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04656184
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235085-4967@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 7235085)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in P
 articipants With Non-Proliferative Diabetic Retinopathy\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/axitinib-intravitreal-implant-otx-tki#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07235085
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241416-11066@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezvilutamide: Phase 3 readout est. (NCT07241416)
DESCRIPTION:Rezvilutamide\, phase 3\, Prostate Cancer.\nStudy: A Phase III 
 Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensit
 ive Prostate Cancer\nEstimated primary completion: March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07241416
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04799275-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04799275)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy
  in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell L
 ymphoma\nEstimated primary completion: 1 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04799275
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04799275-11033@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Azacitidine (Onureg): Phase 2/3 readout est. (NCT04799275)
DESCRIPTION:Azacitidine (Onureg)\, phase 2/3.\nStudy: Testing CC-486 (Oral 
 Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older 
 With Newly Diagnosed Diffuse Large B Cell Lymphoma\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine-onureg#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04799275
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916116-4523@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Gabapentin: Phase 2/3 readout est. (NCT07916116)
DESCRIPTION:Gabapentin\, phase 2/3.\nStudy: Oral Gabapentin Versus Intraven
 ous Neostigmine/Atropine Versus Combination of Both for Prevention of PDPH
 \nEstimated primary completion: 1 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gabapentin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07916116
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011667-121@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0701
 1667)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Well CagriSema Helps People Living With
  Obesity Lose Weight and Maintain Weight Loss in the Long-term\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07011667
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05172518-2272@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Utidelone: Phase 3 readout est. (NCT05172518)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-neg
 ative Locally Advanced or Metastatic Breast Cancer\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /utidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05172518
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05172518-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05172518)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-
 negative Locally Advanced or Metastatic Breast Cancer\nEstimated primary c
 ompletion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05172518
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487727-899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:AND017: Phase 3 readout est. (NCT07487727)
DESCRIPTION:AND017\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of A
 ND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-D
 ialysis-Dependent Chronic Kidney Disease (NDD-CKD)\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /and017#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07487727
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002476-1051@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Recaticimab: Phase 3 readout est. (NCT07002476)
DESCRIPTION:Recaticimab\, phase 3.\nStudy: Early Aggressive Strategy for Tr
 eatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovasc
 ular Therapy for Large Artery Occlusion\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/recaticima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 002476
URL:https://assetmemo.bio/drug/recaticimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671001-1527@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07671001)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Depemokimab 
 in Participants of 6 to 11 Years of Age\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/depemokima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 671001
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-2289@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06952478)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Da
 rzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patien
 ts With Refractory or Relapsed Multiple Myeloma\nEstimated primary complet
 ion: 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06952478
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-3384@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:CT-P44: Phase 3 readout est. (NCT06952478)
DESCRIPTION:CT-P44\, phase 3\, Multiple Myeloma.\nStudy: A Study to Compare
  Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Darzale
 x Faspro in Combination With Lenalidomide and Dexamethasone in Patients Wi
 th Refractory or Relapsed Multiple Myeloma\nEstimated primary completion: 
 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p44#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0695
 2478
URL:https://assetmemo.bio/drug/ct-p44#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506916-92@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06506916)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarker
 s in Study Participants With Moderate to Severe Plaque Psoriasis\nEstimate
 d primary completion: 9 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06506916
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants 
 With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-2009@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Ipilimumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of
  Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants
  With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760546-123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270313
DTEND;VALUE=DATE:20270314
SUMMARY:Imcivree (setmelanotide): Phase 3 readout est. (NCT06760546)
DESCRIPTION:Imcivree (setmelanotide)\, phase 3\, Obesity.\nStudy: A Trial o
 f Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-stud
 y of NCT05774756)\nEstimated primary completion: 13 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/setmelanotide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06760546
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04455750-2060@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Rucaparib: Phase 3 readout est. (NCT04455750)
DESCRIPTION:Rucaparib\, phase 3\, Prostate Cancer.\nStudy: A Clinical Study
  Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With M
 etastatic Prostate Cancer That Has Become Resistant To Testosterone-Depriv
 ation Therapy\nEstimated primary completion: 15 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rucaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04455750
URL:https://assetmemo.bio/drug/rucaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683003-10318@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Adzynma (Apadamtase alfa): Phase 3 readout est. (NCT04683003)
DESCRIPTION:Adzynma (Apadamtase alfa)\, phase 3.\nStudy: A Study of TAK-755
  in Participants With Congenital Thrombotic Thrombocytopenic Purpura\nEsti
 mated primary completion: 16 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/apadamtase-alfa#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04683003
URL:https://assetmemo.bio/drug/apadamtase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05879276-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05879276)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Effect at 3 Months
  of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortal
 ity\, Rehospitalization\, Left Ventricular Ejection Fraction and Renal Fun
 ction.\nEstimated primary completion: 16 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05879276
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624230-15@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT04624230)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: E
 valuation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering
  From Moderate to Severe Ulcerative Colitis\nEstimated primary completion:
  17 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04624230
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04212013-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270318
DTEND;VALUE=DATE:20270319
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04212013)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Study of Ibrutinib Wit
 h Rituximab in People With Untreated Marginal Zone Lymphoma\nEstimated pri
 mary completion: 18 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04212013
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811011-296@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Galvus (Vildagliptin): Phase 2/3 readout est. (NCT07811011)
DESCRIPTION:Galvus (Vildagliptin)\, phase 2/3.\nStudy: Efficacy of Vildagli
 ptin Versus Metformin in Patients With Polycystic Ovary Syndrome\nEstimate
 d primary completion: 20 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/vildagliptin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07811011
URL:https://assetmemo.bio/drug/vildagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338683-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT06338683)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Survival With Olanzapin
 e in Patients With Locally Advanced or Metastatic Upper Gastrointestinal a
 nd Lung Cancer\nEstimated primary completion: 20 March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06338683
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860958-11035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Roflumilast (Daliresp): Phase 3 readout est. (NCT06860958)
DESCRIPTION:Roflumilast (Daliresp)\, phase 3.\nStudy: Roflumilast as an Adj
 unct to Antidepressants in Major Depressive Disorder Patients\nEstimated p
 rimary completion: 20 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/roflumilast-daliresp#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06860958
URL:https://assetmemo.bio/drug/roflumilast-daliresp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-1975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Study With Combinati
 ons of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Adva
 nced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary comp
 letion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06246916
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-2221@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Fianlimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Fianlimab\, phase 3\, Melanoma.\nStudy: A Study With Combinatio
 ns of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advan
 ced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary compl
 etion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06246916
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977893-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06977893)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant Chemotherapy in Comb
 ination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized\, Open
 -label\, Parallel-controlled\, Multi-center Phase III Study (NEOTORCH-BREA
 ST04)\nEstimated primary completion: 23 March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06977893
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347095-5@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05347095)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Participants With Fistulizing\, Perianal Crohn's Disea
 se\nEstimated primary completion: 25 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05347095
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05662319-10760@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Qfitlia (Fitusiran): Phase 3 readout est. (NCT05662319)
DESCRIPTION:Qfitlia (Fitusiran)\, phase 3.\nStudy: A Study to Test a Medici
 ne (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in
  Male Adolescent or Adult Participants With Severe Hemophilia\nEstimated p
 rimary completion: 25 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/fitusiran#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05662319
URL:https://assetmemo.bio/drug/fitusiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05639114-10731@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:VAY736: Phase 3 readout est. (NCT05639114)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Study to Evaluate Two Regimen
 s of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemi
 c Lupus Erythematosus (SIRIUS-SLE 1)\nEstimated primary completion: 26 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05639114
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380348-1958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06380348)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: JMT101 in Combination With Osimertinib\, Versus Cisplatin-pemetrex
 ed in Participants With Locally Advanced or Metastatic Non-small Cell Lung
  Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) 
 Exon 20ins Mutations\nEstimated primary completion: 26 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380348-2224@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Becotatug: Phase 3 readout est. (NCT06380348)
DESCRIPTION:Becotatug\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JMT10
 1 in Combination With Osimertinib\, Versus Cisplatin-pemetrexed in Partici
 pants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCL
 C) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mu
 tations\nEstimated primary completion: 26 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04965675-10396@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT04965675)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine\nEstimated
  primary completion: 26 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04965675
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02320435-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT02320435)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: A Safety and Efficacy Extension S
 tudy of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a 
 Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial\nEstimated primary c
 ompletion: 28 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02320435
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077904-8884@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05077904)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Efficacy and Safety of Staccato Alprazolam in Study Participants 12
  Years of Age and Older With Stereotypical Prolonged Seizures\nEstimated p
 rimary completion: 29 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05077904
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04595565-1992@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04595565)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sacituzumab Govitecan in Primary HER2-negative Breast Cance
 r\nEstimated primary completion: 30 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04595565
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04595565-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04595565)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer\nEstima
 ted primary completion: 30 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04595565
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156500-144@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156500)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM Inadequately Controlled With Diet an
 d Exercise Alone\nEstimated primary completion: 30 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olatorepatide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07156500
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156539-144@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156539)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM\nEstimated primary completion: 30 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olatorepati
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7156539
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462704-591@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05462704)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Iron De
 ficiency Anemia.\nStudy: Intravenous Versus Oral Iron for Treating Iron-De
 ficiency Anemia in Pregnancy\nEstimated primary completion: 30 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ferric-derisomaltose
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 62704
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947928-10880@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IFx-2.0: Phase 2/3 readout est. (NCT06947928)
DESCRIPTION:IFx-2.0\, phase 2/3\, Merkel Cell Carcinoma.\nStudy: Placebo-Co
 ntrolled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibi
 tor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ifx-2-0#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06947928
URL:https://assetmemo.bio/drug/ifx-2-0#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04873362-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04873362)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study Evaluating the Efficacy
  and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine 
 for Participants With HER2-Positive Breast Cancer at High Risk of Recurren
 ce Following Preoperative Therapy\nEstimated primary completion: 31 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048733
 62
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391869-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03391869)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab and Ipilimumab With or Without Local Consolidation Therapy in Treatin
 g Patients With Stage IV Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03391869
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04444921-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04444921)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: EA2176: Phase 3 Clinical Trial of 
 Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patient
 s\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04444921
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-1996@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Binimetinib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391869-2009@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03391869)
DESCRIPTION:Ipilimumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab and Ipilimumab With or Without Local Consolidation Therapy in Treati
 ng Patients With Stage IV Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03391869
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180734-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05180734)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: PD1 Combined With Chemotherapy f
 or Adjuvant Treatment of Gastric Cancer\nEstimated primary completion: 31 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5180734
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-2219@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Encorafenib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Encorafenib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163326-5938@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06163326)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 52-Week Study to Le
 arn About the Safety and Effects of Ritlecitinib in Participants With Nons
 egmental Vitiligo\nEstimated primary completion: 31 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06163326
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03533582-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT03533582)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Cisplatin and Combination Chemot
 herapy in Treating Children and Young Adults With Hepatoblastoma or Liver 
 Cancer After Surgery\nEstimated primary completion: 31 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03533582
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844799-1951@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HS-20137: Phase 3 readout est. (NCT06844799)
DESCRIPTION:HS-20137\, phase 3\, Psoriasis.\nStudy: A Study of HS-20137 in 
 Participants with Moderate-to-severe Plaque Psoriasis\nEstimated primary c
 ompletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/hs-20137#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06844799
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06361238-116@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Liraglutide (Victoza): Phase 3 readout est. (NCT06361238)
DESCRIPTION:Liraglutide (Victoza)\, phase 3.\nStudy: Liraglutide in Prevent
 ing Delirium in Diabetic Elderly After Cardiac Surgery\nEstimated primary 
 completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/liraglutide-victoza#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06361238
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297290-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07297290)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Effect of Metformin U
 se on Weight Loss in Obese\, Non-diabetic People (MOWRI)\nEstimated primar
 y completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07297290
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391319-1220@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Neovasculgen: Phase 3 readout est. (NCT07391319)
DESCRIPTION:Neovasculgen\, phase 3.\nStudy: The Prospective\, Double-blind\
 , Multicenter\, Placebo-controlled\, Randomized\, Comparative Clinical Tri
 al\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/neovasculgen#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07391319
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05794971-2058@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Regorafenib: Phase 3 readout est. (NCT05794971)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: Regorafenib 
 Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Me
 tastases\nEstimated primary completion: 31 March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05794971
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640361-2925@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06640361)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 SDH-deficient GIST.\nEstimated primary completion: 31 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06640361
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-3123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Clinical S
 tudy Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus P
 omalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma P
 atients\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-3173@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sanritatug: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Sanritatug\, phase 3\, Multiple Myeloma.\nStudy: A Clinical Stu
 dy Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pom
 alidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Pat
 ients\nEstimated primary completion: 31 March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/sanritatug#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654296-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07654296)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Assessing Suzetrigine
  for Pain Reduction Following Ureteroscopic Surgery\nEstimated primary com
 pletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07654296
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Clinical Study Comparing SG3
 01 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and De
 xamethasone in Relapsed or Refractory Multiple Myeloma Patients\nEstimated
  primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506955-2756@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Futibatinib (Lytgobi): Phase 2/3 readout est. (NCT06506955)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2/3.\nStudy: Futibatinib in Patie
 nts Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Com
 bination Therapy.\nEstimated primary completion: April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06506955
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04057898-8762@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibudilast: Phase 2/3 readout est. (NCT04057898)
DESCRIPTION:Ibudilast\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: 
 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label E
 xtension for 6 Months in Patients With ALS\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibudilast
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040
 57898
URL:https://assetmemo.bio/drug/ibudilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506955-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 2/3 readout est. (NCT06506955)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2/3.\nStudy: Futibatinib in Pati
 ents Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Co
 mbination Therapy.\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06506955
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504198-5401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rosuvastatin: Phase 2/3 readout est. (NCT07504198)
DESCRIPTION:Rosuvastatin\, phase 2/3.\nStudy: Neuroprotection of Memantine 
 and Rosuvastatin\nEstimated primary completion: April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07504198
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333041-7557@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cannabidiol (Epidiolex): Phase 2/3 readout est. (NCT06333041)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2/3.\nStudy: Study of Cannabidi
 ol in Sanfilippo Syndrome\nEstimated primary completion: April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06333041
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279364-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06279364)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of SKB264 Versus Investigator's Choice Chemotherapy in Patients With U
 nresectable Recurrent or Metastatic Triple-Negative Breast Cancer\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06279364
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05445778)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Mirvetuximab So
 ravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-
 sensitive Epithelial Ovarian\, Fallopian Tube\, or Peritoneal Cancer\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02750319-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT02750319)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Amiodarone and N-Acetylcyst
 eine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic
  Surgery\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT02750319
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04540692-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT04540692)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Evaluation of Sequencing of Anthracyclines and Taxanes for L
 ocally Advanced HER2-negative Breast Cancer\nEstimated primary completion:
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxe
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 540692
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06334133-10930@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:cadisegliatin: Phase 3 readout est. (NCT06334133)
DESCRIPTION:cadisegliatin\, phase 3\, Type 1 Diabetes.\nStudy: Cadisegliati
 n as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes\nE
 stimated primary completion: April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cadisegliatin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06334133
URL:https://assetmemo.bio/drug/cadisegliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-11140@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 3 readout est. (NCT05445
 778)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 3\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as 
 Maintenance in Platinum-sensitive Epithelial Ovarian\, Fallopian Tube\, or
  Peritoneal Cancer\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712030-528@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Entresto (Sacubitril/valsartan): Phase 3 readout est. (NCT06712030)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 3\, Heart Failure.\nStu
 dy: Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin 
 Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacubitril-valsartan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06712030
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565701-874@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Vafseo (Vadadustat): Phase 3 readout est. (NCT07565701)
DESCRIPTION:Vafseo (Vadadustat)\, phase 3\, Chronic Kidney Disease.\nStudy:
  Safety and Efficacy of a Phased Transition From Epogen to Three Times Wee
 kly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-C
 enter Hemodialysis\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vadadustat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07565701
URL:https://assetmemo.bio/drug/vadadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05174052-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0517405
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Dapagliflo
 zin in Patients With Atrial Fibrillation (DAPA-AF)\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 apagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05174052
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667142-819@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05667142)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: A Study to Evaluate X
 EN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/azetukalner#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05667142
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07386743-1376@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GS101: Phase 3 readout est. (NCT07386743)
DESCRIPTION:GS101\, phase 3\, Atopic Dermatitis.\nStudy: A Phase III Study 
 of GS101 Injection to Dupixent®\nEstimated primary completion: April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gs101#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07386743
URL:https://assetmemo.bio/drug/gs101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366464-1724@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pitolisant (Wakix): Phase 3 readout est. (NCT06366464)
DESCRIPTION:Pitolisant (Wakix)\, phase 3\, Prader-Willi Syndrome.\nStudy: A
  Study of Pitolisant in Patients With Prader-Willi Syndrome\nEstimated pri
 mary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pitolisant-wakix#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06366464
URL:https://assetmemo.bio/drug/pitolisant-wakix#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221734-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07221734)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Study to Compare Pharma
 cokinetics\, Efficacy\, Safety\, and Immunogenicity of MB11 Versus EU-/US-
 Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or M
 etastatic] Melanoma\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07221734
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05696626-2159@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05696626)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Evaluation of Lasofoxifene Combined With Abemaciclib Compa
 red With Fulvestrant Combined With Abemaciclib in Locally Advanced or Meta
 static ER+/HER2- Breast Cancer With an ESR1 Mutation\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05696626
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patients 
 Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iber
 domide\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patient
 s Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Ib
 erdomide\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3136@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Isatuximab: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patients 
 Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iber
 domide\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3209@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT05558319)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: NDM
 M Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs.
  Isa-V-Iberdomide\nEstimated primary completion: April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05545384-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05545384)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Immediate Versus Delayed
  Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associate
 d Acute Demyelinating Syndromes in Children: a Randomized Controlled Clini
 cal Trial\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05545384
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990399-5235@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Tabirafusp alfa: Phase 3 readout est. (NCT06990399)
DESCRIPTION:Tabirafusp alfa\, phase 3.\nStudy: A Phase 3 Study to Evaluate 
 the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macul
 ar Edema Secondary to Inflammation (MESI) - PEAK\nEstimated primary comple
 tion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tab
 irafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06990399
URL:https://assetmemo.bio/drug/tabirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818266-6083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0681826
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Efficacy a
 nd Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients Wi
 th Sickle Cell Disease\nEstimated primary completion: April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06818266
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03295981-6494@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zoledronic acid: Phase 3 readout est. (NCT03295981)
DESCRIPTION:Zoledronic acid\, phase 3.\nStudy: Local Bisphosphonate Effect 
 on Recurrence Rate in Extremity Giant Cell Tumor of Bone\nEstimated primar
 y completion: April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zoledronic-acid#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03295981
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: NDMM Patients Candidates for A
 SCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide\nEstimate
 d primary completion: April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462770-8988@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Clemizole (EPX-100): Phase 3 readout est. (NCT04462770)
DESCRIPTION:Clemizole (EPX-100)\, phase 3\, Epilepsy.\nStudy: A Study of EP
 X-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/clemizole-epx-100#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04462770
URL:https://assetmemo.bio/drug/clemizole-epx-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537257-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07537257)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: VEN+ID
 AC vs IDAC in AML\nEstimated primary completion: 1 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07537257
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049952-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT07049952)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: BabySTrong II taVNS Feedi
 ng Trial\nEstimated primary completion: 1 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07049952
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01953588-8888@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Anastrozole: Phase 3 readout est. (NCT01953588)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Fulvestrant and/or Anastrozole i
 n Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergo
 ing Surgery\nEstimated primary completion: 1 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01953588
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03574571-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03574571)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: A Stu
 dy to Test Radium-223 With Docetaxel in Patients With Prostate Cancer\nEst
 imated primary completion: 1 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03574571
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01953588-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT01953588)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, Breast Cancer.\nStudy: Fulve
 strant and/or Anastrozole in Treating Postmenopausal Patients With Stage I
 I-III Breast Cancer Undergoing Surgery\nEstimated primary completion: 1 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT019
 53588
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07433413-6547@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Naltrexone: Phase 3 readout est. (NCT07433413)
DESCRIPTION:Naltrexone\, phase 3.\nStudy: Evaluate the Efficacy and Safety 
 of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07433413
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271240-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05271240)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Repeated Superselective Intraart
 erial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radia
 tion Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM\n
 Estimated primary completion: 1 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05271240
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271240-8999@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Temozolomide: Phase 3 readout est. (NCT05271240)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Repeated Superse
 lective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozo
 lomide and Radiation Compared to Temozolomide and Radiation Alone in Newly
  Diagnosed GBM\nEstimated primary completion: 1 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05271240
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to I
 nvestigate the Clinical Benefit of Isatuximab in Combination With Bortezom
 ib\, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multipl
 e Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT033
 19667
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3136@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Isatuximab: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Investigate the Cli
 nical Benefit of Isatuximab in Combination With Bortezomib\, Lenalidomide 
 and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Elig
 ible for Transplant\nEstimated primary completion: 5 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03319667
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850689-872@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT05850689)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Study of Lumateperone as Adjunctive Therapy in the Treatment of Pat
 ients With Major Depressive Disorder\nEstimated primary completion: 5 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0585
 0689
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-2028@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Olaparib: Phase 3 readout est. (NCT04421963)
DESCRIPTION:Olaparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Roll Over StudY for Patients Who Have Completed a Previous Oncology Stud
 y With Olaparib\nEstimated primary completion: 6 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04421963
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05331183-10838@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT05331183)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (
 ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del\nEs
 timated primary completion: 6 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05331183
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231419-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07231419)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) f
 or Pain Associated With Diabetic Peripheral Neuropathy\nEstimated primary 
 completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07231419
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559331-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07559331)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: High-Dose Dexamethasone Combin
 ed With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo
  in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia\nE
 stimated primary completion: 8 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07559331
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05196035-661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05196035)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Well the Study Treatment Finerenone Wor
 ks\, How Safe it is\, How it Moves Into\, Through\, and Out of the Body\, 
 and the Effects it Has on the Body When Taken With an ACE Inhibitor or Ang
 iotensin Receptor Blocker in Children With Chronic Kidney Disease and Prot
 einuria\nEstimated primary completion: 10 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05196035
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624749-10731@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:VAY736: Phase 3 readout est. (NCT05624749)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Study to Evaluate Ianalumab o
 n Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythema
 tosus (SIRIUS-SLE 2)\nEstimated primary completion: 12 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05624749
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06633900-6547@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Naltrexone: Phase 2/3 readout est. (NCT06633900)
DESCRIPTION:Naltrexone\, phase 2/3.\nStudy: Naltrexone for Overdose Prevent
 ion\nEstimated primary completion: 15 April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06633900
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806592-10645@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06806592)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Test Whet
 her Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Dis
 eases\nEstimated primary completion: 15 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06806592
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364904-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06364904)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Clinical Trail to Determine t
 he Safety and Efficacy of the Combination of Tislelizumab With Cisplatin a
 nd Gemcitabine\, With or Without Trilaciclib for Patients With Untreated U
 nresectable and Metastatic Urothelial Carcinoma.\nEstimated primary comple
 tion: 15 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06364904
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630765
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With Heart Failure and Impaired Kidney Function\nEstimated primary comp
 letion: 16 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06307652
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107945-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07107945)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps 
 Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)\
 nEstimated primary completion: 16 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07107945
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-594@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Balcinrenone: Phase 3 readout est. (NCT06307652)
DESCRIPTION:Balcinrenone\, phase 3\, Heart Failure.\nStudy: Study to Evalua
 te the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure
  and Impaired Kidney Function\nEstimated primary completion: 16 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/balcinrenone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06307652
URL:https://assetmemo.bio/drug/balcinrenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168161-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07168161)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: BDB-001 Phase III Trial 
 in ANCA-Associated Vasculitis\nEstimated primary completion: 16 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07168161
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839771-2867@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Idhifa (Enasidenib): Phase 3 readout est. (NCT03839771)
DESCRIPTION:Idhifa (Enasidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy
  and Consolidation Therapy\, Followed by Maintenance Therapy in Patients W
 ith Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2\,
  With an IDH1 or IDH2 Mutation\, Respectively\, Eligible for Intensive Che
 motherapy\nEstimated primary completion: 17 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03839771
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839771-2899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT03839771)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : A Study of Ivosidenib or Enasidenib in Combination With Induction Therap
 y and Consolidation Therapy\, Followed by Maintenance Therapy in Patients 
 With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2\
 , With an IDH1 or IDH2 Mutation\, Respectively\, Eligible for Intensive Ch
 emotherapy\nEstimated primary completion: 17 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03839771
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427395-1111@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270418
DTEND;VALUE=DATE:20270419
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT06427395)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Open-Label Extension Study of Saroglitazar Magnesium in Particip
 ants With Primary Biliary Cholangitis\nEstimated primary completion: 18 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitaza
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 427395
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700343-7468@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270419
DTEND;VALUE=DATE:20270420
SUMMARY:ABP 692: Phase 3 readout est. (NCT06700343)
DESCRIPTION:ABP 692\, phase 3\, Multiple Sclerosis.\nStudy: Comparison Betw
 een ABP 692 and Ocrevus® (Ocrelizumab)\nEstimated primary completion: 19 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abp-692#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06700
 343
URL:https://assetmemo.bio/drug/abp-692#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05774951-2423@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05774951)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years
  of Standard Adjuvant Endocrine Therapy\nEstimated primary completion: 20 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camizestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05774951
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509645-6083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0750964
 5)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Efficacy a
 nd Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular T
 reatment in Patients With Acute Posterior Circulation Large Vessel Occlusi
 on Stroke\nEstimated primary completion: 20 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07509645
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06028737-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06028737)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Gastric Cancer.\nStudy: Tota
 l Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesop
 hageal Junction Cancer\nEstimated primary completion: 25 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06028737
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526182-1423@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06526182)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-t
 o-Severe Atopic Dermatitis\nEstimated primary completion: 25 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06526182
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731075-335@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:ORMD-0801: Phase 3 readout est. (NCT06731075)
DESCRIPTION:ORMD-0801\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study 
 to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 D
 iabetes Mellitus.\nEstimated primary completion: 25 April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ormd-0801#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06731075
URL:https://assetmemo.bio/drug/ormd-0801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987695-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT069876
 95)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in J
 apan Who Have Obesity Disease\nEstimated primary completion: 27 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06987695
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238622-10645@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06238622)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Idiopathic Pulmonary Fibros
 is.\nStudy: A Follow-up Study to Test Long-term Treatment With Nerandomila
 st in People With Pulmonary Fibrosis Who Took Part in a Previous Study Wit
 h Nerandomilast\nEstimated primary completion: 28 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06238622
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943950-1927@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:SYHX1901: Phase 3 readout est. (NCT06943950)
DESCRIPTION:SYHX1901\, phase 3\, Psoriasis.\nStudy: A Phase III Study of SY
 HX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis\nEs
 timated primary completion: 28 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/syhx1901#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06943950
URL:https://assetmemo.bio/drug/syhx1901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810998-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07810
 998)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3.\nStudy: Efficacy
  of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome\nEstimated
  primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07810998
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156786-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT07156786)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: N-Acetylcysteine Roles in
  Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecu
 le-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemoth
 erapy: A Randomized Placebo-Controlled Trial\nEstimated primary completion
 : 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-ac
 etylcysteine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07156786
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064486-200@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BGM0504: Phase 3 readout est. (NCT07064486)
DESCRIPTION:BGM0504\, phase 3\, Type 2 Diabetes.\nStudy: A Study of BGM0504
  in Participants With Type 2 Diabetes in Indonesia\nEstimated primary comp
 letion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bgm0504#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07064486
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517758-887@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06517758)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Generalized Myasthenia Gravis.
 \nStudy: A Phase III Study to Investigate Efficacy\, Safety and Tolerabili
 ty of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years 
 With gMG.\nEstimated primary completion: 30 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06517758
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)\, 
 With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previo
 usly Untreated CLL\nEstimated primary completion: 30 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)\
 , With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Prev
 iously Untreated CLL\nEstimated primary completion: 30 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-3339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)
 \, With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Pre
 viously Untreated CLL\nEstimated primary completion: 30 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004075-7648@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Luvometinib: Phase 3 readout est. (NCT07004075)
DESCRIPTION:Luvometinib\, phase 3\, Glioma.\nStudy: FCN-159 Monotherapy Ver
 sus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Pa
 tients With BRAF Alteration\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07004075
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282249-9842@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:TVAX-008: Phase 3 readout est. (NCT07282249)
DESCRIPTION:TVAX-008\, phase 3\, Chronic Hepatitis B.\nStudy: Clinical Tria
 l to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatme
 nt of Chronic Hepatitis B\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tvax-008#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07282249
URL:https://assetmemo.bio/drug/tvax-008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586802-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05586802)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Sex Steroids Balance f
 or Metabolic and Reproductive Health in Klinefelter Syndrome\nEstimated pr
 imary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586802
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038356-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07038356)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: Ef
 fects of Continued Administration of Empagliflozin in Patients With Heart 
 Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensat
 ed Heart Failure\nEstimated primary completion: 30 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07038356
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179226-591@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05179226)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Iron De
 ficiency Anemia.\nStudy: Multi-center Trial of Ferric Derisomaltose in Chi
 ldren 0 to <18 Years of Age With Iron Deficiency Anemia\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ferric-derisomaltose#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05179226
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06102395)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Evaluating the Efficacy and S
 afety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treat
 ment of Local Advanced (LA) HNSCC\nEstimated primary completion: 30 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0610
 2395
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06102395)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Evaluating the Efficacy and Safety of Pembrolizumab Plus Standar
 d Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC\n
 Estimated primary completion: 30 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06102395
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515079-4969@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BAT5906: Phase 3 readout est. (NCT07515079)
DESCRIPTION:BAT5906\, phase 3.\nStudy: Efficacy Evaluation Study of BAT5906
  and Lucentis® in Patients With Diabetic Macular Edema\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bat5906#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07515079
URL:https://assetmemo.bio/drug/bat5906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586802-8888@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05586802)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Sex Steroids Balance for Metabol
 ic and Reproductive Health in Klinefelter Syndrome\nEstimated primary comp
 letion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/anastrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05586802
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06102395)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Evaluating the Efficacy and Safety of Pembrolizumab Plus 
 Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) 
 HNSCC\nEstimated primary completion: 30 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06102395
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804811-11030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06804811)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to <
  12 Years Old) With Nonsegmental Vitiligo\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolit
 inib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06804811
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902805-9542@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Botox (onabotulinumtoxinA): Phase 2/3 readout est. (NCT06902805)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2/3.\nStudy: Efficacy of Two
  Ultrasound-guided Intra-articular Injections of Botox® Combined With Cus
 tom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis.\nEstimat
 ed primary completion: May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06902805
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076407-819@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Azetukalner: Phase 3 readout est. (NCT07076407)
DESCRIPTION:Azetukalner\, phase 3\, Major Depressive Disorder.\nStudy: A Ra
 ndomized Study of Azetukalner Versus Placebo in Major Depressive Disorder 
 (X-NOVA3)\nEstimated primary completion: May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/azetukalner#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07076407
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616532-1990@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06616532)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: PM8002 in
  Combination With Paclitaxel Compared With Chemotherapy as Second-line Tre
 atment in Small Cell Lung Cancer\nEstimated primary completion: May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06616532
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670196-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06670196)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Osimertinib Versus Osimerti
 nib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations\, L
 ocally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06670196
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293185-10297@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lovotibeglogene autotemcel (Lyfgenia): Phase 3 readout est. (NCT042
 93185)
DESCRIPTION:Lovotibeglogene autotemcel (Lyfgenia)\, phase 3\, Sickle Cell D
 isease.\nStudy: A Study Evaluating Gene Therapy With BB305 Lentiviral Vect
 or in Sickle Cell Disease\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lovotibeglogene-autotemcel-l
 yfgenia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04293185
URL:https://assetmemo.bio/drug/lovotibeglogene-autotemcel-lyfgenia#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884891-1467@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:QL2108: Phase 3 readout est. (NCT06884891)
DESCRIPTION:QL2108\, phase 3\, Atopic Dermatitis.\nStudy: A Phase Ⅲ Compa
 rative Study of QL2108 to Dupixent®\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ql2108#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06884891
URL:https://assetmemo.bio/drug/ql2108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660693-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06660693)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: C
 omparison of Medical RESCUE Strategies for Patients With Steroid-refractor
 y Acute Severe Ulcerative Colitis\nEstimated primary completion: May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06660693
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613307-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07613307)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who
  Observe Ramadan Fasting\nEstimated primary completion: May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07613307
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338995-1423@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06338995)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3.\nStudy: A Study of Lebrikizum
 ab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyp
 s Treated With Intranasal Corticosteroids (CONTRAST-NP)\nEstimated primary
  completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lebrikizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06338995
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928389-2023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06928389)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Can
 cer\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06928389
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957886-2282@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT06957886)
DESCRIPTION:Trastuzumab brengitecan\, phase 3.\nStudy: A Study of BL-M07D1 
 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Rec
 urrent/Metastatic Breast Cancer\nEstimated primary completion: May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 957886
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429632-2980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:mocravimod: Phase 3 readout est. (NCT05429632)
DESCRIPTION:mocravimod\, phase 3\, Acute Myeloid Leukemia.\nStudy: Mocravim
 od as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo
 -HCT\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mocravimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05429632
URL:https://assetmemo.bio/drug/mocravimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05834855-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05834855)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Non-inferiority Study of
  Rituximab Compared to Ocrelizumab in Relapsing MS\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05834855
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136728-7078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 3 readout est. (NCT06136728)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 3\, Multiple Sclerosis.\n
 Study: Dalfampridine Combined With Physical Therapy for Mobility Impairmen
 t in Multiple Sclerosis\nEstimated primary completion: May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06136728
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06259006-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06259006)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: TREAT-SC: Early\, Short Course
  Oral Dexamethasone for the Treatment of Sydenham Chorea in Children\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06259006
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828354-9096@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06828354)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: A Stu
 dy of SHR-A1811 in Subjects With Ovarian Cancer\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06828354
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125302-10391@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05125302)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study to Ass
 ess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the
  Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05125302
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455383-10854@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07455383)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07455383
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502443-10854@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07502443)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07502443
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0759886
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD 
 With Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07598864)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With 
 Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05715814-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05715814)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis\nE
 stimated primary completion: 1 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05715814
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738616-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT05738616)
DESCRIPTION:Camrelizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Lenv
 atinib Combined With TACE and Camrelizumab in Conversion Resection for Adv
 anced Hepatocellular Carcinoma (LEN-TAC Study)\nEstimated primary completi
 on: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camre
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05738616
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807268-1302@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270502
DTEND;VALUE=DATE:20270503
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT06807268)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3.\nStudy: A Study of the Medicin
 e Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moder
 ate-to-Severe Eczema\nEstimated primary completion: 2 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/abrocitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06807268
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2164@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trast
 uzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-B
 reast09)\nEstimated primary completion: 3 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trastuzumab and P
 ertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)\nEs
 timated primary completion: 3 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894239-2545@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Itovebi (Inavolisib): Phase 3 readout est. (NCT05894239)
DESCRIPTION:Itovebi (Inavolisib)\, phase 3\, Breast Cancer.\nStudy: A Study
  to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phe
 sgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-
 Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer\nEstima
 ted primary completion: 3 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/inavolisib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05894239
URL:https://assetmemo.bio/drug/inavolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by P
 embrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Can
 cer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion: 5 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0438
 0636
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-2028@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Olaparib: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Study of Pembrolizumab With Concurr
 ent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olapa
 rib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-0
 12)\nEstimated primary completion: 5 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04380636
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04380636)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followe
 d by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lu
 ng Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion:
  5 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrex
 ed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4380636
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141473-7194@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141473)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms o
 f Multiple Sclerosis\nEstimated primary completion: 6 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06141473
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931028-183@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:mazdutide: Phase 3 readout est. (NCT06931028)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2\nEstimated p
 rimary completion: 7 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06931028
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023706-8745@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270508
DTEND;VALUE=DATE:20270509
SUMMARY:Capsaicin (Qutenza): Phase 3 readout est. (NCT06023706)
DESCRIPTION:Capsaicin (Qutenza)\, phase 3.\nStudy: Study Evaluating the Ana
 lgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.\nEstimate
 d primary completion: 8 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capsaicin-qutenza#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06023706
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030428-1034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05030428)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study of Inclisiran to Prevent Cardiovascular (CV) Events
  in Participants With Established Cardiovascular Disease\nEstimated primar
 y completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05030428
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06074588-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06074588)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previous
 ly Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (
 NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)\nEst
 imated primary completion: 10 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06074588
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220642-120@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220642)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity Following Treatment With Cagrilintide\n
 Estimated primary completion: 11 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cagrilintide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07220642
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462143-2698@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:RC148: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:RC148\, phase 2/3.\nStudy: A Phase Ⅱ/Ⅲ Clinical Trial of RC
 148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorec
 tal Cancer\nEstimated primary completion: 12 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07462143
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462143-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:Capecitabine\, phase 2/3\, Colorectal Cancer.\nStudy: A Phase 
 Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unrese
 ctable or Metastatic Colorectal Cancer\nEstimated primary completion: 12 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 62143
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220759-120@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220759)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity and Type 2 Diabetes Following Treatment
  With Cagrilintide\nEstimated primary completion: 12 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220759
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848753-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04848753)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Perioperative Toripalimab (JS001
 ) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Local
 ly Advanced Thoracic Esophageal Squamous Cell Carcinoma\nEstimated primary
  completion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04848753
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: A Phase III Study of Ivonesci
 mab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated 
 primary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-2023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase III Study of Ivonescimab
  + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated pri
 mary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-2833@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ligufalimab: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Ligufalimab\, phase 3.\nStudy: A Phase III Study of Ivonescimab
  + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated pri
 mary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ligufalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/ligufalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07199257-1374@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Telikibart: Phase 3 readout est. (NCT07199257)
DESCRIPTION:Telikibart\, phase 3.\nStudy: A Study of GR1802 Injection in Pa
 tients With Seasonal Allergic Rhinitis.\nEstimated primary completion: 15 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telikibart#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0719
 9257
URL:https://assetmemo.bio/drug/telikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383780-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06383780)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab in Combination With GP or TPC Regimen for the Treatment of Nasoph
 aryngeal Carcinoma With Bone Metastasis.\nEstimated primary completion: 15
  May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6383780
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966232-5880@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Entecavir (Baraclude): Phase 3 readout est. (NCT06966232)
DESCRIPTION:Entecavir (Baraclude)\, phase 3\, Chronic Hepatitis B.\nStudy: 
 Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Can
 cer Who Are Inactive Hepatitis B Carriers\nEstimated primary completion: 1
 5 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/entecavir
 -baraclude#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06966232
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799000-1415@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06799000)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva (RECHARGE 1)\nEstimated primary completion: 17 May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06799000
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213778-11309@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07213778)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After To
 tal Knee Arthroplasty in Adult Participants\nEstimated primary completion:
  17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07213778
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671483-101@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671483)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologi
 c Medicines\nEstimated primary completion: 18 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06671483
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671496-101@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671496)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been 
 Treated With Biologic Medicines\nEstimated primary completion: 18 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zasocitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06671496
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745504-120@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07745504)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study to C
 ompare Two Different Versions of Injectable Cagrilintide and Placebo in Pe
 ople With Excess Body Weight\nEstimated primary completion: 18 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07745504
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624554-11239@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05624554)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Prev
 iously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
 CLL/SLL) Without TP53 Aberrations (MK-1026-008\, BELLWAVE-008)\nEstimated 
 primary completion: 19 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05624554
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03958877-6981@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Plegridy (peginterferon beta-1a): Phase 3 readout est. (NCT03958877
 )
DESCRIPTION:Plegridy (peginterferon beta-1a)\, phase 3\, Multiple Sclerosis
 .\nStudy: A Study to Evaluate the Safety\, Tolerability\, and Efficacy of 
 BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatmen
 t of Relapsing-Remitting Multiple Sclerosis\nEstimated primary completion:
  20 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peginte
 rferon-beta-1a#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03958877
URL:https://assetmemo.bio/drug/peginterferon-beta-1a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185347-7078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 3 readout est. (NCT07185347)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 3.\nStudy: A Randomized\,
  Parallel-arm\, Double Blind\, Placebo-controlled Study to Assess the Effi
 cacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused 
 by a GAA Expansion in the FGF14 Gene\nEstimated primary completion: 21 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fampridine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718534
 7
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05173987-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05173987)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Study of Pembrolizumab (MK-347
 5) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Rec
 urrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
 \nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05173987
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05973773-2070@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Zipalertinib: Phase 3 readout est. (NCT05973773)
DESCRIPTION:Zipalertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RE
 ZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumo
 rs)\nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05973773
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759154-825@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT07759154)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Study to Test the Effects of Centanafadine in Ad
 ults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregula
 tion\nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07759154
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-885@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Paroxysmal Nocturnal Hemogl
 obinuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or
  Eculizumab in Pediatric Participants With PNH Who Have Clinically Signifi
 cant Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-886@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Soliris (Eculizumab)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or Ec
 ulizumab in Pediatric Participants With PNH Who Have Clinically Significan
 t Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/eculizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-5401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholeste
 rolaemia\nEstimated primary completion: 28 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07619118
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-8630@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With 
 Hypercholesterolaemia\nEstimated primary completion: 28 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761911
 8
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230119-202@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270529
DTEND;VALUE=DATE:20270530
SUMMARY:zovaglutide: Phase 3 readout est. (NCT07230119)
DESCRIPTION:zovaglutide\, phase 3\, Obesity.\nStudy: A Study of Zovaglutide
  in Subjects With Overweight or Obesity (HORIZON-1)\nEstimated primary com
 pletion: 29 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zovaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07230119
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752108-101@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07752108)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of Zasocitin
 ib in Adults With Non-pustular Palmoplantar Psoriasis\nEstimated primary c
 ompletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07752108
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391306-1220@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Neovasculgen: Phase 2/3 readout est. (NCT07391306)
DESCRIPTION:Neovasculgen\, phase 2/3.\nStudy: The Study is Being Conducted 
 to Find a New Treatment for Patients Suffering From Interstitial Cystitis 
 Without Hunner's Lesions.\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/neovasculgen#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07391306
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02595944-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT02595944)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab After Surgery and Chemotherapy in Treating Patients With Stage IB-III
 A Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)\nEstimated pri
 mary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02595944
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221072-6494@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zoledronic acid: Phase 3 readout est. (NCT06221072)
DESCRIPTION:Zoledronic acid\, phase 3.\nStudy: A Study to Assess the Preven
 tion of Bone-related Events in Patients With Bone Metastases From Malignan
 t Solid Tumors Treated With JMT103 Compared to Zoledronic Acid\nEstimated 
 primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zoledronic-acid#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06221072
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714746-586@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Corlanor (Ivabradine): Phase 3 readout est. (NCT07714746)
DESCRIPTION:Corlanor (Ivabradine)\, phase 3.\nStudy: Ivabradine in the Acut
 e Management of Cardiogenic Shock\nEstimated primary completion: 31 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ivabradine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07714746
URL:https://assetmemo.bio/drug/ivabradine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05085028-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05085028)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab 
 immuNothErapy for First-line Treatment of Patients With Advanced Non-small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05085028
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05342194-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05342194)
DESCRIPTION:Toripalimab\, phase 3\, Cholangiocarcinoma.\nStudy: Toripalimab
  Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Adv
 anced ICC: a Phase III Study\nEstimated primary completion: 31 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05342194
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935357-3402@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06935357)
DESCRIPTION:Felzartamab\, phase 3\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab Infusions on Adults With Immunoglobuli
 n A Nephropathy (IgAN)\nEstimated primary completion: 31 May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06935357
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628908-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06628908)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine for Pai
 n Associated With Diabetic Peripheral Neuropathy\nEstimated primary comple
 tion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/su
 zetrigine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06628908
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020819-10858@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:tanruprubart: Phase 3 readout est. (NCT07020819)
DESCRIPTION:tanruprubart\, phase 3\, Guillain-Barré Syndrome.\nStudy: An O
 pen Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as 
 ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)\nEst
 imated primary completion: 31 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tanruprubart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07020819
URL:https://assetmemo.bio/drug/tanruprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075537-10788@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Avlayah (Tividenofusp alfa): Phase 2/3 readout est. (NCT06075537)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 2/3\, Mucopolysaccharidosis
  Type II.\nStudy: An Extension Study of the Long-Term Safety\, Tolerabilit
 y\, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopo
 lysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-00
 07\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06075537
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03651206-2052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Niraparib: Phase 2/3 readout est. (NCT03651206)
DESCRIPTION:Niraparib\, phase 2/3.\nStudy: Recurrent Ovarian CarcinoSarcoma
  Anti-pd-1 Niraparib\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03651206
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03651206-2162@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dostarlimab: Phase 2/3 readout est. (NCT03651206)
DESCRIPTION:Dostarlimab\, phase 2/3.\nStudy: Recurrent Ovarian CarcinoSarco
 ma Anti-pd-1 Niraparib\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03651206
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06212336-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT06212336)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: ISTH/ANRS 0409s INTEGRATE La
 ssa Fever Study\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06212336
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232719-118@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:retatrutide: Phase 3 readout est. (NCT07232719)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants With Obesity or Overweight\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/retatrutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232719
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027307-312@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Envlo (Enavogliflozin): Phase 3 readout est. (NCT06027307)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 3.\nStudy: Enavogliflozin Outcom
 e Trial in Functional Tricuspid Regurgitation\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enavogl
 iflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06027307
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185843-1044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05185843)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) A
 dministered to Adults With Familial Chylomicronemia Syndrome (FCS) Previou
 sly Treated With Volanesorsen\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olezarsen#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05185843
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908084-1249@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Human Acellular Vessel (Humacyte): Phase 3 readout est. (NCT0590808
 4)
DESCRIPTION:Human Acellular Vessel (Humacyte)\, phase 3.\nStudy: To Compare
  the Efficacy and Safety of the ATEV With AVF in Female Patients With End-
 Stage Renal Disease Requiring Hemodialysis\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/human-acel
 lular-vessel-humacyte#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05908084
URL:https://assetmemo.bio/drug/human-acellular-vessel-humacyte#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857175-2044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06857175)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Urothelial Carcinoma.\nStud
 y: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in P
 atients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
 \nEstimated primary completion: June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06857175
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05566795-2192@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tovorafenib: Phase 3 readout est. (NCT05566795)
DESCRIPTION:Tovorafenib\, phase 3\, Glioma.\nStudy: DAY101 vs. Standard of 
 Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requirin
 g First-Line Systemic Therapy (LOGGIC/FIREFLY-2)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovo
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05566795
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980054-2207@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT03980054)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: A Study of Evaluating The Effects 
 Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast C
 ancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03980054
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03897127-2901@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vyxeos: Phase 3 readout est. (NCT03897127)
DESCRIPTION:Vyxeos\, phase 3\, Acute Myeloid Leukemia.\nStudy: Study of Sta
 ndard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in
  Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Gene
 tics\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03897127
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03206671-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03206671)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Treatment Protocol of the NHL-B
 FM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Le
 ukemia in Children and Adolescents\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03206671
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03206671-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03206671)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Treatment Protocol of th
 e NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma
  and Leukemia in Children and Adolescents\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03206
 671
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05578976)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC
 ) Epcoritamab Combined With Intravenous and Oral Rituximab\, Cyclophospham
 ide\, Doxorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or
  R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Ly
 mphoma (DLBCL)\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03206671-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03206671)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Treatment Protocol of the NHL-
 BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and L
 eukemia in Children and Adolescents\nEstimated primary completion: June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0320667
 1
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03663725-8999@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Temozolomide: Phase 3 readout est. (NCT03663725)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Treatment Intens
 ification With Temozolomide in Adults With a Glioblastoma\nEstimated prima
 ry completion: June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03663725
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-10986@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05578976)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcori
 tamab Combined With Intravenous and Oral Rituximab\, Cyclophosphamide\, Do
 xorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or R-CHOP 
 in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (
 DLBCL)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274137-248@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:MDR-001: Phase 3 readout est. (NCT07274137)
DESCRIPTION:MDR-001\, phase 3\, Obesity.\nStudy: A Phase III Study to Evalu
 ate the Efficacy and Safety of MDR-001 in Adult Participants With Overweig
 ht or Obesity (MOBILE）\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mdr-001#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07274137
URL:https://assetmemo.bio/drug/mdr-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296445-3116@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Arsenic trioxide (SDK001): Phase 3 readout est. (NCT07296445)
DESCRIPTION:Arsenic trioxide (SDK001)\, phase 3\, Acute Myeloid Leukemia.\n
 Study: A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to 
 Intravenous Arsenic Trioxide in Pharmacokinetics\, Safety\, and Efficacy (
 LATITUDE/SDKARS-301)\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/arsenic-trioxide-sdk001#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07296445
URL:https://assetmemo.bio/drug/arsenic-trioxide-sdk001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554495-16@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT07554495)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: Safety\, Tolerability\
 , Pharmacokinetics\, and Efficacy of Filgotinib for the Treatment of Polya
 rticular-course Juvenile Idiopathic Arthritis in Children and Adolescents\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07554495
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174753-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0617475
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: Dapagliflo
 zin in STEMI\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06174753
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363577-840@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:LB-102 (methylated amisulpride): Phase 3 readout est. (NCT07363577)
DESCRIPTION:LB-102 (methylated amisulpride)\, phase 3\, Schizophrenia.\nStu
 dy: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acut
 e Schizophrenia\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07363577
URL:https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06406205-1793@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lupkynis (Voclosporin): Phase 3 readout est. (NCT06406205)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 3\, Systemic Lupus Erythematosus
 .\nStudy: A Study of QLG1074 Combined With Background Therapy in Subjects 
 With Active Lupus Nephritis\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/voclosporin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06406205
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Sacit
 uzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Ch
 oice in Patients With Triple Negative Breast Cancer Who Have Residual Inva
 sive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 Optim
 ICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05633654
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1992@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice in Patients With Triple Negative Breast Cancer Who Have Resid
 ual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-
 65 OptimICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05633654
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-1996@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Binimetinib\, phase 3.\nStudy: Personalized Medicine for Advanc
 ed Biliary Cancer Patients\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994195-2044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06994195)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in 
 Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU
 -GYN01)\nEstimated primary completion: June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06994195
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Niraparib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Niraparib\, phase 3.\nStudy: Personalized Medicine for Advanced
  Biliary Cancer Patients\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2201@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Zanidatamab\, phase 3.\nStudy: Personalized Medicine for Advanc
 ed Biliary Cancer Patients\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2219@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Encorafenib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Encorafenib\, phase 3.\nStudy: Personalized Medicine for Advanc
 ed Biliary Cancer Patients\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2258@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Neratinib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Neratinib\, phase 3.\nStudy: Personalized Medicine for Advanced
  Biliary Cancer Patients\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262567-2279@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 3 readout est. (NCT07262567)
DESCRIPTION:GFH375\, phase 3.\nStudy: Phase III Study to Compare GFH375 and
  Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Canc
 er\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07262567
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152405-2282@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07152405)
DESCRIPTION:Trastuzumab brengitecan\, phase 3.\nStudy: A Study of BL-M07D1 
 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positiv
 e Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Ade
 nocarcinoma\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07152405
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2756@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT05615818)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3.\nStudy: Personalized Medicine 
 for Advanced Biliary Cancer Patients\nEstimated primary completion: June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytg
 obi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05615818
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05615818)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Personalized Medicine f
 or Advanced Biliary Cancer Patients\nEstimated primary completion: June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540897-10854@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alixorexton: Phase 3 readout est. (NCT07540897)
DESCRIPTION:Alixorexton\, phase 3\, Narcolepsy.\nStudy: A Study to Evaluate
  the Efficacy\, Safety and Tolerability of ALKS 2680 in Adults With Narcol
 epsy Type 1 (Brilliance NT1 - 304)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/alixorexton#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07540897
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081997-10863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Yorvipath (palopegteriparatide): Phase 3 readout est. (NCT07081997)
DESCRIPTION:Yorvipath (palopegteriparatide)\, phase 3\, Hypoparathyroidism.
 \nStudy: A Phase 3 Randomized Clinical Trial to Investigate the Safety and
  Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult
  Participants With Hypoparathyroidism\nEstimated primary completion: June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/palopegteripara
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07081997
URL:https://assetmemo.bio/drug/palopegteriparatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06431776-10924@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:molgramostim: Phase 3 readout est. (NCT06431776)
DESCRIPTION:molgramostim\, phase 3\, Autoimmune Pulmonary Alveolar Proteino
 sis.\nStudy: Inhaled Molgramostim in Pediatric Participants With Autoimmun
 e Pulmonary Alveolar Proteinosis (aPAP).\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/molgramostim
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 31776
URL:https://assetmemo.bio/drug/molgramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951971-7619@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT06951971)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3.\nStudy: Dose-modified Emapalu
 mab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
 \nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06951971
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366801-96@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Orencia (Abatacept): Phase 2/3 readout est. (NCT07366801)
DESCRIPTION:Orencia (Abatacept)\, phase 2/3.\nStudy: Co-infusion of Treg-en
 riched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft t
 o Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Ce
 ll Transplantation Among Children With Hematologic Malignancies\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07366801
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366801-7619@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT07366801)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3\, Graft-versus-Host Disease.\n
 Study: Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted He
 matopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After All
 ogeneic Hematopoietic Stem Cell Transplantation Among Children With Hemato
 logic Malignancies\nEstimated primary completion: 1 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07366801
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02997228-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT02997228)
DESCRIPTION:Atezolizumab\, phase 3\, Colorectal Cancer.\nStudy: Testing the
  Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alon
 e for Metastatic Colon or Rectal Cancer\, the COMMIT Study\nEstimated prim
 ary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT02997228
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02997228-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT02997228)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Testing the 
 Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone
  for Metastatic Colon or Rectal Cancer\, the COMMIT Study\nEstimated prima
 ry completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02997228
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258915-8@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Humira (adalimumab): Phase 3 readout est. (NCT06258915)
DESCRIPTION:Humira (adalimumab)\, phase 3\, Non-Infectious Uveitis.\nStudy:
  Treatment FOr Corticosteroid Dependent UveitiS\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ada
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06258915
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134205-2224@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Becotatug: Phase 3 readout est. (NCT07134205)
DESCRIPTION:Becotatug\, phase 3\, Colorectal Cancer.\nStudy: The Study of J
 MT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Co
 lorectal Cancer\nEstimated primary completion: 1 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07134205
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06266221-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT06266221)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Severe Erythema Multiform
 e - CORTICO\nEstimated primary completion: 1 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06266221
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07056699-291@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Actos (Pioglitazone): Phase 3 readout est. (NCT07056699)
DESCRIPTION:Actos (Pioglitazone)\, phase 3.\nStudy: SGLT2i\, Pioglitazone\,
  and Ketone Production in T1D\nEstimated primary completion: 1 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07056699
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002346-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07002346)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: INVIGORATE: A Study of QL1706 an
 d Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma\nEstimat
 ed primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07002346
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002346-2261@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07002346)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: INVIGORATE: A S
 tudy of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell C
 arcinoma\nEstimated primary completion: 1 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07002346
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712913-4854@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pregabalin: Phase 3 readout est. (NCT07712913)
DESCRIPTION:Pregabalin\, phase 3\, Diabetic Peripheral Neuropathic Pain.\nS
 tudy: Extended-release Pregabalin for the Treatment of Neuropathic Pain in
  Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia\n
 Estimated primary completion: 1 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07712913
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532006-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06532006)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ Cl
 inical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for
  the Treatment of Gastroesophageal Junction and Gastric Cancer\nEstimated 
 primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06532006
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263206-1356@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270602
DTEND;VALUE=DATE:20270603
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT05263206)
DESCRIPTION:Dupixent (dupilumab)\, phase 3.\nStudy: Efficacy and Safety of 
 Subcutaneous Dupilumab for the Treatment of Adult Participants With Chroni
 c Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)\nEstimated primary
  completion: 2 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05263206
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840392-1415@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06840392)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva\nEstimated primary completion: 3 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/remibrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06840392
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05329649-10277@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053296
 49)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Safety and Efficacy of CTX001 in Pediatric Part
 icipants With Severe Sickle Cell Disease (SCD)\nEstimated primary completi
 on: 6 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exag
 amglogene-autotemcel-casgevy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05329649
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793397-824@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:Deupsilocin: Phase 3 readout est. (NCT06793397)
DESCRIPTION:Deupsilocin\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressi
 ve Disorder\nEstimated primary completion: 7 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/deupsilocin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06793397
URL:https://assetmemo.bio/drug/deupsilocin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408935-5@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06408935)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: Trans
 mural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Diseas
 e Patients\nEstimated primary completion: 8 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06408935
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-7@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817251-121@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0781
 7251)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: Research Study on How People With Type 2 Diabetes Tolerate Swit
 ching From Semaglutide to Cagrisema\nEstimated primary completion: 9 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-se
 maglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07817251
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477563-10277@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT054775
 63)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Efficacy and Safety of a Single Dose of CTX001 
 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickl
 e Cell Disease\nEstimated primary completion: 9 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0547756
 3
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07658339-1539@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:HSK39004: Phase 3 readout est. (NCT07658339)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39
 004 Inhalation Suspension in Patients With COPD\nEstimated primary complet
 ion: 11 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hs
 k39004#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07658339
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738276-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07738276)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Evaluation 
 of the Efficacy and Safety of Tirzepatide\, a Dual GLP-1/GIP Agonist\, on 
 Functional Capacity in Reduced Ejection Fraction Heart Failure Patients Wi
 th Obesity\nEstimated primary completion: 11 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07738276
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871409-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078714
 09)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Home Self-administration of Maridebart Cafraglutide With Autoinjector in 
 Adults Living With Obesity or Overweight\nEstimated primary completion: 16
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maridebar
 t-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07871409
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220772-147@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:mibavademab: Phase 3 readout est. (NCT07220772)
DESCRIPTION:mibavademab\, phase 3\, Obesity.\nStudy: A Study Evaluating Mib
 avademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Childr
 en\, Adolescents and Adults\nEstimated primary completion: 18 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/mibavademab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07220772
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860984-7141@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Cymbalta (Duloxetine): Phase 3 readout est. (NCT06860984)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 3.\nStudy: Evaluating the Safety 
 and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde
  Cholangiopancreatography Pancreatitis\nEstimated primary completion: 20 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0686
 0984
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06690398-872@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06690398)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder in Pediatric Patients\nEstimated primary completion: 21 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06690
 398
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706674-872@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06706674)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder (ASD) in Pediatric Patients\nEstimated primary completion: 2
 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumatepe
 rone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06706674
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-1507@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06473779)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Open-label S
 tudy to Assess Reduction of Background Asthma Medication While Sustaining 
 Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yr
 s With Severe Asthma.\nEstimated primary completion: 25 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06473779
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-3562@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0647377
 9)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: O
 pen-label Study to Assess Reduction of Background Asthma Medication While 
 Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patie
 nts 12-80yrs With Severe Asthma.\nEstimated primary completion: 25 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/albuterol-budeson
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06473779
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140913-712@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 140913)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Evaluate the Efficacy and Safety of Adjunctive Ka
 rXT for the Treatment of Mania\, With or Without Mixed Features\, in Parti
 cipants With Bipolar-I Disorder Taking Lithium\, Valproate\, or Lamotrigin
 e\nEstimated primary completion: 28 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07140913
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Atezolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies
  as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096663-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT05096663)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] P
 lus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell
  Lung Cancer (A Lung-MAP Treatment Trial)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05096663
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Bevacizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies 
 as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2016@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alecensa (Alectinib): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Alecensa (Alectinib)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Multiple Targeted T
 herapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096663-2051@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2/3 readout est. (NCT
 05096663)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2/3\, Non-Small 
 Cell Lung Cancer.\nStudy: Testing the Use of Combination Immunotherapy Tre
 atment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment fo
 r Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05096663
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2167@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cobimetinib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Cobimetinib\, phase 2/3.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Multiple Targeted Therapies as Treatments for Participant
 s With Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cobimeti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03178552
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2217@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Divarasib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Divarasib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as
  Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2220@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Entrectinib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Entrectinib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies 
 as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Th
 erapies as Treatments for Participants With Non-Small Cell Lung Cancer (NS
 CLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2273@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vemurafenib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Vemurafenib\, phase 2/3.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Multiple Targeted Therapies as Treatments for Participant
 s With Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vemurafe
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03178552
URL:https://assetmemo.bio/drug/vemurafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786768-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2/3 readout est. (NCT05786768)
DESCRIPTION:Obinutuzumab\, phase 2/3.\nStudy: Efficacy and Safety of Obinut
 uzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relaps
 ing Nephrotic Syndrome\nEstimated primary completion: 30 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05786768
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Multiple Targeted T
 herapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203118-9804@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 2/3 readout est. (NCT0720311
 8)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 2/3\, Chronic Hepatitis
  B.\nStudy: A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chron
 ic Hepatitis B\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07203118
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321860-10645@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nerandomilast (Jascayd): Phase 2/3 readout est. (NCT07321860)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 2/3.\nStudy: This Study Evaluat
 es the Safety\, Target Engagement\, and Preliminary Efficacy of Galunisert
 ib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) i
 n GREM2-positive ALS\, a Biomarker-defined Subgroup Hypothesized to Reflec
 t Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07321860
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277582-650@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:THRV-1268: Phase 2/3 readout est. (NCT07277582)
DESCRIPTION:THRV-1268\, phase 2/3.\nStudy: Evaluation of the Efficacy and S
 afety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) an
 d Type 3 (LQTS3)\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/thrv-1268#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07277582
URL:https://assetmemo.bio/drug/thrv-1268#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413368-10897@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Livmarli (maralixibat): Phase 2/3 readout est. (NCT06413368)
DESCRIPTION:Livmarli (maralixibat)\, phase 2/3.\nStudy: Maralixibat in Pati
 ents With Cystic Fibrosis and Constipation\nEstimated primary completion: 
 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maralix
 ibat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06413368
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878769-1435@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:astegolimab: Phase 3 readout est. (NCT05878769)
DESCRIPTION:astegolimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: A Study to Evaluate the Long-Term Safety of Astegolimab in Partici
 pants With Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/astegolimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05878769
URL:https://assetmemo.bio/drug/astegolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04550260-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04550260)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Study of Durvalumab Versus Placeb
 o in Combination With Definitive Chemoradiation Therapy in Patient With ES
 CC\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04550260
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05112965)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: An Extension Study in Participa
 nts Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Spo
 nsored Atezolizumab Study (IMbrella C)\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 112965
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04759586-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04759586)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Nivolumab in Combination With Chem
 o-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B
 -Cell Lymphoma\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04759586
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05112965)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: An Extension Study in Participan
 ts Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Spon
 sored Atezolizumab Study (IMbrella C)\nEstimated primary completion: 30 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0511
 2965
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03967977-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT03967977)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Study of Tislelizumab in Combin
 ation With Chemotherapy Compared to Chemotherapy Alone for Participants Wi
 th Urothelial Carcinoma\nEstimated primary completion: 30 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03967977
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05112965)
DESCRIPTION:Alimta (pemetrexed)\, phase 3.\nStudy: An Extension Study in Pa
 rticipants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche 
 Ltd Sponsored Atezolizumab Study (IMbrella C)\nEstimated primary completio
 n: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05112965
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04759586-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04759586)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Nivolumab in Combination
  With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Med
 iastinal B-Cell Lymphoma\nEstimated primary completion: 30 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04759586
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068516-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07068516)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Perioperative 
 Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positiv
 e Gastric/GEJ Cancer\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07068516
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152600-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07152600)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Adaptive RCT of Corticost
 eroids for Severe Adenovirus Pneumonia in Adults\nEstimated primary comple
 tion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethylprednisolone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07152600
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052981-5453@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07052981)
DESCRIPTION:Telitacicept\, phase 3\, IgA Nephropathy.\nStudy: Clinical Stud
 y on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric
  IgA Nephropathy or IgA Vasculitis Nephritis\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07052981
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623915-6854@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nexletol (Bempedoic acid): Phase 3 readout est. (NCT07623915)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Clinical Study to Evaluate the Efficacy and Safet
 y of Bempedoic Acid\nEstimated primary completion: 30 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07623915
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155265-9526@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Remimazolam: Phase 3 readout est. (NCT07155265)
DESCRIPTION:Remimazolam\, phase 3.\nStudy: REMIMID-ICU: Remimazolam vs Mida
 zolam for Deep Sedation in Hemodynamically Unstable\, Mechanically Ventila
 ted Adults\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/remimazolam#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07155265
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150975-190@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07150975)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Phase III Clinical St
 udy Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (
 Wegovy®) in Adult Obese or Overweight Subjects\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 fanglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07150975
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216927-551@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:INOmax (nitric oxide): Phase 3 readout est. (NCT04216927)
DESCRIPTION:INOmax (nitric oxide)\, phase 3.\nStudy: NO During CPB in Neona
 tes to Reduce Risk of AKI\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04216927
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07496372-609@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HiCM-188 (allogeneic iPSC-cardiomyocytes): Phase 3 readout est. (NC
 T07496372)
DESCRIPTION:HiCM-188 (allogeneic iPSC-cardiomyocytes)\, phase 3\, Heart Fai
 lure.\nStudy: A Pivotal Clinical Trial of Human Induced Pluripotent Stem C
 ell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advan
 ced Heart Failure(NYHA III-IV)\nEstimated primary completion: 30 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hicm-188-allogeneic
 -ipsc-cardiomyocytes#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07496372
URL:https://assetmemo.bio/drug/hicm-188-allogeneic-ipsc-cardiomyocytes#upco
 ming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969329-878@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03969329)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Secondary Hyperparathyroid
 ism.\nStudy: A Phase 3 Study of Etelcalcetide in Children With Secondary H
 yperparathyroidism Receiving Hemodialysis\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etelcalc
 etide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03969329
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05920356-1987@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sotorasib: Phase 3 readout est. (NCT05920356)
DESCRIPTION:Sotorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab 
 Platinum Doublet Combination as a Front-Line Therapy in Participants With 
 Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers 
 (CodeBreaK 202)\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05920356
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235203-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06235203)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Neoad
 juvant vs Adjuvant in Locally Advanced Recurrent NPC\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06235203
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423911-2925@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06423911)
DESCRIPTION:Olverembatinib\, phase 3\, Chronic Myeloid Leukemia.\nStudy: St
 udy of Olverembatinib (HQP1351) in Patients With CML-CP\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06423911
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06853535-6104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT06853535)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Acute Ischemic Stroke.\nStudy
 : Precision Antiplatelet Therapy Guided by Platelet Aggregation Function i
 n Patients With Acute Ischemic STROKE\nEstimated primary completion: 30 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ticagrelor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06853
 535
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235203-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06235203)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Neoadjuvant vs Adjuvant in Local
 ly Advanced Recurrent NPC\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06235203
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123494-9096@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06123494)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Gastric Cancer.\nStudy: SHR-A
 1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal J
 unction Adenocarcinoma After Progression on or After First-line Anti-HER2 
 Therapy-containing Regimen\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06123
 494
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191145-10396@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT07191145)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3.\nStudy: Eary Infusion of Eptine
 zumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07191145
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683806-11037@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Roflumilast (Zoryve foam): Phase 3 readout est. (NCT07683806)
DESCRIPTION:Roflumilast (Zoryve foam)\, phase 3\, Seborrheic Dermatitis.\nS
 tudy: Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants W
 ith Seborrheic Dermatitis\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/roflumilast-zoryve-foam#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0768
 3806
URL:https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07066098-11359@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:TAK-921: Phase 3 readout est. (NCT07066098)
DESCRIPTION:TAK-921\, phase 3.\nStudy: A Multicenter Study of IBI343 Monoth
 erapy Versus Placebo in Subjects With Previously Treated\, Claudin (CLDN) 
 18.2-positive\, Pancreatic Cancer(G-HOPE-002)\nEstimated primary completio
 n: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tak-
 921#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07066098
URL:https://assetmemo.bio/drug/tak-921#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04297683-7528@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Fosigotifator: Phase 2/3 readout est. (NCT04297683)
DESCRIPTION:Fosigotifator\, phase 2/3.\nStudy: HEALEY ALS Platform Trial - 
 Master Protocol\nEstimated primary completion: July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/fosigotifator#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04297683
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684326-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07684
 326)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3.\nStudy: "Explori
 ng the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Live
 r Disease Patients- A Randomized Controlled Trial"\nEstimated primary comp
 letion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 pagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07684326
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04984512-833@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Mitizodone phosphate: Phase 2/3 readout est. (NCT04984512)
DESCRIPTION:Mitizodone phosphate\, phase 2/3\, Major Depressive Disorder.\n
 Study: The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Trea
 tment of Patient With Major Depressive Disorder\nEstimated primary complet
 ion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitiz
 odone-phosphate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04984512
URL:https://assetmemo.bio/drug/mitizodone-phosphate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701581-7078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2/3 readout est. (NCT03701581)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2/3.\nStudy: 4-aminopyrid
 ine Treatment for Nerve Injury\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03701581
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006068-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03006068)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-
 494) in Participants With Ulcerative Colitis (UC)\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upa
 dacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03006068
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374291-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0537429
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapaglifloz
 in on Renal and Cardiovascular Outcomes in Patients With Severe CKD\nEstim
 ated primary completion: July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05374291
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05809531-907@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT05809531)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: An Open-Label\, Non
 randomized\, Multicenter Extension Study to Evaluate the Long-term Safety 
 and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Im
 mune-Complex Membranoproliferative Glomerulonephritis\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05809531
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419621-1990@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06419621)
DESCRIPTION:Pumitamig\, phase 3.\nStudy: PM8002 or Placebo Plus Nab-Paclita
 xel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06419621
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04401748-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04401748)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Study Of Venetoclax Tablet With I
 ntravenous or Subcutaneous Azacitidine to Assess Change in Disease Activit
 y In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic S
 yndrome\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04401748
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06325566-10810@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:rexlemestrocel-L: Phase 3 readout est. (NCT06325566)
DESCRIPTION:rexlemestrocel-L\, phase 3\, Chronic Low Back Pain.\nStudy: Eff
 icacy and Safety of Rexlemestrocel-L Combined With HA* in Participants Wit
 h Moderate to Severe Chronic Low Back Pain\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rexlemestr
 ocel-l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06325566
URL:https://assetmemo.bio/drug/rexlemestrocel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04711109-11057@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Denosumab (Xgeva): Phase 3 readout est. (NCT04711109)
DESCRIPTION:Denosumab (Xgeva)\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Studying the Effect of Denosumab on Preventing Breast Cancer in
  Women With a BRCA1 Germline Mutation\nEstimated primary completion: July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-xgeva
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047
 11109
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672237-11313@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nexiguran ziclumeran: Phase 3 readout est. (NCT06672237)
DESCRIPTION:Nexiguran ziclumeran\, phase 3.\nStudy: A Phase 3 Study of NTLA
 -2001 in ATTRv-PN\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06672237
URL:https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336953-2161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07336953)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: A Phase III\, Randomized\, Clini
 cal Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Li
 ne Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (
 WGOG-PAN 006/ICSBR-2)\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07336953
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895512-3168@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HLX15: Phase 3 readout est. (NCT06895512)
DESCRIPTION:HLX15\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evaluate
  the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with
  Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/hlx15#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06895512
URL:https://assetmemo.bio/drug/hlx15#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786624-810@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06786624)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Stud
 y to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatm
 ent in Participants With Major Depressive Disorder (MDD)\nEstimated primar
 y completion: July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osavampator#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06786624
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911112-810@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06911112)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06911112
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963021-810@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06963021)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963021
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803994-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04803994)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: The 
 ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoemboli
 zation (TACE) in Intermediate-stage HepatoCellular Carcinoma\nEstimated pr
 imary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04803994
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071337-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07071337)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SKB264 Versus Investigator's Choice of Chemoth
 erapy in Subjects With Unresectable Locally Advanced\, Relapsed\, or Metas
 tatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07071337
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803994-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04803994)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: The A
 BC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoemboliz
 ation (TACE) in Intermediate-stage HepatoCellular Carcinoma\nEstimated pri
 mary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04803994
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05188313-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05188313)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: TRAstuzumab and Pertuzumab for HE
 R2+ Resectable Oesophageal Cancer\nEstimated primary completion: July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05188313
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362459-2721@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SCTB14: Phase 3 readout est. (NCT07362459)
DESCRIPTION:SCTB14\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in
  Non-Small Cell Lung Cancer.\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sctb14#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07362459
URL:https://assetmemo.bio/drug/sctb14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525219-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07525219)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine Frame Tri
 al Comparing Suzetrigine and Acetaminophen\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/suzetrigin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 525219
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104383-178@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104383)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Type 2 Diabetes Phase 3 (VANQUISH 2)\nEstimated primary completion: 1 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07104383
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104500-178@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104500)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Phase 3\nEstimated primary completion: 1 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vk2735#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07104500
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05876832-2879@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:XY0206: Phase 3 readout est. (NCT05876832)
DESCRIPTION:XY0206\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study of X
 Y0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory 
 AML With FLT3-ITD-Mutation (ALIVE)\nEstimated primary completion: 1 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/xy0206#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05876832
URL:https://assetmemo.bio/drug/xy0206#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159763-11242@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:MK-1406: Phase 3 readout est. (NCT07159763)
DESCRIPTION:MK-1406\, phase 3.\nStudy: A Study to Evaluate the Safety and E
 fficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ
 .3.06)\nEstimated primary completion: 2 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/mk-1406#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07159763
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05897320-10396@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05897320)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study of E
 ptinezumab in Pediatric Participants With Episodic Migraine\nEstimated pri
 mary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05897320
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629544-225@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:DA-302168S: Phase 3 readout est. (NCT07629544)
DESCRIPTION:DA-302168S\, phase 3\, Obesity.\nStudy: A Study of DA-302168S i
 n Participants With Overweight/Obesity\nEstimated primary completion: 9 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/da-302168s#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07629
 544
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186621-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07186621)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Adjuvant Radiotherapy of Sintilim
 ab Versus TACE for HCC\nEstimated primary completion: 9 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07186621
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06290141-11341@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Riliprubart: Phase 3 readout est. (NCT06290141)
DESCRIPTION:Riliprubart\, phase 3\, Chronic Inflammatory Demyelinating Poly
 neuropathy.\nStudy: A Study to Test the Efficacy and Safety of Riliprubart
  Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in Peopl
 e With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\nEstimated
  primary completion: 9 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/riliprubart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06290141
URL:https://assetmemo.bio/drug/riliprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767540-1280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Manfidokimab: Phase 3 readout est. (NCT06767540)
DESCRIPTION:Manfidokimab\, phase 3\, Atopic Dermatitis.\nStudy: A Clinical 
 Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis\nE
 stimated primary completion: 10 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/manfidokimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06767540
URL:https://assetmemo.bio/drug/manfidokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496308-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06496308)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Bendamustine and Rituximab With o
 r Without Orelabrutinib in MCL Treatment\nEstimated primary completion: 10
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 496308
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496308-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06496308)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Bendamustine and Rituxim
 ab With or Without Orelabrutinib in MCL Treatment\nEstimated primary compl
 etion: 10 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06496308
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Pembrolizumab\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and 
 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician'
 s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or M
 etastatic Breast Cancer (MK-2870-010)\nEstimated primary completion: 11 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 312176
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single 
 Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of 
 Physician's Choice in Participants With HR+/HER2- Unresectable Locally Adv
 anced or Metastatic Breast Cancer (MK-2870-010)\nEstimated primary complet
 ion: 11 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06312176
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326813-62@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07326813)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: A Clinical
  Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of M
 oderate to Severe Plaque Psoriasis\nEstimated primary completion: 12 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nomelcitinib-d-
 2570#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07326813
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079879-2890@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06079879)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (
 BAT) in Participants With Essential Thrombocythemia and an Inadequate Resp
 onse or Intolerance of Hydroxyurea (MK-3543-006)\nEstimated primary comple
 tion: 14 July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 omedemstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06079879
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab
  in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic
  Lymphoma\nEstimated primary completion: 15 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzum
 ab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocyt
 ic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-3339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzu
 mab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocy
 tic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325292-7194@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07325292)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Non-inferior
 ity Study of Frexalimab Subcutaneous Administration Compared to Intravenou
 s Administration in Adult Participants With Multiple Sclerosis\nEstimated 
 primary completion: 15 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/frexalimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07325292
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321601-955@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270718
DTEND;VALUE=DATE:20270719
SUMMARY:Tavneos (Avacopan): Phase 3 readout est. (NCT06321601)
DESCRIPTION:Tavneos (Avacopan)\, phase 3.\nStudy: Study to Evaluate Avacopa
 n in Combination With a Rituximab or Cyclophosphamide-containing Regimen\,
  in Children From 6 Years to < 18 Years of Age With AAV.\nEstimated primar
 y completion: 18 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06321601
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04997837-2242@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:S-1: Phase 3 readout est. (NCT04997837)
DESCRIPTION:S-1\, phase 3\, Gastric Cancer.\nStudy: Study of Adjuvant Chemo
 therapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected 
 pN3 Gastric (G) or GEJ Adenocarcinoma\nEstimated primary completion: 21 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/s-1#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04997837
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04997837-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04997837)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Study of Adjuv
 ant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in 
 Resected pN3 Gastric (G) or GEJ Adenocarcinoma\nEstimated primary completi
 on: 21 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04997837
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044297-1010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07044297)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Clinical Study of MK-852
 7 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)\nEs
 timated primary completion: 22 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07044297
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Everolimus: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07062965)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Learn About the Study Medicine Called PF-072481
 44 in Combination With Fulvestrant in People With HR-positive\, HER2-negat
 ive Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line
  of Treatment.\nEstimated primary completion: 22 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9038@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Exemestane: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9082@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Prifetrastat: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Prifetrastat\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-07248144 in Comb
 ination With Fulvestrant in People With HR-positive\, HER2-negative Advanc
 ed or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatm
 ent.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/prifetrastat#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/prifetrastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975865-1477@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270723
DTEND;VALUE=DATE:20270724
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT06975865)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: The Efficacy and Safety of Ril
 zabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease\nE
 stimated primary completion: 23 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06975865
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007793-525@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07007793)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3.\nStudy: Parent Study: A Study 
 to Assess Efficacy and Safety of Baxdrostat in Participants With Primary A
 ldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA
  Main Study.\nEstimated primary completion: 27 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07007793
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130604-62@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07130604)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: Evaluate t
 he Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaqu
 e Psoriasis\nEstimated primary completion: 28 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07130604
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Phase III Study of Dato-DXd Wit
 h or Without Durvalumab Compared With Investigator's Choice of Chemotherap
 y in Combination With Pembrolizumab in Patients With PD-L1 Positive Locall
 y Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIO
 N-Breast05)\nEstimated primary completion: 28 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06103864
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Study of Dato-DXd With or Without Durvalumab Compared With Investig
 ator's Choice of Chemotherapy in Combination With Pembrolizumab in Patient
 s With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-ne
 gative Breast Cancer (TROPION-Breast05)\nEstimated primary completion: 28 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06103864
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635824-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06635824)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 rial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Ove
 r Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC
 -06)\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06635824
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-2289@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/darat
 umumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-3123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study Comp
 aring Talquetamab in Combination With Daratumumab or in Combination With D
 aratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalid
 omide and Dexamethasone in Participants With Multiple Myeloma That Returns
  After Treatment or is Resistant to Treatment\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/poma
 lidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05455320
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-3135@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Talquetamab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talqu
 etamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904028-4978@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:faricimab: Phase 3 readout est. (NCT05904028)
DESCRIPTION:faricimab\, phase 3\, Age-Related Macular Degeneration.\nStudy:
  Home OCT-Guided Treatment Versus Treat and Extend for the Management of N
 eovascular AMD\nEstimated primary completion: 30 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05904028
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072183-5938@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06072183)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 104-Week Study of R
 itlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and
  Stable) Tranquillo 2\nEstimated primary completion: 30 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06072183
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422117-8791@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Crisugabalin: Phase 3 readout est. (NCT06422117)
DESCRIPTION:Crisugabalin\, phase 3.\nStudy: Efficacy and Safety of HSK16149
  Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain 
 in China\nEstimated primary completion: 30 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/crisugabalin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06422117
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578533-608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 06578533)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: Keeping RAASi Treatment With Optimal Potassium Contr
 ol\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06578533
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-1050@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04996017-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04996017)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: Atezolizumab Versus Placebo for
  the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)\nEst
 imated primary completion: 30 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04996017
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-5401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-8630@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Laroprovstat\, Rosuvastatin and Placebo
  on LDL-C in LLT-naïve Patients.\nEstimated primary completion: 30 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat-ros
 uvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02262832-129@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Myalept (metreleptin): Phase 3 readout est. (NCT02262832)
DESCRIPTION:Myalept (metreleptin)\, phase 3.\nStudy: Compassionate Use of M
 etreleptin in Previously Treated People With Generalized Lipodystrophy\nEs
 timated primary completion: 31 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/metreleptin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT02262832
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04055493-2228@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ribociclib: Phase 3 readout est. (NCT04055493)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Adj. Marker-adjus
 ted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Interm
 ediate Risk\, HR+/HER2- EBC\nEstimated primary completion: 31 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04055493
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510816-5301@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Vonaprument: Phase 3 readout est. (NCT06510816)
DESCRIPTION:Vonaprument\, phase 3\, Age-Related Macular Degeneration.\nStud
 y: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Inj
 ections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Rela
 ted Macular Degeneration (AMD) With Geographic Atrophy (GA)\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/vonaprument#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06510816
URL:https://assetmemo.bio/drug/vonaprument#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030621-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07030621)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Efficacy of Semaglutid
 e in Improving Neurological Outcomes After Endovascular Thrombectomy for A
 cute Ischemic Stroke: A Randomized Double-Blind Controlled Trial\nEstimate
 d primary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07030621
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908304-1975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06908304)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment
  in Advanced/Metastatic NSCLC\nEstimated primary completion: 31 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06908304
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985798-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05985798)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab+Bevacizumab+TACE vs. L
 envatinib+TACE for Advanced HCC\nEstimated primary completion: 31 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05985798
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985798-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05985798)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05985798
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095583-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06095583)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase 3 Study of Toripalimab Alo
 ne or in Combination With Tifcemalimab as Consolidation Therapy in Patient
 s With Limited-stage Small Cell Lung Cancer (LS-SCLC)\nEstimated primary c
 ompletion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06095583
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020247-2161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07020247)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: Personalized Long-course Radioth
 erapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Stu
 dy\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07020247
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908304-2297@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ateganosine (THIO): Phase 3 readout est. (NCT06908304)
DESCRIPTION:Ateganosine (THIO)\, phase 3\, Non-Small Cell Lung Cancer.\nStu
 dy: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line T
 reatment in Advanced/Metastatic NSCLC\nEstimated primary completion: 31 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ateganosine-
 thio#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06908304
URL:https://assetmemo.bio/drug/ateganosine-thio#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02945566-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT02945566)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: Can we Save the Rectum by Wat
 chful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus To
 tal Mesorectal Excision for Early REctal Cancer?\nEstimated primary comple
 tion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 pecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02945566
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742280-666@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Brexpiprazole (Rexulti): Phase 2/3 readout est. (NCT07742280)
DESCRIPTION:Brexpiprazole (Rexulti)\, phase 2/3\, Schizophrenia.\nStudy: A 
 Study to Evaluate the Pharmacokinetics\, Safety and Tolerability of Brexpi
 prazole for Extended-Release Injection in Subjects With Schizophrenia\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07742280
URL:https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722728-803@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cariprazine (Vraylar): Phase 2/3 readout est. (NCT07722728)
DESCRIPTION:Cariprazine (Vraylar)\, phase 2/3\, Schizophrenia.\nStudy: A St
 udy to Investigate Pharmacokinetics\, Safety\, and Tolerability of B2227 E
 xtended-Release Injectable Suspension and Vraylar® in Participants With S
 chizophrenia\nEstimated primary completion: August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07722728
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086313-825@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Simtriyo (Centanafadine): Phase 2/3 readout est. (NCT07086313)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 2/3\, Attention Deficit Hypera
 ctivity Disorder.\nStudy: A Trial to Evaluate the Efficacy and Safety of E
 B-1020 in Pediatric Patients With ADHD\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/centanafadin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 086313
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976268-1604@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:BHV-8000: Phase 2/3 readout est. (NCT06976268)
DESCRIPTION:BHV-8000\, phase 2/3\, Parkinson's Disease.\nStudy: A Study to 
 Determine if BHV-8000 is Effective\, Safe and Tolerable as a Treatment for
  Adults Living With Early Parkinson's Disease\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bhv-8
 000#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06976268
URL:https://assetmemo.bio/drug/bhv-8000#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bortezomib: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Bortezomib\, phase 2/3\, Multiple Myeloma.\nStudy: Expression-l
 inked and R-ISS-adapted Stratification for First Line Therapy in Multiple 
 Myeloma Patients\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Lenalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: Expression
 -linked and R-ISS-adapted Stratification for First Line Therapy in Multipl
 e Myeloma Patients\nEstimated primary completion: August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3136@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Isatuximab: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Isatuximab\, phase 2/3\, Multiple Myeloma.\nStudy: Expression-l
 inked and R-ISS-adapted Stratification for First Line Therapy in Multiple 
 Myeloma Patients\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Expression-linked and R-ISS-
 adapted Stratification for First Line Therapy in Multiple Myeloma Patients
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-3@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Change in Disease Activity in Adult Participants Wit
 h Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared
  to Vedolizumab\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-7@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Assess the Change in Disease Activity in Adult Participants With
  Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared 
 to Vedolizumab\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972459-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972459)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and a
 t Least One Weight-Related Comorbidity\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 72459
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972472-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972472)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and T
 ype 2 Diabetes\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06972472
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993792-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06993792)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Obesity or Overw
 eight With and Without Type 2 Diabetes\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 93792
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265479-1783@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tapinarof: Phase 3 readout est. (NCT07265479)
DESCRIPTION:Tapinarof\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Inv
 estigate Safety and Efficacy of Tapinarof Cream\, 1% in Participants Ages 
 3 Months to < 24 Months With Atopic Dermatitis\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tapi
 narof#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07265479
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03576417-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03576417)
DESCRIPTION:Nivolumab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Tre
 atment of Cancers of the Head and Neck\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT035764
 17
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bortezomib: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: UARK 2006-66\,
  Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy\nEstimated p
 rimary completion: August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT00572169
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-3130@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Thalidomide: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Thalidomide\, phase 3\, Multiple Myeloma.\nStudy: UARK 2006-66\
 , Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy\nEstimated 
 primary completion: August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/thalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT00572169
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06464991-3255@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Equecabtagene autoleucel: Phase 3 readout est. (NCT06464991)
DESCRIPTION:Equecabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy: 
 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANB
 A-03)\nEstimated primary completion: August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06464991
URL:https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: UARK 2006-66\, Total Therapy 3
 B: An Extension of UARK 2003-33 Total Therapy\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexam
 ethasone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT00572169
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914609-10803@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obudanersen: Phase 3 readout est. (NCT06914609)
DESCRIPTION:Obudanersen\, phase 3\, Angelman Syndrome.\nStudy: REVEAL: A Ph
 ase 3 Study of Obudanersen (ION582) in Angelman Syndrome\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obudanersen#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06914609
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-2058@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Regorafenib: Phase 3 readout est. (NCT07483684)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: A Clinical S
 tudy to Evaluate Injection TQB2102 for the Treatment of Patients With HER2
  IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal
 iplatin\, Irinotecan and Fluoropyrimidine-Based Drugs\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07483684
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-2237@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0748368
 4)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: A Clinical Study to Evaluate Injection TQB2102 for the Treatment
  of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed Aft
 er Treatment With Oxaliplatin\, Irinotecan and Fluoropyrimidine-Based Drug
 s\nEstimated primary completion: August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07483684
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440381-6854@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nexletol (Bempedoic acid): Phase 3 readout est. (NCT07440381)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: triPle Oral thERapy With Bempedoic Acid vs uSual Ca
 re in Early Lipid Management of Patients With acUte coronAry synDromE\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bempedoic-acid#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07440381
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839715-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07839715)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine Post DIEP
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07839715
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087327-825@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT07087327)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Long-term Trial of EB-1020 in Pediatric Patients
  With ADHD\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07087327
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05918861-1099@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dalcetrapib: Phase 3 readout est. (NCT05918861)
DESCRIPTION:Dalcetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Effect of Dalcetrapib on CV Risk in a Genetically Defined Populat
 ion With a Recent ACS\nEstimated primary completion: August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dalcetrapib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05918861
URL:https://assetmemo.bio/drug/dalcetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319456-2883@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06319456)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: A Study of Lisaftoclax (APG-2575
 ) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnose
 d CLL/SLL.\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06319456
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319456-3339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT06319456)
DESCRIPTION:Acalabrutinib\, phase 3.\nStudy: A Study of Lisaftoclax (APG-25
 75) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagno
 sed CLL/SLL.\nEstimated primary completion: August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06319456
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863193-6740@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Denifanstat: Phase 3 readout est. (NCT07863193)
DESCRIPTION:Denifanstat\, phase 3.\nStudy: Phase 3 Study of Denifanstat in 
 Participants With Moderate to Severe Acne (AURORA)\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 denifanstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07863193
URL:https://assetmemo.bio/drug/denifanstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868419-10655@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Haduvio (Nalbuphine ER): Phase 3 readout est. (NCT07868419)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 3\, Chronic Cough in Idiopathic
  Pulmonary Fibrosis.\nStudy: Idiopathic Pulmonary Fibrosis (IPF)-Related C
 hronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nalbuphine-er#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07868419
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706764-10863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Yorvipath (palopegteriparatide): Phase 3 readout est. (NCT07706764)
DESCRIPTION:Yorvipath (palopegteriparatide)\, phase 3\, Hypoparathyroidism.
 \nStudy: A Study to Test the Effects and Safety of Palopegteriparatide in 
 Adolescents With Long-term Hypoparathyroidism\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palop
 egteriparatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07706764
URL:https://assetmemo.bio/drug/palopegteriparatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024173-11068@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07024173)
DESCRIPTION:HRS-8080\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Loc
 ally Advanced and Metastatic Breast Cancer\nEstimated primary completion: 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 24173
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287644-1310@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:BFB759: Phase 2/3 readout est. (NCT07287644)
DESCRIPTION:BFB759\, phase 2/3\, Hidradenitis Suppurativa.\nStudy: A Study 
 Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa\nEstimate
 d primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bfb759#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07287644
URL:https://assetmemo.bio/drug/bfb759#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900087-11035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Roflumilast (Daliresp): Phase 2/3 readout est. (NCT07900087)
DESCRIPTION:Roflumilast (Daliresp)\, phase 2/3.\nStudy: Evaluating the Safe
 ty and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Live
 r Disease Patients\nEstimated primary completion: 1 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/roflumilast-daliresp#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07900087
URL:https://assetmemo.bio/drug/roflumilast-daliresp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05587374-1994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT05587374)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Cadonilimab (PD-1/CTLA-4 Bispeci
 fic Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
 \nEstimated primary completion: 1 August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05587374
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05496166-2166@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT05496166)
DESCRIPTION:Adebrelimab\, phase 3\, Small Cell Lung Cancer.\nStudy: The Eff
 iciency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Plati
 num-containing Doublet Induction Therapy for Limited-stage Small Cell Lung
  Cancer\nEstimated primary completion: 1 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05496166
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973319-2207@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT04973319)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Trastuzumab Combined With Pertuzum
 ab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy\nEsti
 mated primary completion: 1 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04973319
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973319-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT04973319)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Trastuzumab Combi
 ned With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuv
 ant Therapy\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04973319
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120349-1958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05120349)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Global Study to Assess the Effects of Osimertinib in Participant
 s With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection\nEsti
 mated primary completion: 2 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05120349
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317416-3143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05317416)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: Study With El
 ranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple My
 eloma After Transplant\nEstimated primary completion: 4 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05317416
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04856982-10800@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Qalsody (Tofersen): Phase 3 readout est. (NCT04856982)
DESCRIPTION:Qalsody (Tofersen)\, phase 3\, Amyotrophic Lateral Sclerosis.\n
 Study: Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and Abo
 ut Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Develop
 ed ALS Symptoms\nEstimated primary completion: 7 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04856982
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185672-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07185672)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: PRRT Versus PRRT Plus Chemother
 apy in GEP NET (PReCedeNT Trial)\nEstimated primary completion: 7 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718567
 2
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356129-11182@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06356129)
DESCRIPTION:Golcadomide\, phase 3\, Large B-Cell Lymphoma.\nStudy: Study to
  Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placeb
 o Plus R-CHOP in Participants With Previously Untreated High-risk Large B-
 cell Lymphoma\nEstimated primary completion: 9 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06356129
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852938-909@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Zigakibart: Phase 3 readout est. (NCT05852938)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: A Study 
 of Zigakibart in Adults With IgA Nephropathy\nEstimated primary completion
 : 10 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zig
 akibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05852938
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449910-98@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Olumiant (baricitinib): Phase 2/3 readout est. (NCT07449910)
DESCRIPTION:Olumiant (baricitinib)\, phase 2/3.\nStudy: Safety and Efficacy
  of Baricitinib After Endovascular Treatment in Acute Anterior Circulation
  Large Vessel Occlusion: A Multicenter\, Randomized Controlled Clinical Tr
 ial\nEstimated primary completion: 17 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07449910
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: A Study to Compare the Efficacy an
 d Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in C
 ombination With Carboplatin Plus Etoposide to That of Atezolizumab With Ca
 rboplatin Plus Etoposide as First-Line Therapy in Participants With Extens
 ive-Stage Small Cell Lung Cancer (TIGOS).\nEstimated primary completion: 1
 7 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06646276
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-11178@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Atigotatug: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Atigotatug\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fi
 xed Dose Combination) in Combination With Carboplatin Plus Etoposide to Th
 at of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy i
 n Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).\nEstim
 ated primary completion: 17 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/atigotatug#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06646276
URL:https://assetmemo.bio/drug/atigotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225686-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072256
 86)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstruc
 tive Sleep Apnea on Positive Airway Pressure Therapy\nEstimated primary co
 mpletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07225686
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037771-1192@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Zodasiran: Phase 3 readout est. (NCT07037771)
DESCRIPTION:Zodasiran\, phase 3\, Homozygous Familial Hypercholesterolemia.
 \nStudy: A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects Wit
 h Homozygous Familial Hypercholesterolemia (YOSEMITE)\nEstimated primary c
 ompletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zodasiran#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07037771
URL:https://assetmemo.bio/drug/zodasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596784-885@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07596784)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Myasthenia Gravis.\nStudy: 
 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Gen
 eralized Myasthenia Gravis (gMG)\nEstimated primary completion: 24 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0759678
 4
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314203-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:Apatinib: Phase 3 readout est. (NCT07314203)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Clinical Efficacy of Adebrelimab Wi
 th or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Adv
 anced Gastric Cancer\nEstimated primary completion: 25 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07314203
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650084-1312@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:BLU-5937: Phase 3 readout est. (NCT07650084)
DESCRIPTION:BLU-5937\, phase 3.\nStudy: A 24-Week Study of the Efficacy and
  Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extens
 ion\nEstimated primary completion: 27 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/blu-5937#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07650084
URL:https://assetmemo.bio/drug/blu-5937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612268-10273@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06612268)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate How Well Etavopivat Works in People With Sickle Cell Disease\nEst
 imated primary completion: 27 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/etavopivat#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06612268
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394114-196@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270828
DTEND;VALUE=DATE:20270829
SUMMARY:HDM1005: Phase 3 readout est. (NCT07394114)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 28 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07394114
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226765-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072267
 65)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3.\nStudy: Maridebar
 t Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep
  Apnea Not on Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07226765
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04483466-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04483466)
DESCRIPTION:Methotrexate\, phase 3.\nStudy: Methotrexate Treatment of Arthr
 itis Caused by Chikungunya Virus (MARCH)\nEstimated primary completion: 30
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotr
 exate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04483466
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417306-196@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HDM1005: Phase 3 readout est. (NCT07417306)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With T2DM Not Controlled With Metformin Alone or in Combi
 nation With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor\nEstimated 
 primary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07417306
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06723080-1511@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:VC005: Phase 3 readout est. (NCT06723080)
DESCRIPTION:VC005\, phase 3\, Atopic Dermatitis.\nStudy: Phase III Clinical
  Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic D
 ermatitis\nEstimated primary completion: 30 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06723080
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172360-1511@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:VC005: Phase 3 readout est. (NCT07172360)
DESCRIPTION:VC005\, phase 3.\nStudy: Efficacy and Safety Phase III Clinical
  Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.\nE
 stimated primary completion: 30 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/vc005#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07172360
URL:https://assetmemo.bio/drug/vc005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132684-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07132684)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Comparis
 on of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia
  Patients\nEstimated primary completion: 30 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07132684
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132684-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07132684)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Compari
 son of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemi
 a Patients\nEstimated primary completion: 30 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07132684
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05506943-10870@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:tovecimig: Phase 2/3 readout est. (NCT05506943)
DESCRIPTION:tovecimig\, phase 2/3\, Biliary Tract Cancer.\nStudy: A Study o
 f CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectab
 le Advanced\, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002
 )\nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tovecimig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05506943
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217873-590@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 2/3 readout e
 st. (NCT07217873)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 2/3.\nSt
 udy: IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study\nEs
 timated primary completion: 31 August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07217873
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04695600-9542@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Botox (onabotulinumtoxinA): Phase 2/3 readout est. (NCT04695600)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2/3.\nStudy: Onabotulinum To
 xin A (Botox) in the Treatment of Pharyngo-esophageal Dysphagia\nEstimated
  primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04695600
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649489-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04649489)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study to Evaluate Efficacy an
 d Safety of Hepatic Resection for Liver Cancer With PVTT\, HVTT or IVCTT A
 fter Initial Ate/Bev\nEstimated primary completion: 31 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04649489
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649489-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04649489)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: A Study to Evaluate Efficacy and
  Safety of Hepatic Resection for Liver Cancer With PVTT\, HVTT or IVCTT Af
 ter Initial Ate/Bev\nEstimated primary completion: 31 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04649489
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671510-2413@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gotistobart: Phase 3 readout est. (NCT05671510)
DESCRIPTION:Gotistobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ONC
 -392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 In
 hibitors\nEstimated primary completion: 31 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gotistobart#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05671510
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04465968-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04465968)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy and Safety of CRT\, Durvalumab and Surgery for SST\nEstimated primary
  completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04465968
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132398-5632@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07132398)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: Slow vs. Rapid Glucocorticoids 
 Tapering With Inebilizumab in NMOSD\nEstimated primary completion: 31 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 32398
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05487391-2261@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05487391)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 Combined With Platinum-containing Chemothe
 rapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer Aft
 er Complete Surgical Resection.\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-
 tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05487391
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06084936)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: A Study to Evaluate Glofitamab 
 as a Single Agent vs. Investigator's Choice in Participants With Relapsed/
 Refractory Mantle Cell Lymphoma\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0608493
 6
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-6083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0608493
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Study to
  Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Partic
 ipants With Relapsed/Refractory Mantle Cell Lymphoma\nEstimated primary co
 mpletion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06084936
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123467-7557@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cannabidiol (Epidiolex): Phase 3 readout est. (NCT07123467)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 3.\nStudy: Cannabidiol-Assisted
  Learning for Managing Generalized Anxiety Disorder\nEstimated primary com
 pletion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cannabidiol-epidiolex#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07123467
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210723-596@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Danicamtiv: Phase 2/3 readout est. (NCT07210723)
DESCRIPTION:Danicamtiv\, phase 2/3.\nStudy: A Study of the Efficacy and Saf
 ety of Danicamtiv in Participants With Symptomatic Genetic and Familial Di
 lated Cardiomyopathy\nEstimated primary completion: September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07210723
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03345823-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03345823)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A Ma
 intenance and Long-Term Extension Study of the Efficacy and Safety of Upad
 acitinib (ABT-494) in Participants With Crohn's Disease Who Completed the 
 Studies M14-431 or M14-433\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03345823
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948422-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948422)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Hypertension and
  Obesity or Overweight: (ATTAIN-Hypertension Screening)\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06948422
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948435-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948435)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL1\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06948435
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952530-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06952530)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL2\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06952530
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035093-118@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:retatrutide: Phase 3 readout est. (NCT07035093)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Lo
 w Back Pain\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07035093
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04309409-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04309409)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Adjuvant Nivolumab Trea
 tment in Stage II (IIA\, IIB\, IIC) High-risk Melanoma\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04309409
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608318-2041@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT04608318)
DESCRIPTION:Ibrutinib\, phase 3.\nStudy: Ibrutinib Monotherapy Versus Fixed
 -duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plu
 s Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leu
 kaemia (CLL)\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04608318
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608318-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04608318)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Ibrutinib Monotherapy Versus Fixe
 d-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Pl
 us Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Le
 ukaemia (CLL)\nEstimated primary completion: September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04608318
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608318-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04608318)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: Ibrutinib Monotherapy Versus Fi
 xed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib 
 Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic 
 Leukaemia (CLL)\nEstimated primary completion: September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04608318
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722848-5633@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04722848)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and I
 matinib in Newly Diagnosed Adult Ph+ ALL\nEstimated primary completion: Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04722848
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05895838-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT05895838)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: The Danish Out-of-Hospi
 tal Cardiac Arrest Study\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05895838
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05895838-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05895838)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: The Danish Out-of-Hospital Car
 diac Arrest Study\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05895838
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722848-10794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ICLUSIG (Ponatinib): Phase 3 readout est. (NCT04722848)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 3\, Acute Lymphoblastic Leukemia.\n
 Study: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherap
 y and Imatinib in Newly Diagnosed Adult Ph+ ALL\nEstimated primary complet
 ion: September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04722848
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653322-11077@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SHR-1703: Phase 3 readout est. (NCT06653322)
DESCRIPTION:SHR-1703\, phase 3.\nStudy: A Multi-centered，Randomized，Dou
 ble-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety o
 f SHR-1703 in Eosinophilic Asthma\nEstimated primary completion: September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1703#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06653322
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04987229-9210@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine/samidorphan (Lybalvi): Phase 3 readout est. (NCT04987229
 )
DESCRIPTION:Olanzapine/samidorphan (Lybalvi)\, phase 3\, Schizophrenia.\nSt
 udy: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04987229
URL:https://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181239-3157@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07181239)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336 in Relapsed or Refractory Multiple Myeloma Patients\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07181239
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06354985-5607@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Provigil (Modafinil): Phase 3 readout est. (NCT06354985)
DESCRIPTION:Provigil (Modafinil)\, phase 3.\nStudy: Modafinil and Exercise 
 for Post Stroke Fatigue\nEstimated primary completion: September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/modafinil#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06354985
URL:https://assetmemo.bio/drug/modafinil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678827-10826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT07678827)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: A Phase 3 Study of Viloxazine ER Capsules in Korean Ch
 ildren and Adolescents With ADHD\nEstimated primary completion: September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/viloxazine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07678827
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724366-52@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:TQH3906: Phase 3 readout est. (NCT07724366)
DESCRIPTION:TQH3906\, phase 3\, Psoriasis.\nStudy: A Clinical Trial of TQH3
 906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07724366
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944016-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0594401
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney
  Disease in Adolescents and Young Adult Patients\nEstimated primary comple
 tion: September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05944016
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736574-593@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Omecamtiv mecarbil: Phase 3 readout est. (NCT06736574)
DESCRIPTION:Omecamtiv mecarbil\, phase 3\, Heart Failure.\nStudy: Study Wit
 h Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Seve
 rely Reduced Ejection Fraction\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/omecamtiv-mecarbi
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 736574
URL:https://assetmemo.bio/drug/omecamtiv-mecarbil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325645-666@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brexpiprazole (Rexulti): Phase 3 readout est. (NCT05325645)
DESCRIPTION:Brexpiprazole (Rexulti)\, phase 3\, Schizophrenia.\nStudy: Tria
 l of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Sch
 izophrenia\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05325645
URL:https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592689-827@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:DT120 (Lysergide tartrate (LSD)): Phase 3 readout est. (NCT07592689
 )
DESCRIPTION:DT120 (Lysergide tartrate (LSD))\, phase 3\, Major Depressive D
 isorder.\nStudy: A Phase 3 Trial of DT120 for Major Depressive Disorder (A
 scend)\nEstimated primary completion: September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lysergide-tartrate-lsd#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07592689
URL:https://assetmemo.bio/drug/lysergide-tartrate-lsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767253-1275@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SSGJ-611: Phase 3 readout est. (NCT07767253)
DESCRIPTION:SSGJ-611\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of 6
 11 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)\nEsti
 mated primary completion: September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ssgj-611#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07767253
URL:https://assetmemo.bio/drug/ssgj-611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592326-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06592326)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: 9MW2821 in Combination With Tori
 palimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothel
 ial Cancer\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06592326
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604766-2708@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07604766)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatme
 nt of Investigator's Choice in Participants With Platinum Resistant Ovaria
 n Cancer in China\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076047
 66
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006117-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06006117)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: Mosunetuzumab-Lenalidomide Vers
 us Investigator Choices in Patients With Relapsed or Refractory Marginal Z
 one Lymphoma\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06006117
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05327894-5633@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT05327894)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearra
 nged ALL or Mixed Phenotype Acute Leukemia\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blina
 tumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05327894
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413809-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT07413809)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Prevention of Delayed C
 INV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamet
 hasone-Containing Regimen\nEstimated primary completion: September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0741380
 9
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382948-9023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Everolimus: Phase 3 readout est. (NCT06382948)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant + Everolimus in Patients ER+/HER2-\, ESR1mut\, Advanced Br
 east Cancer Progressing to ET and CDK4/6i.\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/evero
 limus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06382948
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of QL1706 in Combination With Bevacizumab and/or Chemotherapy as Firs
 t-line Treatment in Patients With Advanced Hepatocellular Carcinoma\nEstim
 ated primary completion: 1 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05976568
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-2261@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Iparomlimab and tuvonralimab: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2/3.\nStudy: A Study of QL
 1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Tre
 atment in Patients With Advanced Hepatocellular Carcinoma\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05976568
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590375-4393@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Phenytoin: Phase 2/3 readout est. (NCT07590375)
DESCRIPTION:Phenytoin\, phase 2/3.\nStudy: Topical Phenytoin for Management
  of Gingival Recession\nEstimated primary completion: 1 September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/phenytoin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07590375
URL:https://assetmemo.bio/drug/phenytoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Study of QL1706 in Combinat
 ion With Bevacizumab and/or Chemotherapy as First-line Treatment in Patien
 ts With Advanced Hepatocellular Carcinoma\nEstimated primary completion: 1
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05976568
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Study of Dato-DXd With or Witho
 ut Durvalumab Versus Investigator's Choice of Therapy in Patients With Sta
 ge I-III Triple-negative Breast Cancer Without Pathological Complete Respo
 nse Following Neoadjuvant Therapy (TROPION-Breast03)\nEstimated primary co
 mpletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05629585
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of 
 Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without
  Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Bre
 ast03)\nEstimated primary completion: 1 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05629585
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Trial That 
 Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible fo
 r Transplant\nEstimated primary completion: 1 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Trial That
  Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible f
 or Transplant\nEstimated primary completion: 1 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Trial That Compare Two Treat
 ments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant\nEst
 imated primary completion: 1 September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016737-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07016737)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Immunochemotherapy ± Salvage Che
 moradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma Aft
 er Definitive Chemoradiotherapy\nEstimated primary completion: 1 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701673
 7
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05476991-6104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05476991)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Evaluation of Low Dose Colchicine and Ticagrelor in Pre
 vention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis\
 nEstimated primary completion: 1 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05476991
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980949-712@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270907
DTEND;VALUE=DATE:20270908
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT05
 980949)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: Open-Label Extension Study to Assess the Long-Term Safety
  and Tolerability of KarXT in Subjects With Psychosis Associated With Alzh
 eimer's Disease (ADEPT-3)\nEstimated primary completion: 7 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-
 chloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05980949
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05323149-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT05323149)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone in Traumatic Bra
 in Injury\nEstimated primary completion: 10 September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05323149
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04779320-7@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT04779320)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn
 's Disease (CD)\nEstimated primary completion: 13 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04779320
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925398-11067@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Hetrombopag: Phase 3 readout est. (NCT07925398)
DESCRIPTION:Hetrombopag\, phase 3.\nStudy: Hetrombopag for Thrombocytopenia
  in Patients Scheduled for Elective Hepatic Interventional Diagnostic and 
 Therapeutic Procedures: A Clinical Study\nEstimated primary completion: 15
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hetr
 ombopag#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07925398
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649292-11072@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:SHR-A1904: Phase 3 readout est. (NCT06649292)
DESCRIPTION:SHR-A1904\, phase 3.\nStudy: SHR-A1904 Compared With Investigat
 or's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line A
 dvanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\
 nEstimated primary completion: 20 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/shr-a1904#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06649292
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311850-179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07311850)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f MET097 Once-Weekly in People With Overweight or Obesity\nEstimated prima
 ry completion: 21 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07311850
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05126277-10731@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:VAY736: Phase 3 readout est. (NCT05126277)
DESCRIPTION:VAY736\, phase 3.\nStudy: Safety\, Efficacy and Tolerability of
  Ianalumab Versus Placebo\, Combination With SoC Therapy\, in Participants
  With Active Lupus Nephritis\nEstimated primary completion: 21 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05126277
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416526-11331@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07416526)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: A Clinical Study to Evaluate the E
 ffects of NXT007 Compared to Factor VIII Prophylaxis in Participants With 
 Hemophilia A\nEstimated primary completion: 23 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zemocimig#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07416526
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With St
 andard of Care in Participants With Relapsed or Refractory Diffuse Large B
 -Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05139017
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-9128@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With S
 tandard of Care in Participants With Relapsed or Refractory Diffuse Large 
 B-Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilov
 ertamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05139017
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03221036-7@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT03221036)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: E
 fficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerati
 ve Colitis\nEstimated primary completion: 24 September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03221036
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067790-10799@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT05067790)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB0
 58) Given as Injections to Participants With Spinal Muscular Atrophy (SMA)
  Who Were Previously Treated With Risdiplam (ASCEND)\nEstimated primary co
 mpletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nusinersen#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05067790
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659574-199@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:UBT251: Phase 3 readout est. (NCT07659574)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate
  Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）\nEstimated pr
 imary completion: 24 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ubt251#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07659574
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778316-2753@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07778316)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Phase 3 
 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer A
 fter Platinum Based First-line Chemotherapy (ES-SCLC)\nEstimated primary c
 ompletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07778316
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-1975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05785767)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemipli
 mab Alone is More Effective for Adult Participants With Advanced Non-Small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 28 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05785767
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-2221@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Fianlimab: Phase 2/3 readout est. (NCT05785767)
DESCRIPTION:Fianlimab\, phase 2/3.\nStudy: A Study to Learn if a Combinatio
 n of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective fo
 r Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)\nEst
 imated primary completion: 28 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05785767
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456346-2890@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06456346)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: Bome
 demstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)\nEstima
 ted primary completion: 28 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06456346
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585774-3003@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06585774)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment
  for Chronic Graft-Versus-Host Disease\nEstimated primary completion: 28 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axatil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06585774
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013474-11275@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT07013474)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severel
 y Immunocompromised\nEstimated primary completion: 28 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ibuzatrelvir#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07013474
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092269-6@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Stelara (ustekinumab): Phase 3 readout est. (NCT05092269)
DESCRIPTION:Stelara (ustekinumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-term Extension Study of Ustekinumab in Pediatric Participants\nEstim
 ated primary completion: 29 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ustekinumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05092269
URL:https://assetmemo.bio/drug/ustekinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648225-199@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:UBT251: Phase 3 readout est. (NCT07648225)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (Overweight or Obesity)\nEstimated primary completion: 29 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07648225
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04583462-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04583462)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Impact of Metformin o
 n Peripheral Arterial Calcification in Type 1 Diabetes\nEstimated primary 
 completion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04583462
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628767-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT04628767)
DESCRIPTION:Durvalumab\, phase 2/3\, Urothelial Carcinoma.\nStudy: Testing 
 the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for P
 atients With High-Grade Upper Urinary Tract Cancer\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04628767
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628767-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT04628767)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Testing the Addition of MEDI4
 736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Gra
 de Upper Urinary Tract Cancer\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046287
 67
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082192-8958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CB03-154: Phase 2/3 readout est. (NCT07082192)
DESCRIPTION:CB03-154\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 
 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)\nEstimated prim
 ary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cb03-154#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07082192
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598708-11231@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cleminorexton: Phase 2/3 readout est. (NCT07598708)
DESCRIPTION:Cleminorexton\, phase 2/3\, Narcolepsy.\nStudy: A Study to Inve
 stigate the Effects of Cleminorexton Compared With Placebo in the Treatmen
 t of Participants With Central Disorders of Hypersomnolence\nEstimated pri
 mary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cleminorexton#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07598708
URL:https://assetmemo.bio/drug/cleminorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06138613-1508@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:tradipitant: Phase 3 readout est. (NCT06138613)
DESCRIPTION:tradipitant\, phase 3.\nStudy: Motion Delos: An Open Label Safe
 ty and Efficacy of Tradipitant in Participants Affected by Motion Sickness
 \nEstimated primary completion: 30 September 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tradipitant#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06138613
URL:https://assetmemo.bio/drug/tradipitant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793179-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03793179)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 esting the Timing of Pembrolizumab Alone or With Chemotherapy as First Lin
 e Treatment and Maintenance in Non-small Cell Lung Cancer\nEstimated prima
 ry completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03793179
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120491-2090@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Saruparib: Phase 3 readout est. (NCT06120491)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib (AZD53
 05) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer
  Receiving Physician's Choice New Hormonal Agents\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06120491
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793179-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT03793179)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as Fir
 st Line Treatment and Maintenance in Non-small Cell Lung Cancer\nEstimated
  primary completion: 30 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03793179
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Pa
 tients With Newly Diagnosed B-Lymphoblastic Leukemia\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-5633@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Pa
 tients With Newly Diagnosed B-Lymphoblastic Leukemia\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629779-7732@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06629779)
DESCRIPTION:Mevrometostat\, phase 3\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: A Study to Learn How PF-06821497 (Mevrometostat) Works
  in Men With Metastatic Castration-resistant Prostate Cancer.\nEstimated p
 rimary completion: 30 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/mevrometostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06629779
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Investigate Blinatu
 momab in Combination With Chemotherapy in Patients With Newly Diagnosed B-
 Lymphoblastic Leukemia\nEstimated primary completion: 30 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06460506-10838@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT06460506)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Evaluation of Long-term Safety and Efficacy of ELX/T
 EZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06460506
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132008-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07132008)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Neoadjuvant CAPOX Plus Tisleliz
 umab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer\nEstimated pr
 imary completion: 30 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07132008
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-2211@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CPO301: Phase 3 readout est. (NCT07633873)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SYS6010 
 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemothera
 py for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC
 （SYNSTAR 04）\nEstimated primary completion: 30 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07633873
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06613035-2266@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Selinexor: Phase 3 readout est. (NCT06613035)
DESCRIPTION:Selinexor\, phase 3.\nStudy: Twice-per-weekSelinexor\, 2 Days M
 elphalan\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06613035
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-2291@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07633873)
DESCRIPTION:Enlonstobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SY
 S6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chem
 otherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic N
 SCLC（SYNSTAR 04）\nEstimated primary completion: 30 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07633873
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583849-1539@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HSK39004: Phase 3 readout est. (NCT07583849)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: A Multicenter\, Randomized\, Double-blind\, Placebo-controlled\, Para
 llel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment
  of COPD\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07583849
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients
  With Acute Myeloid Leukaemia\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07514936
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2286@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Chidamide: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Chidamide\, phase 3.\nStudy: Venetoclax-Azacitidine in Combinat
 ion With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukae
 mia\nEstimated primary completion: 30 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07514936
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patient
 s With Acute Myeloid Leukaemia\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075149
 36
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04851717-9526@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Remimazolam: Phase 2/3 readout est. (NCT04851717)
DESCRIPTION:Remimazolam\, phase 2/3.\nStudy: Investigation of Remimazolam i
 n Children Undergoing Sedation for Medical Procedures\nEstimated primary c
 ompletion: October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remimazolam#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04851717
URL:https://assetmemo.bio/drug/remimazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707377-10908@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Brukinsa (zanubrutinib): Phase 2/3 readout est. (NCT05707377)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2/3.\nStudy: A Study to Examine
  the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Memb
 ranous Nephropathy\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05707377
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134218-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07134218)
DESCRIPTION:Bevacizumab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy 
 Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Adva
 nced Rectal Cancer\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07134218
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134218-2161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT07134218)
DESCRIPTION:Serplulimab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy 
 Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Adva
 nced Rectal Cancer\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07134218
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827157-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT07827157)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Comparison of Dexmedetomidin
 e Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Er
 ector Spinae Plane Block for Acute Pain Management in Patients With Trauma
 tic Rib Fractures\nEstimated primary completion: October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07827157
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05710692-10978@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT05710692)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: Study
  to Evaluate the Safety\, PK\, PD\, and Efficacy of PRX-102 in Japanese Pa
 tients With Fabry Disease\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pegunigalsidase-alfa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0571069
 2
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514054-9192@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Inluriyo (Imlunestrant): Phase 3 readout est. (NCT05514054)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant Versus Standard Endocrine Therapy in Participants With
  Early Breast Cancer\nEstimated primary completion: October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05514054
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556512-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT05556512)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adu
 lts With Obesity\nEstimated primary completion: October 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05556512
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014826-11076@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-5965: Phase 3 readout est. (NCT07014826)
DESCRIPTION:HRS-5965\, phase 3.\nStudy: A Trial of HRS-5965 Capsule in Prim
 ary IgA Nephropathy\nEstimated primary completion: October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/hrs-5965#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07014826
URL:https://assetmemo.bio/drug/hrs-5965#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897630-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07897630)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Suprachoroidal Bevacizumab Versu
 s Intravitreal Bevacizumab in Diabetic Macular Edema\nEstimated primary co
 mpletion: October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07897630
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628985-190@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07628985)
DESCRIPTION:Bofanglutide\, phase 3\, Type 2 Diabetes.\nStudy: BALANCE-DM2 S
 tudy of Bofanglutide in Adults With Type 2 Diabetes\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bofanglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07628985
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920939-489@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07920939)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Safe
 ty of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Ad
 ults With Insulin-Naive Type 2 Diabetes\nEstimated primary completion: Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07920
 939
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847047-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07847047)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Safety and Efficacy of Dexamet
 hasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries 
 for Postoperative Pain Management\nEstimated primary completion: October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078470
 47
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781293-9208@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lurasidone: Phase 3 readout est. (NCT07781293)
DESCRIPTION:Lurasidone\, phase 3.\nStudy: Study of Lurasidone as Adjunctive
  Treatment in Patients With Major Depressive Disorder With Inadequate Resp
 onse to Antidepressant Monotherapy\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lurasidone#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07781293
URL:https://assetmemo.bio/drug/lurasidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844462-518@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Adcirca (Tadalafil): Phase 3 readout est. (NCT05844462)
DESCRIPTION:Adcirca (Tadalafil)\, phase 3.\nStudy: Tadalafil for Severe Pul
 monary Hypertension Due to Chronic Obstructive Pulmonary Disease\nEstimate
 d primary completion: October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tadalafil#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05844462
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884280-591@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT06884280)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3.\nStudy: 
 Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialy
 sis: The PALaDIN Study\nEstimated primary completion: October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ferric-derisomaltose#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06884280
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230730-1231@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-1918: Phase 3 readout est. (NCT07230730)
DESCRIPTION:SHR-1918\, phase 3.\nStudy: A Trial to Evaluate the Efficacy an
 d Safety of SHR-1918 in Patients With Hyperlipidemia\nEstimated primary co
 mpletion: October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/shr-1918#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07230730
URL:https://assetmemo.bio/drug/shr-1918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05254743-3359@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT05254743)
DESCRIPTION:Pirtobrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With
  Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05254743
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714838-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06714838)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab Induced Remiss
 ion in Patients With Chronic Inflammatory Demyelinating Polyneuropathy\nEs
 timated primary completion: October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06714838
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588413-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT06588413)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Olanzapine 2.5 vs 5 mg 
 in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06588413
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963034-9196@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Direclidine: Phase 3 readout est. (NCT06963034)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06963034
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816367-10397@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Elismetrep: Phase 3 readout est. (NCT07816367)
DESCRIPTION:Elismetrep\, phase 3\, Migraine.\nStudy: A Study to Assess the 
 Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migrai
 ne\nEstimated primary completion: October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/elismetrep#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07816367
URL:https://assetmemo.bio/drug/elismetrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439277-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06439277)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (
 SURMOUNT-ADOLESCENTS-2)\nEstimated primary completion: October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06439277
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725562-1735@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:VG081821AC: Phase 2/3 readout est. (NCT07725562)
DESCRIPTION:VG081821AC\, phase 2/3\, Parkinson's Disease.\nStudy: VG081821A
 C Tablets for Early to Mid-stage Parkinson's Disease\nEstimated primary co
 mpletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/vg081821ac#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07725562
URL:https://assetmemo.bio/drug/vg081821ac#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356388-661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07356388)
DESCRIPTION:Kerendia (Finerenone)\, phase 3.\nStudy: FINEPKT - Finerenone i
 n Proteinuria Patients After Kidney Transplan\nEstimated primary completio
 n: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fi
 nerenone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07356388
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06047080)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: An Open-Label Study Comp
 aring Glofitamab and Polatuzumab Vedotin + Rituximab\, Cyclophosphamide\, 
 Doxorubicin\, and Prednisone Versus Pola-R-CHP in Previously Untreated Pat
 ients With Large B-Cell Lymphoma\nEstimated primary completion: 1 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047080
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05819138-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05819138)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Type 1 Diabetes Impact
 s of Semaglutide on Cardiovascular Outcomes\nEstimated primary completion:
  1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sema
 glutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05819138
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229041-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06229041)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Total Neoadjuvant Treatment ±I
 mmunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06229041
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174453-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07174453)
DESCRIPTION:Pembrolizumab\, phase 3\, Solid Tumors.\nStudy: Trial to Evalua
 te irAEs With Different Standard of Care Dosing Strategies of Standard of 
 Care Immunotherapies\nEstimated primary completion: 1 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07174453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174453-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07174453)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Trial to Evaluate irAEs With Diffe
 rent Standard of Care Dosing Strategies of Standard of Care Immunotherapie
 s\nEstimated primary completion: 1 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07174453
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950945-2164@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT05950945)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormon
 e Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 M
 etastatic Breast Cancer\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05950
 945
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05805930-3446@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Anakinra: Phase 3 readout est. (NCT05805930)
DESCRIPTION:Anakinra\, phase 3.\nStudy: Therapeutic Approach in Colchicine-
 resistant Recurrent pEricarditis in Children\nEstimated primary completion
 : 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ana
 kinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05805930
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07844512-11096@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tegileridine: Phase 3 readout est. (NCT07844512)
DESCRIPTION:Tegileridine\, phase 3.\nStudy: Safety and Analgesic Efficacy o
 f the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative An
 algesia in Patients Undergoing Bariatric Surgery\nEstimated primary comple
 tion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tegileridine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07844512
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679140-11275@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT06679140)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients W
 ith COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease\n
 Estimated primary completion: 1 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ibuzatrelvir#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06679140
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471257-3562@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0647125
 7)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: A
  Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in 
 Symptomatic Chinese Adults With Asthma\nEstimated primary completion: 4 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/albuterol
 -budesonide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06471257
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444086-1055@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:QLC7401: Phase 3 readout est. (NCT07444086)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dys
 lipidemia\nEstimated primary completion: 7 October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07444086
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723911-5633@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07723911)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R
  CD19+ B-ALL\nEstimated primary completion: 10 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07723911
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-1050@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-5401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-8630@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Laroprovstat\, Rosuvastatin\, and Place
 bo on LDL-C in LLT-naïve Patients\nEstimated primary completion: 11 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat
 -rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400653-179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07400653)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine (PF-08653944) in People With Obesity or Overweight an
 d Type 2 Diabetes (T2D)\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07400653
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214779-10796@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:INCB123667: Phase 3 readout est. (NCT07214779)
DESCRIPTION:INCB123667\, phase 3\, Ovarian Cancer.\nStudy: Study to Evaluat
 e INCB123667 Versus Investigator's Choice of Chemotherapy in Participants 
 With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression\nEsti
 mated primary completion: 12 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/incb123667#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07214779
URL:https://assetmemo.bio/drug/incb123667#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027436-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07027436)
DESCRIPTION:Durvalumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Radiat
 ion Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery
  Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellula
 r Carcinoma.\nEstimated primary completion: 12 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07027436
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027436-2015@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT07027436)
DESCRIPTION:Tremelimumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Radi
 ation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surge
 ry Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellu
 lar Carcinoma.\nEstimated primary completion: 12 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07027436
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307665-3562@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0630766
 5)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: E
 valuating the Efficacy and Safety of PT027 Compared With PT007 Administere
 d As Needed in Participants 12 to < 18 Years of Age With Asthma\nEstimated
  primary completion: 13 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/albuterol-budesonide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06307665
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044336-2375@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Puxitatug samrotecan: Phase 3 readout est. (NCT07044336)
DESCRIPTION:Puxitatug samrotecan\, phase 3\, Endometrial Cancer.\nStudy: Pu
 xitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected
  Endometrial Cancer (Bluestar-Endometrial01)\nEstimated primary completion
 : 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pu
 xitatug-samrotecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07044336
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05907057)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Open
 -label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adu
 lt Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Inelig
 ible for Intensive Induction Chemotherapy.\nEstimated primary completion: 
 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05907057
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05907057)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidi
 ne in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AM
 L) Ineligible for Intensive Induction Chemotherapy.\nEstimated primary com
 pletion: 15 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05907057
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112314-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271016
DTEND;VALUE=DATE:20271017
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06112314)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: IMC-F106C Regimen Versu
 s Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-
 301)\nEstimated primary completion: 16 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06112314
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112314-10943@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271016
DTEND;VALUE=DATE:20271017
SUMMARY:brenetafusp: Phase 3 readout est. (NCT06112314)
DESCRIPTION:brenetafusp\, phase 3.\nStudy: IMC-F106C Regimen Versus Nivolum
 ab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)\nEst
 imated primary completion: 16 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenetafusp#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06112314
URL:https://assetmemo.bio/drug/brenetafusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747613-887@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04747613)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Long-term Safety and Tolerability of Iptacopan in Patients 
 With Paroxysmal Nocturnal Hemoglobinuria\nEstimated primary completion: 18
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptaco
 pan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04747613
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071623-1010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07071623)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Study of MK-8527 to Prev
 ent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)\nEstimated p
 rimary completion: 18 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071623
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923073-5@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271027
DTEND;VALUE=DATE:20271028
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05923073)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Pediatric Participants With Moderately to Severely Act
 ive Crohn's Disease\nEstimated primary completion: 27 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05923073
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04624204)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Placebo-controlled\, Study of 
 Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembroliz
 umab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small 
 Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)\nEstimated primary co
 mpletion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04624204
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-2028@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Olaparib: Phase 3 readout est. (NCT04624204)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Placebo-controlled\, Study of Concu
 rrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab 
 and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell 
 Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)\nEstimated primary complet
 ion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04624204
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293053-1356@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06293053)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Prurigo Nodularis.\nStudy: A S
 tudy to Investigate the Pharmacokinetics and Safety of Dupilumab in Partic
 ipants ≥6 Months to <18 Years of Age With Prurigo Nodularis\nEstimated p
 rimary completion: 28 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06293053
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-1524@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemluvio (nemolizumab): Phase 3 readout est. (NCT07762833)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 3\, Atopic Dermatitis.\nStudy: R
 andomized\, Double-blind\, Placebo-controlled Study of Nemolizumab in Chin
 ese Subjects With Moderate-to-severe Atopic Dermatitis\nEstimated primary 
 completion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762833
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06452277-2723@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Hyrnuo (Sevabertinib): Phase 3 readout est. (NCT06452277)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Learn More About How Well Sevabertinib Works and How Saf
 e it is Compared With Standard Treatment\, in Participants Who Have Advanc
 ed Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epiderma
 l Growth Factor Receptor 2 (HER2)\nEstimated primary completion: 28 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sevabertinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0645
 2277
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05334368-1527@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271029
DTEND;VALUE=DATE:20271030
SUMMARY:Depemokimab: Phase 3 readout est. (NCT05334368)
DESCRIPTION:Depemokimab\, phase 3.\nStudy: Depemokimab in Participants With
  Hypereosinophilic Syndrome\, Efficacy\, and Safety Trial\nEstimated prima
 ry completion: 29 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/depemokimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05334368
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047040-4523@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Gabapentin: Phase 2/3 readout est. (NCT07047040)
DESCRIPTION:Gabapentin\, phase 2/3.\nStudy: Analgesic Efficacy of Pre-opera
 tive Dose of Ketorolac and Gabapentin\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gabapenti
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 047040
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459790-1220@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Neovasculgen: Phase 2/3 readout est. (NCT07459790)
DESCRIPTION:Neovasculgen\, phase 2/3.\nStudy: The Study is Being Conducted 
 to Find a New Treatment for Patients Suffering From Interstitial Cystitis 
 With Hunner's Lesions\nEstimated primary completion: 30 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/neovasculgen#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07459790
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970172-873@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT05970172)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chr
 onic Kidney Disease\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/roxadustat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05970172
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06612814)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therap
 y in HR+/ HER2-Advanced Breast Cancer\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6612814
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT06612814)
DESCRIPTION:Fluzoparib\, phase 3.\nStudy: PARP Inhibitor With CDK4/ 6 Inhib
 itor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer\nEstimated 
 primary completion: 30 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06612814
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9053@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT06612814)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ H
 ER2-Advanced Breast Cancer\nEstimated primary completion: 30 October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06612814
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05018286-10886@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:apraglutide: Phase 3 readout est. (NCT05018286)
DESCRIPTION:apraglutide\, phase 3\, Short Bowel Syndrome.\nStudy: Open-labe
 l Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short
  Bowel Syndrome.\nEstimated primary completion: 30 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/apraglutide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05018286
URL:https://assetmemo.bio/drug/apraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043400-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07043400)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study to Investigate Tisleliz
 umab Administered as Subcutaneous Injection Versus Intravenous Infusion Pl
 us Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07043400
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043400-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07043400)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study to Investigate Tisleliz
 umab Administered as Subcutaneous Injection Versus Intravenous Infusion Pl
 us Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07043400
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203600-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT06203600)
DESCRIPTION:Nivolumab\, phase 2/3\, Gastric Cancer.\nStudy: Adding Nivoluma
 b to Usual Treatment for People With Advanced Stomach or Esophageal Cancer
 \, PARAMUNE Trial\nEstimated primary completion: 31 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06203600
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203600-2013@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ramucirumab: Phase 2/3 readout est. (NCT06203600)
DESCRIPTION:Ramucirumab\, phase 2/3\, Gastric Cancer.\nStudy: Adding Nivolu
 mab to Usual Treatment for People With Advanced Stomach or Esophageal Canc
 er\, PARAMUNE Trial\nEstimated primary completion: 31 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ramucirumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06203600
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154368-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07154368)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive P
 atients Previously Treated With ROS1-TKIs.\nEstimated primary completion: 
 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07154368
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154368-2440@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Fudotinib: Phase 3 readout est. (NCT07154368)
DESCRIPTION:Fudotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JYP03
 22 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Pr
 eviously Treated With ROS1-TKIs.\nEstimated primary completion: 31 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fudotinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07154368
URL:https://assetmemo.bio/drug/fudotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255209-183@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:mazdutide: Phase 3 readout est. (NCT07255209)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Adolescents With Obesity or Overweight\nEstimated primary completion:
  31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maz
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07255209
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670884-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ribupatide: Phase 3 readout est. (NCT07670884)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Eva
 luate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Su
 bjects\nEstimated primary completion: 31 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07670884
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06542549-1994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06542549)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Efficacy and Safety of AK104 Com
 bined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Canc
 er\nEstimated primary completion: 31 October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06542549
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-2356@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ASKC202: Phase 3 readout est. (NCT07109531)
DESCRIPTION:ASKC202\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC202
  Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment 
 of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpress
 ion After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/askc202#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07109
 531
URL:https://assetmemo.bio/drug/askc202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03900988-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT03900988)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Intravenous N-acetylcystein
 e and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza
  and Pneumonia\nEstimated primary completion: 31 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03900988
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-7622@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Limertinib: Phase 3 readout est. (NCT07109531)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatme
 nt of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpr
 ession After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07109531
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026866-664@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05026866)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's D
 isease (TRAILBLAZER-ALZ 3)\nEstimated primary completion: November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05026866
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Trial of Carf
 ilzomib\, Lenalidomide\, Dexamethasone Versus Lenalidomide Alone After Ste
 m-cell Transplant for Multiple Myeloma\nEstimated primary completion: Nove
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 659293
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Trial of Car
 filzomib\, Lenalidomide\, Dexamethasone Versus Lenalidomide Alone After St
 em-cell Transplant for Multiple Myeloma\nEstimated primary completion: Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 02659293
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04662255-3359@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT04662255)
DESCRIPTION:Pirtobrutinib\, phase 3\, Mantle Cell Lymphoma.\nStudy: Study o
 f BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients W
 ith Mantle Cell Lymphoma (MCL)\nEstimated primary completion: November 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04662255
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Trial of Carfilzomib\, Lenalid
 omide\, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant
  for Multiple Myeloma\nEstimated primary completion: November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02659293
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417775-10391@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT06417775)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study of Ora
 l Ubrogepant to Assess Adverse Events and Change in Disease Activity in Ad
 ult Participants With Menstrual Migraine\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ubrogepa
 nt-ubrelvy#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06417775
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619833-312@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Envlo (Enavogliflozin): Phase 3 readout est. (NCT07619833)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: To 
 Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16
 001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monothera
 py in Patients With Type 2 Diabetes Mellitus\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enav
 ogliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07619833
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807826-1337@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:CM512: Phase 3 readout est. (NCT07807826)
DESCRIPTION:CM512\, phase 3.\nStudy: A Study of CM512 in Patients With Chro
 nic Rhinosinusitis With Nasal Polyposis (NEZHA-3)\nEstimated primary compl
 etion: November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cm512#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07807826
URL:https://assetmemo.bio/drug/cm512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379333-230@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:efpeglenatide: Phase 3 readout est. (NCT07379333)
DESCRIPTION:efpeglenatide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to E
 valuate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes M
 ellitus Inadequately Controlled With Metformin and Dapagliflozin\nEstimate
 d primary completion: November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/efpeglenatide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07379333
URL:https://assetmemo.bio/drug/efpeglenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06024746-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06024746)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: A 
 Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Com
 bination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)\nEs
 timated primary completion: November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06024746
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05943535-520@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Treprostinil (Tyvaso): Phase 3 readout est. (NCT05943535)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 3.\nStudy: Study of the Efficacy 
 and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary 
 Fibrosis (TETON-PPF)\nEstimated primary completion: November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05943535
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008197-661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06008197)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Determine the Efficacy and Safety of Finerenone on Morbidity and Mort
 ality Among Hospitalized Heart Failure Patients\nEstimated primary complet
 ion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/f
 inerenone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06008197
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06024746-661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06024746)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combina
 tion in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06024746
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309055-1489@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07309055)
DESCRIPTION:SHR-1819\, phase 3\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 Injection in Adolescents With Severe Atopic Dermatitis\nEstimated pri
 mary completion: November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07309055
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561048-1499@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:soquelitinib: Phase 3 readout est. (NCT06561048)
DESCRIPTION:soquelitinib\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: So
 quelitinib vs Standard of Care in Participants With Relapsed/Refractory Pe
 ripheral T-cell Lymphoma Not Otherwise Specified\, Follicular Helper T-cel
 l Lymphomas\, or Systemic Anaplastic Large-cell Lymphoma\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06561048
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961968-1732@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iloperidone (Fanapt): Phase 3 readout est. (NCT06961968)
DESCRIPTION:Iloperidone (Fanapt)\, phase 3\, Schizophrenia.\nStudy: Randomi
 zed Withdrawal Study in Patients With Schizophrenia\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iloperidone-fanapt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06961968
URL:https://assetmemo.bio/drug/iloperidone-fanapt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119581-2053@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06119581)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without
  Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lu
 ng Cancer\nEstimated primary completion: November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06119581
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105098-9196@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Direclidine: Phase 3 readout est. (NCT07105098)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07105098
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953869-10836@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Hetlioz (tasimelteon): Phase 3 readout est. (NCT06953869)
DESCRIPTION:Hetlioz (tasimelteon)\, phase 3.\nStudy: Evaluating the Effects
  of Tasimelteon vs. Placebo in Treating Pediatric Insomnia\nEstimated prim
 ary completion: November 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tasimelteon#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06953869
URL:https://assetmemo.bio/drug/tasimelteon#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplas
 m Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimate
 d primary completion: 1 November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neopla
 sm Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimat
 ed primary completion: 1 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1959@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e III\, Open-label\, First-line Study of Dato-DXd in Combination With Durv
 alumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alter
 ations\nEstimated primary completion: 1 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, First-line Study of Dato-DXd in Combinati
 on With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable G
 enomic Alterations\nEstimated primary completion: 1 November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-2159@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04862663)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastat
 ic HR+/HER2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 
 1 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abem
 aciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04862663
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-2228@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ribociclib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2-
  Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862663
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06200181-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT06200181)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Effect of Olanzapine on
  Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-rel
 ated Pain: A Pilot Double-Blind\, Randomized Control Trial\nEstimated prim
 ary completion: 1 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06200181
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-7646@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Capivasertib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER
 2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862
 663
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-9034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT04862663)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastati
 c HR+/HER2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1
  November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04862663
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520683-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06520683)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Adjuvant PD-1 Blockade for High
 -risk Stage-II DMMR/MSI-H Colorectal Cancer\nEstimated primary completion:
  1 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tis
 lelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06520683
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465953-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 3 readout est. (NCT06465953)
DESCRIPTION:Azacitidine\, phase 3\, Myelodysplastic Syndromes.\nStudy: Ivos
 idenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients Wit
 h Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With a
 n IDH1 Mutation\nEstimated primary completion: 1 November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06465953
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465953-2899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT06465953)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Ivosidenib (IVO) Monoth
 erapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating A
 gent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation\nEs
 timated primary completion: 1 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06465953
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03150693)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults 
 With Newly Diagnosed B Acute Lymphoblastic Leukemia\nEstimated primary com
 pletion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03150693
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03150693)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Inotuzumab Ozogamicin an
 d Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B A
 cute Lymphoblastic Leukemia\nEstimated primary completion: 1 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03150693
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226700-8794@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07226700)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine in Total 
 Hip Arthroplasty\nEstimated primary completion: 1 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07226700
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT03150693)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Inotuzumab Ozogamicin and Fron
 tline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute L
 ymphoblastic Leukemia\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03150693
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624450-1426@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:tozorakimab: Phase 3 readout est. (NCT05624450)
DESCRIPTION:tozorakimab\, phase 3.\nStudy: Efficacy and Safety of Tozorakim
 ab in Patients Hospitalised for Viral Lung Infection Requiring Supplementa
 l Oxygen\nEstimated primary completion: 4 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tozorakimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05624450
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007962-1477@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07007962)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With
  Immune Thrombocytopenia (ITP) Who Failed First-line Treatment\nEstimated 
 primary completion: 5 November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07007962
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099898-2501@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07099898)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Canc
 er (SCLC) [EMBOLD SCLC-301]\nEstimated primary completion: 5 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 099898
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03811561-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271107
DTEND;VALUE=DATE:20271108
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT03811561)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: A Re
 search Study to Look at How Semaglutide Compared to Placebo Affects Diabet
 ic Eye Disease in People With Type 2 Diabetes\nEstimated primary completio
 n: 7 November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03811561
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05064878-8885@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271108
DTEND;VALUE=DATE:20271109
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT05064878)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Epilepsy.\nStudy: A Phase 3
  Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 
 Deficiency Disorder.\nEstimated primary completion: 8 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fenfluramine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05064878
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908226-8867@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06908226)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Study to Investigat
 e LP352 in Children and Adults With Developmental and Epileptic Encephalop
 athy (DEE)\nEstimated primary completion: 11 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06908226
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624670-42@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:Spevigo (spesolimab): Phase 3 readout est. (NCT06624670)
DESCRIPTION:Spevigo (spesolimab)\, phase 3.\nStudy: A Study to Test Whether
  Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
 \nEstimated primary completion: 12 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/spesolimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06624670
URL:https://assetmemo.bio/drug/spesolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05356195-10277@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053561
 95)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3.\nStudy: Evaluatio
 n of Safety and Efficacy of CTX001 in Pediatric Participants With Transfus
 ion-Dependent β-Thalassemia (TDT)\nEstimated primary completion: 14 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exagamgloge
 ne-autotemcel-casgevy#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05356195
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493057-190@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07493057)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Not Treated With Positive Airway Pressure (PAP) Therapy\nEstimated pri
 mary completion: 14 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bofanglutide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07493057
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07482176-11228@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Ixoberogene soroparvovec: Phase 3 readout est. (NCT07482176)
DESCRIPTION:Ixoberogene soroparvovec\, phase 3\, Wet Age-Related Macular De
 generation.\nStudy: Efficacy and Safety Study of Ixoberogene Soroparvovec 
 (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneratio
 n (AQUARIUS)\nEstimated primary completion: 15 November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07482176
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-2289@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04975997)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Open-label St
 udy Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd) Versus D
 aratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participants With Rel
 apsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary completion:
  16 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04975997
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-3209@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT04975997)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: Ope
 n-label Study Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd
 ) Versus Daratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participant
 s With Relapsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary c
 ompletion: 16 November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04975997
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04975997)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Open-label Study Comparing Ibe
 rdomide\, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab\, Bort
 ezomib\, and Dexamethasone (DVd) in Participants With Relapsed or Refracto
 ry Multiple Myeloma (RRMM)\nEstimated primary completion: 16 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04975997
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449780-1994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271117
DTEND;VALUE=DATE:20271118
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07449780)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Study of AK104 (SC) in Combina
 tion With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combin
 ation With XELOX in Participants With Unresectable Locally Advanced or Met
 astatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
 \nEstimated primary completion: 17 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07449780
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449780-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271117
DTEND;VALUE=DATE:20271118
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07449780)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study of AK104 (SC) in Combin
 ation With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combi
 nation With XELOX in Participants With Unresectable Locally Advanced or Me
 tastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinom
 a\nEstimated primary completion: 17 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07449780
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06468033-9910@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0646803
 3)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3\, Myelofibrosis.\nS
 tudy: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Int
 ermediate-1 Risk\nEstimated primary completion: 18 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besre
 mi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6468033
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07225946)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Doc
 etaxel in Participants With Metastatic Castration-Resistant Prostate Cance
 r\nEstimated primary completion: 19 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-11218@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07225946)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Docetaxel in 
 Participants With Metastatic Castration-Resistant Prostate Cancer\nEstimat
 ed primary completion: 19 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669611-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06669611)
DESCRIPTION:Camrelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Nab-
 TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metasta
 tic Nasopharyngeal Carcinoma\nEstimated primary completion: 20 November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06669611
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821944-1048@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT07821944)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: A Clinical Study of Enlicitide (MK-0616) in Adults Wit
 h Hyperlipidemia in India (MK-0616-038)\nEstimated primary completion: 26 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlici
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07821944
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079671-1985@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06079671)
DESCRIPTION:Volrustomig\, phase 3\, Cervical Cancer.\nStudy: Study of Volru
 stomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Ce
 rvical)\nEstimated primary completion: 26 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06079671
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-7646@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capivasertib: Phase 3 readout est. (NCT06764186)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combinatio
 n With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relaps
 ed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Pr
 actice in Spain\nEstimated primary completion: 30 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06764186)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in 
 Combination With Fulvestrant in Patients With Advanced Breast Cancer Who H
 ave Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World C
 linical Practice in Spain\nEstimated primary completion: 30 November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-2058@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Regorafenib: Phase 3 readout est. (NCT07384377)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: JSKN003 Vers
 us Physician Choiced Treatment in Patients With HER2-positive and Advanced
  Colorectal Cancer Who Had Failed to Respond to Oxaliplatin\, 5-Fu\, and I
 rinotecan\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07384377
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-2237@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0738437
 7)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Colorectal Cancer
 .\nStudy: JSKN003 Versus Physician Choiced Treatment in Patients With HER2
 -positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxal
 iplatin\, 5-Fu\, and Irinotecan\nEstimated primary completion: 30 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07384
 377
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526624-2501@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT06526624)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell L
 ung Cancer\nEstimated primary completion: 30 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06526624
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-9179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Anbenitamab repodatecan: Phase 3 readout est. (NCT07384377)
DESCRIPTION:Anbenitamab repodatecan\, phase 3\, Colorectal Cancer.\nStudy: 
 JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive 
 and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin\, 
 5-Fu\, and Irinotecan\nEstimated primary completion: 30 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/anbenitamab-repodatecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 4377
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05354141-50@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:ExoFlo: Phase 3 readout est. (NCT05354141)
DESCRIPTION:ExoFlo\, phase 3.\nStudy: Extracellular Vesicle Treatment for A
 cute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)\nEstimated pri
 mary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/exoflo#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05354141
URL:https://assetmemo.bio/drug/exoflo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05230758-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05230758)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Effect of Metformin o
 n Behaviour and the Brain in Children Treated for a Brain Tumour\nEstimate
 d primary completion: 30 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05230758
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830798-885@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06830798)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3.\nStudy: Double-blind\, Rando
 mized\, Placebo-controlled\, Multicenter Study to Evaluate the Efficacy an
 d Safety of Ravulizumab Administered Intravenously in Adult Participants a
 t High Risk of Delayed Graft Function After Kidney Transplantation\nEstima
 ted primary completion: 30 November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06830798
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586074-3016@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Clifutinib Besylate: Phase 3 readout est. (NCT05586074)
DESCRIPTION:Clifutinib Besylate\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/clifutinib-besylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586074
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05371613-10788@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avlayah (Tividenofusp alfa): Phase 2/3 readout est. (NCT05371613)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 2/3\, Mucopolysaccharidosis
  Type II.\nStudy: A Study to Determine the Efficacy and Safety of Tivideno
 fusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participant
 s With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis 
 Type II (nnMPS II)\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05371613
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893250-1277@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ADSTEM: Phase 2/3 readout est. (NCT06893250)
DESCRIPTION:ADSTEM\, phase 2/3.\nStudy: Orthobiologic Treatment for Knee Os
 teoarthritis\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/adstem#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06893250
URL:https://assetmemo.bio/drug/adstem#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06387199-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Ozempic): Phase 2/3 readout est. (NCT06387199)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2/3.\nStudy: Alleviating Carbohyd
 rate Counting for Patients With Type-1 Diabetes Using a Closed Loop System
  With Weekly Subcutaneous Semaglutide\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -ozempic#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06387199
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931080-825@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Simtriyo (Centanafadine): Phase 2/3 readout est. (NCT06931080)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 2/3\, Attention Deficit Hypera
 ctivity Disorder.\nStudy: Evaluation of the Efficacy and Safety of EB-1020
  in Adult ADHD Patients\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/centanafadine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06931080
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax 
 + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07255872
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax
  + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07255872
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2893@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BL-M11D1: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:BL-M11D1\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Study 
 of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + 
 Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bl-m11d1#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07255872
URL:https://assetmemo.bio/drug/bl-m11d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04893525-8925@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Naloxone (Narcan): Phase 2/3 readout est. (NCT04893525)
DESCRIPTION:Naloxone (Narcan)\, phase 2/3.\nStudy: Evaluating Buprenorphine
 /Naloxone Microdosing vs. Standard Dosing in Emergency Departments\nEstima
 ted primary completion: December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04893525
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511416-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04511416)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Preventing Cognitive 
 Decline with Metformin\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04511416
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709014-738@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Buntanetap: Phase 3 readout est. (NCT06709014)
DESCRIPTION:Buntanetap\, phase 3\, Alzheimer's Disease.\nStudy: A Double-bl
 ind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants
  With Early AD\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/buntanetap#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06709014
URL:https://assetmemo.bio/drug/buntanetap#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02999087-1965@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT02999087)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: Randomized Trial of Avelumab-cetux
 imab-radiotherapy Versus SOCs in LA SCCHN (REACH)\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02999087
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112861-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05112861)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: A 3-month Study to Compare the S
 afety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visu
 al Impairment Due to Retinal Disorders\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 112861
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02999087-2017@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avelumab: Phase 3 readout est. (NCT02999087)
DESCRIPTION:Avelumab\, phase 3.\nStudy: Randomized Trial of Avelumab-cetuxi
 mab-radiotherapy Versus SOCs in LA SCCHN (REACH)\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT02999087
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06388733-2052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 3 readout est. (NCT06388733)
DESCRIPTION:Niraparib\, phase 3\, Glioblastoma.\nStudy: A Study Comparing N
 iraparib With Temozolomide in Adult Participants With Newly-diagnosed\, MG
 MT Unmethylated Glioblastoma\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06388733
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04967521-2159@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04967521)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3.\nStudy: SARC041: Study of Abe
 maciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposar
 coma\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04967521
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-2266@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selinexor: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Selinexor\, phase 3\, Multiple Myeloma.\nStudy: Study Assessing
  Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Availa
 ble Therapies in Adult Participants With Relapsed or Refractory Multiple M
 yeloma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Study Assessi
 ng Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avai
 lable Therapies in Adult Participants With Relapsed or Refractory Multiple
  Myeloma\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265428-2448@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06265428)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265428
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05294172-2581@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagitanlimab: Phase 3 readout est. (NCT05294172)
DESCRIPTION:Tagitanlimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: KL-A
 167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined 
 With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic
  Nasopharyngeal Carcinoma\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05294172
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Study Assess
 ing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Ava
 ilable Therapies in Adult Participants With Relapsed or Refractory Multipl
 e Myeloma\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3132@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3229@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Etentamig: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Etentamig\, phase 3\, Multiple Myeloma.\nStudy: Study Assessing
  Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Availa
 ble Therapies in Adult Participants With Relapsed or Refractory Multiple M
 yeloma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06037460-6083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0603746
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: TocilizuMa
 b discontinuAtion in GIant Cell Arteritis\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tociliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06037460
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Study Assessing Activity of In
 travenous (IV) Etentamig Monotherapy Versus Standard Available Therapies i
 n Adult Participants With Relapsed or Refractory Multiple Myeloma\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196774-9096@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07196774)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoa
 djuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast
  Cancer\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196774
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878976-866@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT06878976)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3.\nStudy: A Study to Assess the 
 Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eatin
 g Disorder\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/solriamfetol#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06878976
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773883-866@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07773883)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: An Open-Label Study to Assess the Long-Term Safety of
  Solriamfetol in Children and Adolescents With ADHD\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/solriamfetol#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07773883
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735483-1423@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT05735483)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650
 150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe 
 Atopic Dermatitis\nEstimated primary completion: December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05735483
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622810-190@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07622810)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: BALANCE-OBS: Bofanglu
 tide (GZR18) Versus Semaglutide in Latin American Adults With Overweight o
 r Obesity\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bofanglutide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07622810
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741240-839@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KH607: Phase 3 readout est. (NCT07741240)
DESCRIPTION:KH607\, phase 3\, Major Depressive Disorder.\nStudy: A Study of
  KH607 as Monotherpy in Adults Participants With Major Depressive Disorder
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/kh607#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07741240
URL:https://assetmemo.bio/drug/kh607#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741331-839@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KH607: Phase 3 readout est. (NCT07741331)
DESCRIPTION:KH607\, phase 3\, Major Depressive Disorder.\nStudy: Compare th
 e Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Ta
 blets in Adult Patients With Major Depressive Disorder\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/kh607#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07741331
URL:https://assetmemo.bio/drug/kh607#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441317-1055@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLC7401: Phase 3 readout est. (NCT07441317)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyp
 erlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07441317
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643260-1801@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Piclidenoson: Phase 3 readout est. (NCT06643260)
DESCRIPTION:Piclidenoson\, phase 3\, Psoriasis.\nStudy: A Phase 3 Study in 
 Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and 
 Efficacy\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/piclidenoson#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06643260
URL:https://assetmemo.bio/drug/piclidenoson#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077215-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05077215)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Efficacy 
 and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem i
 n Advanced Endometrial Cancer\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05077215
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730489-2282@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07730489)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Colorectal Cancer.\nStudy: 
 A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients Wit
 h HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Ox
 aliplatin\, Fluorouracil and Irinotecan\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07730489
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-3123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06742138)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate 
 the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myelom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-3369@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QL2109: Phase 3 readout est. (NCT06742138)
DESCRIPTION:QL2109\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate the Ef
 ficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ql2109#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/ql2109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06742138)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: To Evaluate the Efficacy and S
 afety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma\nEstimated prima
 ry completion: December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dexamethasone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05509777-4@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT05509777)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Crohn's Disease.\nStudy: A Stud
 y of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Diseas
 e\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mirikizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05509777
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553182-16@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT07553182)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: OLE Study With Filgoti
 nib in JIA\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07553182
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672939-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672939)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Adolescent Participants With Obesity\, or Ove
 rweight With Related Comorbidities\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06672
 939
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739122-127@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trulicity (dulaglutide): Phase 3 readout est. (NCT06739122)
DESCRIPTION:Trulicity (dulaglutide)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participan
 ts With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dulaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06739122
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528027-186@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07528027)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Obesity.\nStudy: Phase III S
 tudy of HRS-7535 for Hypertension With Overweight or Obesity\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07528027
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187570-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0718757
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: RECURrence
  of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapa
 gliflozin or Usual Care\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07187570
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955260-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06955260)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: SGLT2 Inhibition W
 ith Empagliflozin in Fontan Circulatory Failure\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 mpagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06955260
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766655-667@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Auvelity (Dextromethorphan/bupropion): Phase 3 readout est. (NCT077
 66655)
DESCRIPTION:Auvelity (Dextromethorphan/bupropion)\, phase 3.\nStudy: Studyi
 ng NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)\nEstimated pri
 mary completion: December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dextromethorphan-bupropion#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07766655
URL:https://assetmemo.bio/drug/dextromethorphan-bupropion#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03127267-787@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Masitinib: Phase 3 readout est. (NCT03127267)
DESCRIPTION:Masitinib\, phase 3\, Amyotrophic Lateral Sclerosis.\nStudy: Ef
 ficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Pati
 ents\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/masitinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03127267
URL:https://assetmemo.bio/drug/masitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926829-825@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT06926829)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Long-term Trial of EB-1020 in Adult Patients Wit
 h ADHD\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06926829
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904261-912@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT06904261)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease an
 d Amenable GLA Variants\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06904261
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633810-1199@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 3 readout est. (NCT0563
 3810)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 3.\nStudy: COLchic
 ine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of
  Patients With Type 2 Diabetes\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/colchicine-cardiov
 ascular#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05633810
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761936-1777@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Xadago (Safinamide): Phase 3 readout est. (NCT07761936)
DESCRIPTION:Xadago (Safinamide)\, phase 3\, Parkinson's Disease.\nStudy: Sa
 finamide vs Placebo for Pain in Patients With Parkinson's Disease and Moto
 r Fluctuations\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/safinamide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07761936
URL:https://assetmemo.bio/drug/safinamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06956001-1983@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06956001)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Versus Platinum Based Chemotherapy as First-line Treatment fo
 r NSCLC With EGFR PACC or EGFR l861q Mutation\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fur
 monertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06956001
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800223-1984@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Almonertinib: Phase 3 readout est. (NCT05800223)
DESCRIPTION:Almonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ar
 matinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated
  Non-small Cell Lung Cancer\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/almonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05800223
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05941741-1994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT05941741)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: IC Plus Low-dose Radiation Plus 
 Cadonilimab in LANPC\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05941741
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132463-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07132463)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Neoadjuvant Chemoradiotherapy F
 ollowed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-
 low Rectal Cancer: The RELIEVE-02 Study\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07132463
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418749-2064@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07418749)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Cervical Cancer.\nStudy: A St
 udy of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients 
 With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Re
 current or Metastatic Cervical Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/notiretatug
 -rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07418749
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528716-2207@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07528716)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Artificial Intelligence Model-Guid
 ed Neoadjuvant Anti-HER2 Targeted Therapy\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7528716
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072612-2210@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retifanlimab: Phase 3 readout est. (NCT06072612)
DESCRIPTION:Retifanlimab\, phase 3.\nStudy: Study of the Bria-IMT Regimen a
 nd CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.\nEstima
 ted primary completion: December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06072612
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178795-2282@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07178795)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in Fir
 st-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07178795
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138209-3122@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS32015: Phase 3 readout est. (NCT07138209)
DESCRIPTION:QLS32015\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparin
 g QLS32015 Monotherapy Versus Pomalidomide\, Dexamethasone (Pd) or Selinex
 or\, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multip
 le Myeloma\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qls32015#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07138209
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, 
 Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple M
 yeloma Not Eligible for Transplant\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729732
 9
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07388602)
DESCRIPTION:Bortezomib\, phase 3.\nStudy: A Study to Evaluate the Safety an
 d Efficacy of SCTC21C in Combination With Bortezomib\, Cyclophosphamide\, 
 and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Am
 yloidosis (NDSLCA)\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to E
 valuate the Safety and Efficacy of SCTC21C in Combination With Bortezomib\
 , Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple
  Myeloma Not Eligible for Transplant\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 97329
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3146@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07297329)
DESCRIPTION:SCTC21C\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evalua
 te the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Len
 alidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myel
 oma Not Eligible for Transplant\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07297329
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-3146@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07388602)
DESCRIPTION:SCTC21C\, phase 3\, AL Amyloidosis.\nStudy: A Study to Evaluate
  the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Cyclo
 phosphamide\, and Dexamethasone in Patients With Newly Diagnosed Systemic 
 Light-Chain Amyloidosis (NDSLCA)\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582549-3789@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:fluticasone propionate: Phase 3 readout est. (NCT07582549)
DESCRIPTION:fluticasone propionate\, phase 3.\nStudy: Finnish Children´s P
 rotracted Cough\nEstimated primary completion: December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/fluticasone-propionate#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07582549
URL:https://assetmemo.bio/drug/fluticasone-propionate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04745728-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04745728)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Different Immunosuppress
 ive Treatment in iMN\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04745728
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136976-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05136976)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab Therapy in Ant
 i-Myelin Associated Glycoprotein Patients With Characteristics of Good Res
 ponders\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05136976
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04574960-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT04574960)
DESCRIPTION:Gemcitabine\, phase 3.\nStudy: Neoadjuvant Upper Tract Invasive
  Cancer Trial (NAUTICAL)\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04574960
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate the Safety
  and Efficacy of SCTC21C in Combination With Bortezomib\, Lenalidomide and
  Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligi
 ble for Transplant\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07297329
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07388602)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Evaluate the Safety
  and Efficacy of SCTC21C in Combination With Bortezomib\, Cyclophosphamide
 \, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain
  Amyloidosis (NDSLCA)\nEstimated primary completion: December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520345-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06520345)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: The Study of 177Lu-TLX591 Plus SOC Versus SOC A
 lone in Patients With mCRPC (ProstACT Global)\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06520345
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565428-9264@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Roluperidone: Phase 3 readout est. (NCT07565428)
DESCRIPTION:Roluperidone\, phase 3\, Schizophrenia.\nStudy: Study to Evalua
 te Efficacy and Safety of Roluperidone in Adult Subjects With Negative Sym
 ptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Re
 lapse Rate of Roluperidone and Antipsychotic Medications\nEstimated primar
 y completion: December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/roluperidone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07565428
URL:https://assetmemo.bio/drug/roluperidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768189-10784@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07768189)
DESCRIPTION:Sutantatug envedotin\, phase 3.\nStudy: A Study to Evaluate CRB
 -701 Compared to Investigator's Choice Therapy in Previously Treated Oroph
 aryngeal Squamous Cell Carcinoma\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sutantatug-enved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07768189
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039916-10825@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Imeroprubart: Phase 3 readout est. (NCT07039916)
DESCRIPTION:Imeroprubart\, phase 3\, Myasthenia Gravis.\nStudy: Study to As
 sess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Sev
 ere Generalized Myasthenia Gravis\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070399
 16
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226089-10909@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:NGENLA (somatrogon): Phase 3 readout est. (NCT07226089)
DESCRIPTION:NGENLA (somatrogon)\, phase 3.\nStudy: Comparison of Weekly Som
 atrogon to Daily Genotropin in Children Born Small for Gestational Age or 
 With Idiopathic Short Stature.\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/somatrogon#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07226089
URL:https://assetmemo.bio/drug/somatrogon#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499857-11054@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06499857)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide f
 or Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06499857
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311694-11070@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4357: Phase 3 readout est. (NCT07311694)
DESCRIPTION:HRS-4357\, phase 3\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Phase III Study Comparing HRS-4357 With Novel Androgen Re
 ceptor Pathway Inhibitors in Patients With Progressive\, PSMA-Positive Met
 astatic Castration-Resistant Prostate Cancer\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-
 4357#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07311694
URL:https://assetmemo.bio/drug/hrs-4357#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128629-11313@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nexiguran ziclumeran: Phase 3 readout est. (NCT06128629)
DESCRIPTION:Nexiguran ziclumeran\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Partic
 ipants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128629
URL:https://assetmemo.bio/drug/nexiguran-ziclumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115499-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06115499)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: The PLATINUM Trial: Optimiz
 ing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PA
 LB2-Associated Metastatic Pancreatic Cancer\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06115499
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115499-7671@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06115499)
DESCRIPTION:Gemcitabine\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treat
 ment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cance
 r\nEstimated primary completion: 1 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06115499
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612151-2817@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06612151)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-3
 02)\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06612151
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629597-2817@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06629597)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Nasopharyngeal Carcinoma.\nStu
 dy: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal C
 arcinoma (TAISHAN-301)\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-pelitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0662959
 7
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05876754-2899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05876754)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: An Early Access Study o
 f Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic 
 Cholangiocarcinoma\nEstimated primary completion: 1 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05876754
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280572-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07280572)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: RECLAIM Adaptive Plat
 form Trial for PCC Treatments\nEstimated primary completion: 1 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07280572
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-2286@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Chidamide: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: AC-CH
 OP Versus CHOP in Patients With Previously Untreated PTCL-TFH\nEstimated p
 rimary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05678933
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Azacitidine\, phase 3.\nStudy: AC-CHOP Versus CHOP in Patients 
 With Previously Untreated PTCL-TFH\nEstimated primary completion: 1 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0567
 8933
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-9113@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Epirubicin: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Epirubicin\, phase 3.\nStudy: AC-CHOP Versus CHOP in Patients W
 ith Previously Untreated PTCL-TFH\nEstimated primary completion: 1 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056789
 33
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929806-591@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT06929806)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Heart F
 ailure.\nStudy: Multi-center Trial of Ferric Derisomaltose Versus no Intra
 venous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Fail
 ure\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06929806
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881784-2216@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT06881784)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSC
 LC (RASolve 301)\nEstimated primary completion: 1 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06881784
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980727-3575@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:terbutaline: Phase 3 readout est. (NCT06980727)
DESCRIPTION:terbutaline\, phase 3.\nStudy: Comparative Efficacy of IV Dexam
 ethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED\nEstimat
 ed primary completion: 1 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/terbutaline#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06980727
URL:https://assetmemo.bio/drug/terbutaline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980727-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06980727)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Comparative Efficacy of IV Dex
 amethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED\nEstim
 ated primary completion: 1 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06980727
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283966-7606@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Breztri Aerosphere (Budesonide/glycopyrrolate/formoterol fumarate):
  Phase 3 readout est. (NCT06283966)
DESCRIPTION:Breztri Aerosphere (Budesonide/glycopyrrolate/formoterol fumara
 te)\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStudy: A Study Eva
 luating the Efficacy of Budesonide\, Glycopyrronium and Formoterol Fumarat
 e Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive
  Pulmonary Disease\nEstimated primary completion: 3 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/budesonide-glycopyrrolate-fo
 rmoterol-fumarate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06283966
URL:https://assetmemo.bio/drug/budesonide-glycopyrrolate-formoterol-fumarat
 e#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852704-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271204
DTEND;VALUE=DATE:20271205
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0585270
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3.\nStudy: SGLT2 Inhi
 bitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Red
 uce Post-opErative AF\nEstimated primary completion: 4 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05852704
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075146-960@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT07075146)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: DOR/TDF/3TC COmp
 ared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight 
 or Obesity\nEstimated primary completion: 5 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/doravirine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07075146
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075146-8395@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT07
 075146)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, HIV.\nStudy:
  DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HI
 V and Overweight or Obesity\nEstimated primary completion: 5 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-disoproxi
 l-fumarate-viread#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07075146
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06183931-11166@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Cliramitug: Phase 3 readout est. (NCT06183931)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM\nEs
 timated primary completion: 6 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06183931
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890909-10841@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07890909)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3b St
 udy of Participant Experience on Povetacicept Administered Via Autoinjecto
 r as Compared to Sibeprenlimab Administered Via Prefilled Syringe\nEstimat
 ed primary completion: 12 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07890909
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Atezolizumab\, phase 2/3.\nStudy: Testing the Use of Investigat
 ional Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemo
 therapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cance
 rs\nEstimated primary completion: 15 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05063552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-1965@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Cetuximab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Cetuximab\, phase 2/3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Testing the Use of Investigational Drugs Atezolizumab and/or Bevac
 izumab With or Without Standard Chemotherapy in the Second-Line Treatment 
 of Advanced-Stage Head and Neck Cancers\nEstimated primary completion: 15 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05063552
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Bevacizumab\, phase 2/3.\nStudy: Testing the Use of Investigati
 onal Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemot
 herapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancer
 s\nEstimated primary completion: 15 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05063552
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Head and Neck Squamous Cell 
 Carcinoma.\nStudy: Testing the Use of Investigational Drugs Atezolizumab a
 nd/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line
  Treatment of Advanced-Stage Head and Neck Cancers\nEstimated primary comp
 letion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05063552
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246330-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07246330)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Stratified Treatment in Unresect
 able Locally Advanced ESCC Without Progression After Chemoimmunotherapy In
 duction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective
 \, Randomized\, Controlled Phase III Multicenter Study\nEstimated primary 
 completion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07246330
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750094-2020@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06750094)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Partici
 pants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previou
 sly Received Chemotherapy\nEstimated primary completion: 15 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06750094
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387094-193@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271216
DTEND;VALUE=DATE:20271217
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07387094)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of XW003 in Ob
 ese Participants With Obstructive Sleep Apnea But Not Receive Positive Air
 way Pressure Therapy\nEstimated primary completion: 16 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07387094
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869227-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05869227)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Maint
 enance Therapy With Toripalimab Combined With Capecitabine/Placebo for Rec
 urrent and Metastatic Nasopharyngeal Carcinoma\nEstimated primary completi
 on: 20 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05869227
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869227-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05869227)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Maintenance Therapy With Toripa
 limab Combined With Capecitabine/Placebo for Recurrent and Metastatic Naso
 pharyngeal Carcinoma\nEstimated primary completion: 20 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05869227
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625280-11034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 3 readout est. (NCT07625280)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 3\, Narcolepsy.\nStudy: A Study Evaluating the Efficacy and Safety of
  Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH\nE
 stimated primary completion: 23 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxybates-
 xywav#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07625280
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634367-1539@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271224
DTEND;VALUE=DATE:20271225
SUMMARY:HSK39004: Phase 3 readout est. (NCT07634367)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in CO
 PD\nEstimated primary completion: 24 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07634367
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684144-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076841
 44)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-2-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684144
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684235-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076842
 35)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-1-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684235
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219420-92@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT07219420)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Bimekizumab in Study Participants With Palmoplant
 ar Pustulosis\nEstimated primary completion: 27 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07219420
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223203-10761@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07223203)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Polyneuro
 pathy.\nStudy: TRITON-PN: A Study to Evaluate the Efficacy and Safety of N
 ucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyn
 europathy\nEstimated primary completion: 27 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nucresiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07223203
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952621-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06952621)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant Treatment of Toripal
 imab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxe
 l Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous 
 Cell Carcinoma\nEstimated primary completion: 28 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06952621
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423599-11054@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Semaglutide (Wegovy): Phase 2/3 readout est. (NCT06423599)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2/3\, Obesity.\nStudy: Effect of W
 eight Loss on Physical and Cardiac Performance in People With Obesity and 
 Heart Failure\nEstimated primary completion: 30 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06423599
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511647-1920@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:QL2106: Phase 3 readout est. (NCT07511647)
DESCRIPTION:QL2106\, phase 3\, Psoriasis.\nStudy: A Phase 3 Clinical Study 
 of QL2106 Injection\nEstimated primary completion: 30 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ql2106#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07511647
URL:https://assetmemo.bio/drug/ql2106#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272109-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07272109)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Active Anti-diabetic Treatmen
 t Plus Chemotherapy for Pancreatic Cancer Related Diabetes\nEstimated prim
 ary completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07272109
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442565-2211@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:CPO301: Phase 3 readout est. (NCT07442565)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SYS6010 
 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ\nE
 stimated primary completion: 30 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07442565
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07597395-3071@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Vesanoid (Tretinoin): Phase 3 readout est. (NCT07597395)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 3.\nStudy: ATRA for Management of 
 Primary ITP\nEstimated primary completion: 30 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07597395
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05407987-591@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05407987)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3.\nStudy: 
 Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology:
  ERAS (Enhanced Recovery After Surgery)\nEstimated primary completion: 30 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ferric
 -derisomaltose#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05407987
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123754-994@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Envafolimab: Phase 3 readout est. (NCT06123754)
DESCRIPTION:Envafolimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable
  Stage III NSCLC\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06123754
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297096-1977@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nintedanib (Ofev): Phase 3 readout est. (NCT06297096)
DESCRIPTION:Nintedanib (Ofev)\, phase 3\, Systemic Sclerosis.\nStudy: Study
  of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Scler
 osis and Interstitial Lung Disease\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-
 ofev#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06297096
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258811-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06258811)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Neoadjuvant Immunochemotherapy 
 for LAOSCC\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06258811
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Ad
 ult Participants With Relapsed or Refractory and Lenalidomide-exposed Mult
 iple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066154
 79
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-2289@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Ad
 ult Participants With Relapsed or Refractory and Lenalidomide-exposed Mult
 iple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066154
 79
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-3123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to C
 ompare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in A
 dult Participants With Relapsed or Refractory and Lenalidomide-exposed Mul
 tiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0661
 5479
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-3253@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Arlocabtagene autoleucel: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Arlocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy: 
 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard R
 egimens in Adult Participants With Relapsed or Refractory and Lenalidomide
 -exposed Multiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion
 : 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 rlocabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06615479
URL:https://assetmemo.bio/drug/arlocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05509933-4382@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pulmicort (Budesonide): Phase 3 readout est. (NCT05509933)
DESCRIPTION:Pulmicort (Budesonide)\, phase 3.\nStudy: Budesonide Prophylaxi
 s for Engraftment Syndrome After Hematopoietic Cell Transplantation\nEstim
 ated primary completion: 30 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/budesonide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05509933
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297096-6083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0629709
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: Study of t
 he Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis 
 and Interstitial Lung Disease\nEstimated primary completion: 30 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06297096
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208305-7608@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Olanzapine (Zyprexa): Phase 3 readout est. (NCT07208305)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 3.\nStudy: Olanzapine Plus Metoclo
 pramide for the Prevention of Opioid-Induced Nausea and Vomiting\nEstimate
 d primary completion: 30 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07208305
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study to Compare the Efficac
 y and Safety of BMS-986393 Versus Standard Regimens in Adult Participants 
 With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUI
 NTESSENTIAL-2)\nEstimated primary completion: 30 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06615479
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05712200-11264@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Abelacimab: Phase 3 readout est. (NCT05712200)
DESCRIPTION:Abelacimab\, phase 3.\nStudy: Study to evaLuate the effIcacy an
 d Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who 
 Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/abelacimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05712200
URL:https://assetmemo.bio/drug/abelacimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04695080-7191@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cladribine (MAVENCLAD®): Phase 2/3 readout est. (NCT04695080)
DESCRIPTION:Cladribine (MAVENCLAD®)\, phase 2/3\, Multiple Sclerosis.\nStu
 dy: ChariotMS - Cladribine to Halt Deterioration in People With Advanced M
 ultiple Sclerosis\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cladribine-mavenclad#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04695080
URL:https://assetmemo.bio/drug/cladribine-mavenclad#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719622-4382@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pulmicort (Budesonide): Phase 2/3 readout est. (NCT06719622)
DESCRIPTION:Pulmicort (Budesonide)\, phase 2/3.\nStudy: Evaluation of the E
 fficacy of Local Budesonide Treatment in Children with Crohn's Disease Loc
 ated in the Esophagus And/or Stomach And/or Duodenum\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/budesonide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06719622
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325591-789@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tazbentetol (SPG302): Phase 2/3 readout est. (NCT07325591)
DESCRIPTION:Tazbentetol (SPG302)\, phase 2/3\, Amyotrophic Lateral Sclerosi
 s.\nStudy: Efficacy and Safety of Tazbentetol in ALS Participants\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tazbentetol-spg302#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07325591
URL:https://assetmemo.bio/drug/tazbentetol-spg302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926867-1524@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nemluvio (nemolizumab): Phase 2/3 readout est. (NCT07926867)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2/3.\nStudy: A Pilot Multicentri
 c Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients 
 ≥ 12yo With Dystrophic Epidermolysis Bullosa\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nemolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07926867
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Camrelizumab\, phase 2/3.\nStudy: Precision Medicine for Immuno
 therapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 amrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07653451
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-1976@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gilotrif (Afatinib): Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Gilotrif (Afatinib)\, phase 2/3.\nStudy: Precision Medicine for
  Immunotherapy-Resistant Advanced Esophageal Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/afatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07653451
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Apatinib\, phase 2/3.\nStudy: Precision Medicine for Immunother
 apy-Resistant Advanced Esophageal Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apati
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07653451
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Precision Medicine for Immunot
 herapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 ripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07653451
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052422-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07052422)
DESCRIPTION:Venetoclax\, phase 2/3.\nStudy: VEN+DAC+Bu2Flu4 vs Bu2Flu5 Cond
 itioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07052422
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-2207@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Pyrotinib\, phase 2/3.\nStudy: Precision Medicine for Immunothe
 rapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyro
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07653451
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662811-2291@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Enlonstobart: Phase 2/3 readout est. (NCT07662811)
DESCRIPTION:Enlonstobart\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Th
 erapy for Squamous Non-Small Cell Lung Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 enlonstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07662811
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-9053@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Dalpiciclib\, phase 2/3.\nStudy: Precision Medicine for Immunot
 herapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 lpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07653451
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435090-10363@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rimegepant (Nurtec ODT): Phase 2/3 readout est. (NCT07435090)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 2/3.\nStudy: Efficacy and Safet
 y of Rimegepant for Acute Dizziness\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant
 -nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07435090
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227103-849@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:D-cycloserine/lurasidone (NRX-101): Phase 2/3 readout est. (NCT0722
 7103)
DESCRIPTION:D-cycloserine/lurasidone (NRX-101)\, phase 2/3\, Major Depressi
 ve Disorder.\nStudy: A Randomized\, Double-Blind Controlled Comparison of 
 NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Mag
 netic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/d-cycloserine-lurasidone-nrx-101#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07227103
URL:https://assetmemo.bio/drug/d-cycloserine-lurasidone-nrx-101#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410169-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07410169)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Na
 b-paclitaxel-Induced Peripheral Neuropathy\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07410169
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-1975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 ding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With 
 Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platin
 um Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: A Study to Evaluate the Efficac
 y and Safety of IBI310 and Sintilimab Combination Therapy in Patients With
  Hepatocellular Carcinoma as First-line Treatment.\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07490262
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combinat
 ion Therapy in Patients With Hepatocellular Carcinoma as First-line Treatm
 ent.\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07490262
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-2013@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ramucirumab: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Ramucirumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
 dding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With
  Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Plati
 num Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04708054-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT04708054)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With
  High-Risk AML and MDS\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04708054
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724252-4523@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gabapentin: Phase 2/3 readout est. (NCT04724252)
DESCRIPTION:Gabapentin\, phase 2/3.\nStudy: Gabapentin to Reduce Opioid Use
  Postoperatively (GROUP) in Children\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gabapenti
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 724252
URL:https://assetmemo.bio/drug/gabapentin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: Adding the Immunotherapy Dru
 g Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lu
 ng Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immuno
 therapy (An Expanded Lung-MAP Treatment Trial)\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dexamethasone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06616584
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for Pe
 ople With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment W
 ith Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatmen
 t Trial)\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07319429-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2/3 readout est. (NCT07319429)
DESCRIPTION:Letrozole\, phase 2/3.\nStudy: Refining Fertility-sparing Treat
 ment in Endometrial Carcinoma Based on Molecular Classification\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07319429
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Study to Evaluate the Effic
 acy and Safety of IBI310 and Sintilimab Combination Therapy in Patients Wi
 th Hepatocellular Carcinoma as First-line Treatment.\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07490262
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721520-9542@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Botox (onabotulinumtoxinA): Phase 2/3 readout est. (NCT06721520)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 2/3.\nStudy: Effectiveness o
 f Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06721520
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860021-11045@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo): Phase 2/3 re
 adout est. (NCT07860021)
DESCRIPTION:Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)\, phase 2
 /3.\nStudy: VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/efgartigimod-alfa-and-hyaluronidase-vyvgart-h
 ytrulo#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07860021
URL:https://assetmemo.bio/drug/efgartigimod-alfa-and-hyaluronidase-vyvgart-
 hytrulo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03233711-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03233711)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Nivolumab After Combined Modality 
 Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03233711
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253651-2271@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 3 readout est. (NCT05253651)
DESCRIPTION:Tucatinib\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 atinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in 
 First-line HER2+ Metastatic Colorectal Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05253651
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269004-6975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT05269004)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: A Rollover 
 Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Pati
 ents With Multiple Sclerosis\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ocrelizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05269004
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05515536-8966@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vatiquinone (PTC743): Phase 3 readout est. (NCT05515536)
DESCRIPTION:Vatiquinone (PTC743)\, phase 3\, Friedreich Ataxia.\nStudy: A S
 tudy to Assess the Safety and Efficacy of Vatiquinone in Participants With
  Friedreich Ataxia\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/vatiquinone-ptc743#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05515536
URL:https://assetmemo.bio/drug/vatiquinone-ptc743#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181135-661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07181135)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic 
 Kidney Disease Not Using Renin-angiotensin-system Inhibitors\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07181135
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120815-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07120815)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Optimizing Metformin 
 Use in Polycystic Ovary Syndrome\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0712081
 5
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421284-1056@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421284)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 in Chinese Parti
 cipants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on
  a Background of Lipid-lowering Therapy\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 421284
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933679-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07933679)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: SCRT Combined With CAPOX and PD-1
  Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cance
 r (TORCH-E3)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07933679
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2208@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ve
 breltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patie
 nts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGF
 R-TKI Failure\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/andamertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2213@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vebreltinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Vebreltinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patien
 ts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGFR
 -TKI Failure\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242274-2566@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JMKX001899: Phase 3 readout est. (NCT07242274)
DESCRIPTION:JMKX001899\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or
  Metastatic KRAS G12C-Mutant NSCLC\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jmkx001899#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 2274
URL:https://assetmemo.bio/drug/jmkx001899#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588945-7619@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT07588945)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3.\nStudy: daGOAT-Guided Preventio
 n of Severe aGVHD After Allo-HSCT\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-
 jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07588945
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933679-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07933679)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: SCRT Combined With CAPOX and PD
 -1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Can
 cer (TORCH-E3)\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07933679
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06033131-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT06033131)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: PI4 - A Trial Assessi
 ng Metformin to Prolong Gestation in Preterm Preeclampsia\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06033131
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045142-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07045142)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Metformin Alleviates 
 Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07045142
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744219-590@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 3 readout est
 . (NCT05744219)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 3.\nStud
 y: Improved Recovery by Iron Following Surgery With Blood Loss\, the IRIS-
 trial\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05744219
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813964-969@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 3 readout est.
  (NCT05813964)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 3\, HIV.\
 nStudy: Efficacy\, Acceptability and Safety of Event-driven HIV PrEP Using
  TAF/FTC in MSM in Thailand and France.\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofo
 vir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05813964
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421297-1056@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421297)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 as Monotherapy i
 n Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyp
 erlipidemia\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/syh2053#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07421297
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461454-1982@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07461454)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: YL202 Versus Treatment of Physician's Choice in Patients Wi
 th HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7461454
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925243-1995@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 3 readout est. (NCT06925243)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Neoadjuvant Apatinib Combined Wit
 h Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined 
 With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6925243
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925243-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 3 readout est. (NCT06925243)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Neoadjuvant Apatinib Combined With 
 Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined Wi
 th Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastr
 oesophageal Junction Adenocarcinoma\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06925
 243
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738694-2018@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05738694)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant of Axitinib Plus PD-
 1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05738694
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992648-2058@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Regorafenib: Phase 3 readout est. (NCT06992648)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: Trifluridine
 /Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for
  Refractory Metastatic Colorectal Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regor
 afenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06992648
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738694-2214@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 3 readout est. (NCT05738694)
DESCRIPTION:Axitinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Neoadjuvant 
 of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Re
 nal Cell Carcinoma\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05738694
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-2289@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Testing the U
 se of Combination Therapy in Adult Patients With Newly Diagnosed Multiple 
 Myeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04400695-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT04400695)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of RC48-ADC for the Treatment of Locally Advanced or Me
 tastatic Breast Cancer With Low Expression of HER2\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04400695
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496048-2601@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06496048)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin or in Combination with Irinotecan Versus Topotecan in Patients wi
 th Relapsed SCLC\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06496048
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416474-2698@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 3 readout est. (NCT07416474)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RC148 Plu
 s Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemothe
 rapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07416474
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051409-2925@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06051409)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06051409
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-3125@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Testing the Us
 e of Combination Therapy in Adult Patients With Newly Diagnosed Multiple M
 yeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Testing the 
 Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple
  Myeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04786262-3443@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zimislecel: Phase 3 readout est. (NCT04786262)
DESCRIPTION:Zimislecel\, phase 3\, Type 1 Diabetes.\nStudy: A Safety\, Tole
 rability\, and Efficacy Study of VX-880 and VX-017 in Participants With Ty
 pe 1 Diabetes\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zimislecel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04786262
URL:https://assetmemo.bio/drug/zimislecel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141303-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07141303)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Intra-arterial Methylpred
 nisolone After Successful Endovascular Thrombectomy Anterior Circulation L
 arge Vessel Occlusion\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07141303
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650396-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07650396)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: The ASPIRE Trial: Achille
 S tendinoPathy Treated With cortIcosteRoid injEctions\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/methylprednisolone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07650396
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287321-5478@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT05287321)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: The Efficacy of Aspirin C
 ombined With Hydroxychloroquine Treatment in High Risk Pregnancies for Pre
 eclampsia\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05287321
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Testing the Use of Combination
  Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma\, the EQU
 ATE Trial\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03977493-10441@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:IncobotulinumtoxinA (Xeomin): Phase 3 readout est. (NCT03977493)
DESCRIPTION:IncobotulinumtoxinA (Xeomin)\, phase 3.\nStudy: Incobotulinumto
 xinA (Xeomin) to Treat Focal Hand Dystonia\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inc
 obotulinumtoxina-xeomin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03977493
URL:https://assetmemo.bio/drug/incobotulinumtoxina-xeomin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284511-115@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tirzepatide (Mounjaro): Phase 2/3 readout est. (NCT07284511)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2/3.\nStudy: A Clinical Trial Us
 ing Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control 
 Their Blood Sugar\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07284511
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159673-702@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Remlifanserin: Phase 2/3 readout est. (NCT06159673)
DESCRIPTION:Remlifanserin\, phase 2/3\, Alzheimer's Disease.\nStudy: ACP-20
 4 in Adults With Alzheimer's Disease Psychosis\nEstimated primary completi
 on: January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rem
 lifanserin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06159673
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03900429-1161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT03900429)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in P
 atients With NASH and Fibrosis\nEstimated primary completion: January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03900429
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05127954-10391@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05127954)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Long-term Ex
 tension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets
  for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
 \nEstimated primary completion: January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05127954
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913061-489@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07913061)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: A Study Comparing
  SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently T
 reated With Basal Insulin\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07913061
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303701-729@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tertomotide: Phase 3 readout est. (NCT05303701)
DESCRIPTION:Tertomotide\, phase 3\, Alzheimer's Disease.\nStudy: GV1001 Sub
 cutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)\
 nEstimated primary completion: January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tertomotide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05303701
URL:https://assetmemo.bio/drug/tertomotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571461-2242@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:S-1: Phase 3 readout est. (NCT06571461)
DESCRIPTION:S-1\, phase 3.\nStudy: Liposomal Irinotecan in Combination With
  Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Post
 operative Adjuvant Therapy for Pancreatic Cancer\nEstimated primary comple
 tion: January 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 -1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6571461
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947368-10814@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Crinecerfont: Phase 3 readout est. (NCT07947368)
DESCRIPTION:Crinecerfont\, phase 3\, Congenital Adrenal Hyperplasia.\nStudy
 : Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and R
 elated Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH
 )\nEstimated primary completion: January 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/crinecerfont#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07947368
URL:https://assetmemo.bio/drug/crinecerfont#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282600-278@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07282600)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, and Type 2 Dia
 betes\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07282600
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05716100-819@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05716100)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: A Randomized Study of
  XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)\nEstimated prima
 ry completion: January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azetukalner#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05716100
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822426-918@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Defencath / Neutrolin (Taurolidine/heparin): Phase 3 readout est. (
 NCT06822426)
DESCRIPTION:Defencath / Neutrolin (Taurolidine/heparin)\, phase 3.\nStudy: 
 Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line 
 Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Rec
 eiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)\
 nEstimated primary completion: January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/taurolidine-heparin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06822426
URL:https://assetmemo.bio/drug/taurolidine-heparin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203132-960@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT06203132)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: DORAvirine Versu
 s DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Li
 ving With HIV-1 Infection\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/doravirine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06203132
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098403-3551@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07098403)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Trial of SHR-1905 i
 n Subjects With Severe Uncontrolled Asthma\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcore
 kibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07098403
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04319627-5401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT04319627)
DESCRIPTION:Rosuvastatin\, phase 3.\nStudy: Statins for Venous Event Reduct
 ion in Patients With Venous Thromboembolism\nEstimated primary completion:
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuva
 statin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04319627
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203132-8395@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT06
 203132)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, HIV.\nStudy:
  DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment
 -naïve People Living With HIV-1 Infection\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofov
 ir-disoproxil-fumarate-viread#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06203132
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719479-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT06719479)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: A Clinical Trial to Evaluate 
 Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It
  is Currently Phase II.).\nEstimated primary completion: 1 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06719479
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719479-9029@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06719479)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3.\nStudy: A Clinical Trial to E
 valuate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(
 Note: It is Currently Phase II.).\nEstimated primary completion: 1 January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06719479
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719479-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT06719479)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Clinical Trial to Evaluate 
 Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It
  is Currently Phase II.).\nEstimated primary completion: 1 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06719479
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271162-308@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05271162)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Empagliflozin in t
 he Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy
  Based on Anthracyclines\nEstimated primary completion: 1 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05271162
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07056478-3268@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Denosumab (Prolia): Phase 3 readout est. (NCT07056478)
DESCRIPTION:Denosumab (Prolia)\, phase 3.\nStudy: RANKL Inhibition to Comba
 t Sarcopenia in Hip Fracture Patients\nEstimated primary completion: 1 Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-
 prolia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07056478
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230626-10784@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07230626)
DESCRIPTION:Sutantatug envedotin\, phase 3\, Cervical Cancer.\nStudy: SYS60
 02 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer\nEstimated p
 rimary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sutantatug-envedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07230626
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113275-2161@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07113275)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: A Clinical Trial Comparing Long-
 Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined
  With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed
  by TNT in Locally Advanced Rectal Cancer\nEstimated primary completion: 1
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplu
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07113275
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113275-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07113275)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Clinical Trial Comparing Long
 -Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combine
 d With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followe
 d by TNT in Locally Advanced Rectal Cancer\nEstimated primary completion: 
 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capec
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07113275
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575399-143@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT075753
 99)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy\, Safety and Tolerability of Switching From Glucagon-like Peptid
 e-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With 
 Obesity or Overweight (MARITIME-SWITCH)\nEstimated primary completion: 3 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/marideba
 rt-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07575399
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979323-1527@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280105
DTEND;VALUE=DATE:20280106
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06979323)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: Depemokimab Asthma Imag
 ing and Bronchoscopy Sub-Study\nEstimated primary completion: 5 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979323
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969004-1975@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280107
DTEND;VALUE=DATE:20280108
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT03969004)
DESCRIPTION:Cemiplimab\, phase 3.\nStudy: Study of Adjuvant Cemiplimab Vers
 us Placebo After Surgery and Radiation Therapy in Patients With High Risk 
 Cutaneous Squamous Cell Carcinoma\nEstimated primary completion: 7 January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0396900
 4
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants W
 ith Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 10 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132958-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06132958)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy
  Endometrial Cancer (MK-2870-005)\nEstimated primary completion: 10 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-t
 irumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06132958
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-2085@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Abp 234: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Ad
 vanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstimated pr
 imary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abp-234#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06455449-5367@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT06455449)
DESCRIPTION:Anifrolumab\, phase 3\, Idiopathic Inflammatory Myopathies.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Anifrolumab Adminis
 tered as Subcutaneous Injection and Added to Standard of Care Compared Wit
 h Placebo Added to Standard of Care in Adult Participants With Idiopathic 
 Inflammatory Myopathies (Polymyositis and Dermatomyositis)\nEstimated prim
 ary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06455449
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196748-19@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280114
DTEND;VALUE=DATE:20280115
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT07196748)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With
  Moderately to Severely Active Ulcerative Colitis\nEstimated primary compl
 etion: 14 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/icotrokinra#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07196748
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06264531-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06264531)
DESCRIPTION:Bevacizumab\, phase 2/3.\nStudy: Efficacy and Safety of Anti-an
 giogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral
  Arteriovenous Malformations\nEstimated primary completion: 15 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06264531
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294508-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT07294508)
DESCRIPTION:Pertuzumab\, phase 2/3\, Breast Cancer.\nStudy: A Study to Eval
 uate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurr
 ent or Metastatic Breast Cancer\nEstimated primary completion: 15 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07294508
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366840-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280116
DTEND;VALUE=DATE:20280117
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT07366840)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, HER2-Positive Breast Cancer.\nS
 tudy: RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Can
 cer Patients With Prior TOP1i-ADC Failure\nEstimated primary completion: 1
 6 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disit
 amab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07366840
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366840-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280116
DTEND;VALUE=DATE:20280117
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07366840)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: RC48 Combined With Chemothera
 py in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC F
 ailure\nEstimated primary completion: 16 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07366840
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754461-119@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280117
DTEND;VALUE=DATE:20280118
SUMMARY:survodutide: Phase 3 readout est. (NCT07754461)
DESCRIPTION:survodutide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Tes
 t Whether Survodutide Helps People With Type 2 Diabetes Control Their Bloo
 d Sugar\nEstimated primary completion: 17 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07754461
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05255471-2028@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:Olaparib: Phase 3 readout est. (NCT05255471)
DESCRIPTION:Olaparib\, phase 3\, Ovarian Cancer.\nStudy: MITO 35B: Olaparib
  Beyond Progression Compared to Platinum Chemotherapy After Secondary Cyto
 reductive Surgery in Recurrent Ovarian Cancer Patients.\nEstimated primary
  completion: 21 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olaparib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05255471
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989437-642@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280123
DTEND;VALUE=DATE:20280124
SUMMARY:Ponsegromab: Phase 2/3 readout est. (NCT06989437)
DESCRIPTION:Ponsegromab\, phase 2/3.\nStudy: A Study to Learn About the Med
 icine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread a
 nd Caused Significant Body Weight Loss and Fatigue\nEstimated primary comp
 letion: 23 January 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ponsegromab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06989437
URL:https://assetmemo.bio/drug/ponsegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345729-1988@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Calderasib: Phase 3 readout est. (NCT06345729)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants W
 ith KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Ce
 ll Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004
 /KANDLELIT-004)\nEstimated primary completion: 24 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06345729
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054555-1974@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06054555)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: A Study to Evaluate ABP
  206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or M
 etastatic Melanoma\nEstimated primary completion: 25 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06054555
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 acituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus 
 Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With 
 Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50
 % (MK-2870-007)\nEstimated primary completion: 25 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06170788
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1991@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizum
 ab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NS
 CLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (T
 PS) ≥ 50% (MK-2870-007)\nEstimated primary completion: 25 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6170788
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226882-11283@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280127
DTEND;VALUE=DATE:20280128
SUMMARY:PF-07307405: Phase 3 readout est. (NCT07226882)
DESCRIPTION:PF-07307405\, phase 3\, Lyme Disease.\nStudy: A Study to Learn 
 About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adul
 ts\nEstimated primary completion: 27 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pf-07307405#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07226882
URL:https://assetmemo.bio/drug/pf-07307405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564142-10841@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Povetacicept: Phase 3 readout est. (NCT06564142)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: Evaluation of
  Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgA
 N)\nEstimated primary completion: 30 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06564142
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203210-2527@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06203210)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Small Cell Lung Cancer.\nStud
 y: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice
  in Subjects With Relapsed Small Cell Lung Cancer\nEstimated primary compl
 etion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06203210
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469722-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07469
 722)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3\, Heart Failure.\
 nStudy: POcus INTERvention for Tailoring Diuretic Strategy in Acute Decomp
 ensated Heart Failure\nEstimated primary completion: 31 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07469722
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05664789-3863@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT05664789)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: Targeting the Neurobiolog
 y of RRB in Autism Using N-acetylcysteine: Trial\nEstimated primary comple
 tion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05664789
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04457596-2271@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tucatinib: Phase 3 readout est. (NCT04457596)
DESCRIPTION:Tucatinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: T-DM
 1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People
  With High Risk HER2-Positive Breast Cancer\, the CompassHER2 RD Trial\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04457596
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07051915-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07051915)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: The Holistic Study\nEsti
 mated primary completion: 31 January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07051915
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052201-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07052201)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Dexamethasone Regimens for BPD
  Prevention in Preterm Infants\nEstimated primary completion: 31 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dexamethasone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070522
 01
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468554-280@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05468554)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Evaluation of Metform
 in Effect on the Fertility of Women Treated With 131I for Thyroid Cancer\n
 Estimated primary completion: 31 January 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05468554
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497465-1031@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT06497465)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Dolutegravir/Lamivudine Dual Therapy for ART-naï
 ve People With HIV and TB Receiving Rifampin-based TB Treatment\nEstimated
  primary completion: 31 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06497465
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393542-2064@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07393542)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Urothelial Carcinoma.\nStudy:
  A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic U
 rothelial Carcinoma\nEstimated primary completion: 31 January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07393542
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393542-2166@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07393542)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Trial of SHR-A2102 With Adebre
 limab in Locally Advanced or Metastatic Urothelial Carcinoma\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07393542
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501507-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07501507)
DESCRIPTION:Methotrexate\, phase 2/3.\nStudy: Methotrexate Treatment in Han
 d Osteoarthritis Refractory to Usual Treatments\nEstimated primary complet
 ion: February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07501507
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524611-3@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04524611)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: Stu
 dy Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Uste
 kinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult
  Participants With Moderate to Severe Crohn's Disease (CD)\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04524611
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284875-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284875)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide in Participants Living With Obesity or Overweight With Weight-R
 elated Comorbidities Who Do Not Have Diabetes\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rib
 upatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07284875
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05130450-1044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tryngolza (Olezarsen): Phase 3 readout est. (NCT05130450)
DESCRIPTION:Tryngolza (Olezarsen)\, phase 3\, Familial Chylomicronemia Synd
 rome.\nStudy: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) i
 n Participants With Familial Chylomicronemia Syndrome (FCS)\nEstimated pri
 mary completion: February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/olezarsen#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05130450
URL:https://assetmemo.bio/drug/olezarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788626-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06788626)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Glucagon-like Peptide 
 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascul
 ar Treatment\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06788626
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873801-1423@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT07873801)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic
  Dermatitis\nEstimated primary completion: February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07873801
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07084285-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT07084285)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: Cervical Facet Injection of Co
 rticosteroids for the Management of Cervicobrachialgia\nEstimated primary 
 completion: February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dexamethasone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07084285
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05698979-9542@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Botox (onabotulinumtoxinA): Phase 3 readout est. (NCT05698979)
DESCRIPTION:Botox (onabotulinumtoxinA)\, phase 3.\nStudy: Evaluation of Bot
 ulinum TOXin Type A in the Treatment of Buerger's Disease\nEstimated prima
 ry completion: February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/onabotulinumtoxina#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05698979
URL:https://assetmemo.bio/drug/onabotulinumtoxina#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860750-111@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:vunakizumab: Phase 3 readout est. (NCT06860750)
DESCRIPTION:vunakizumab\, phase 3.\nStudy: A Trial of SHR-1314 Injection in
  Adult Patients With Active Non-radiographic Axial Spondyloarthritis\nEsti
 mated primary completion: February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/vunakizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06860750
URL:https://assetmemo.bio/drug/vunakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412756-822@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07412756)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Adult Participants With Major Depressive Disorder\nE
 stimated primary completion: February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07412756
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933057-3348@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Givinostat: Phase 3 readout est. (NCT05933057)
DESCRIPTION:Givinostat\, phase 3\, Duchenne Muscular Dystrophy.\nStudy: Eff
 icacy\, Safety and Tolerability of Givinostat in Non-ambulant Patients Wit
 h Duchenne Muscular Dystrophy\nEstimated primary completion: February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05933057
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06983821-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06983821)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Safe Effective Therapy W
 ith Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)\nEsti
 mated primary completion: February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06983821
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221851-10862@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skytrofa (lonapegsomatropin): Phase 3 readout est. (NCT07221851)
DESCRIPTION:Skytrofa (lonapegsomatropin)\, phase 3.\nStudy: Trial Investiga
 ting the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily
  Somatropin in Children and Adolescents With Short Stature or Growth Failu
 re Due to Growth Hormone Sufficient Disorders\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lon
 apegsomatropin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07221851
URL:https://assetmemo.bio/drug/lonapegsomatropin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389616-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07389616)
DESCRIPTION:Azacitidine\, phase 2/3.\nStudy: A Clinical Trial of Cidabenami
 ne Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Pe
 ripheral T-Cell Lymphoma\nEstimated primary completion: 1 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07389616
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04111978-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Letrozole: Phase 3 readout est. (NCT04111978)
DESCRIPTION:Letrozole\, phase 3.\nStudy: MAintenance Therapy With Aromatase
  Inhibitor in Epithelial Ovarian Cancer (MATAO)\nEstimated primary complet
 ion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04111978
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407660-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07407660)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Shortene
 d Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in
  Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus
  Venetoclax\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07407660
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407660-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07407660)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Shorten
 ed Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy i
 n Elderly or Frail Patients With AML Patients Treated With Azacitidine Plu
 s Venetoclax\nEstimated primary completion: 1 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07407660
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05819853-114@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT05819853)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3.\nStudy: Role of Semaglutide in
  Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome\nE
 stimated primary completion: 1 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05819853
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06080776-2226@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Rilertinib (SH-1028): Phase 3 readout est. (NCT06080776)
DESCRIPTION:Rilertinib (SH-1028)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage
  II-IIIB NSCLC With Sensitizing EGFR Mutations\nEstimated primary completi
 on: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rilertinib-sh-1028#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06080776
URL:https://assetmemo.bio/drug/rilertinib-sh-1028#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06127407-2899@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT06127407)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Ivosidenib in Participa
 nts With Locally Advanced or Metastatic Conventional Chondrosarcoma Untrea
 ted or Previously Treated With 1 or 2 Systemic Treatment Regimens\nEstimat
 ed primary completion: 1 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06127407
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562466-3771@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:indacaterol maleate / mometasone furoate: Phase 3 readout est. (NCT
 05562466)
DESCRIPTION:indacaterol maleate / mometasone furoate\, phase 3\, Asthma.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol A
 cetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Th
 an 12 Years of Age With Asthma\nEstimated primary completion: 1 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/indacaterol-male
 ate-mometasone-furoate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05562466
URL:https://assetmemo.bio/drug/indacaterol-maleate-mometasone-furoate#upcom
 ing-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205822-1980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07205822)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Dato-DXd in Inoperable or Metastatic Hormone Re
 ceptor-positive\, HER2 IHC 0 Breast Cancer\nEstimated primary completion: 
 2 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dato
 potamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07205822
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06813911)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Backgrou
 nd Inclisiran in Participants With Elevated Lp(a) and Established ASCVD\nE
 stimated primary completion: 3 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1038@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06813911)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclis
 iran in Participants With Elevated Lp(a) and Established ASCVD\nEstimated 
 primary completion: 3 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223138-104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280204
DTEND;VALUE=DATE:20280205
SUMMARY:sonelokimab: Phase 3 readout est. (NCT07223138)
DESCRIPTION:sonelokimab\, phase 3\, Psoriatic Arthritis.\nStudy: A Study to
  Evaluate the Long-term Safety\, Tolerability\, and Efficacy of Subcutaneo
 us Sonelokimab in Participants With Psoriatic Arthritis\nEstimated primary
  completion: 4 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonelokimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07223138
URL:https://assetmemo.bio/drug/sonelokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363642-1507@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07363642)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Phase 3b Stu
 dy in Patients With Severe Asthma Treated With Tezepelumab\nEstimated prim
 ary completion: 7 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363642
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686120-525@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07686120)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participant
 s With Uncontrolled Hypertension.\nEstimated primary completion: 9 Februar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076861
 20
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791460-2166@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06791460)
DESCRIPTION:Adebrelimab\, phase 2/3.\nStudy: Pegylated Liposomal Doxorubici
 n Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer\n
 Estimated primary completion: 14 February 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06791460
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906717-11219@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:JNJ-101556143: Phase 3 readout est. (NCT07906717)
DESCRIPTION:JNJ-101556143\, phase 3\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 With Best Supportive Care in Participants With Metastatic Pro
 state Cancer\nEstimated primary completion: 14 February 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/jnj-101556143#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07906717
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829459-1958@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06829459)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Glumetinib Combined
  With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N
 on-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs\nEstimate
 d primary completion: 15 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06829459
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829459-2222@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Glumetinib: Phase 3 readout est. (NCT06829459)
DESCRIPTION:Glumetinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimer
 tinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cel
 l Lung Cancer Patients After Resistance to EGFR-TKIs\nEstimated primary co
 mpletion: 15 February 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/glumetinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06829459
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169578-670@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07169578)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Participants With Early Symptomatic Alzheimer's Disease\nE
 stimated primary completion: 16 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07169578
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170150-670@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07170150)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Clinical
  Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's D
 isease\nEstimated primary completion: 16 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07170150
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845500-179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07845500)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) 
 to Help Keep Weight Off in People With Overweight or Obesity\nEstimated pr
 imary completion: 16 February 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07845500
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05760612-2258@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Neratinib: Phase 3 readout est. (NCT05760612)
DESCRIPTION:Neratinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Adju
 vant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epiderm
 al Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trast
 uzumab Plus Pertuzumab\nEstimated primary completion: 16 February 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/neratinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05760612
URL:https://assetmemo.bio/drug/neratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174987-2164@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06174987)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study to Provide Co
 ntinued Access to and Assess Long-Term Safety of the Study Drug(s)\nEstima
 ted primary completion: 17 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06174987
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796803-1972@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06796803)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Ca
 mrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemoth
 erapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellul
 ar Carcinoma(HCC)\nEstimated primary completion: 20 February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06796803
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796803-2014@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT06796803)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Camrel
 izumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherap
 y (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular C
 arcinoma(HCC)\nEstimated primary completion: 20 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06796803
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06512883-1322@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT06512883)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3.\nStudy: A Trial to Investigat
 e Benralizumab in Children With Eosinophilic Diseases\nEstimated primary c
 ompletion: 20 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/benralizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06512883
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947941-712@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 947941)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate Safety and Efficacy of KarXT + KarX-E
 C as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-
 5)\nEstimated primary completion: 21 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06947941
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770841-11055@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Semaglutide (Wegovy tablets): Phase 3 readout est. (NCT07770841)
DESCRIPTION:Semaglutide (Wegovy tablets)\, phase 3\, Obesity.\nStudy: Resea
 rch Study on How Well Oral Semaglutide Works for Weight Loss in Adults Wit
 h Excess Body Weight\nEstimated primary completion: 22 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy-tablet
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 770841
URL:https://assetmemo.bio/drug/semaglutide-wegovy-tablets#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564414-121@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0756
 4414)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Two Different Doses of CagriSema and On
 e Dose of Semaglutide Help People Living With Obesity With or Without Type
  2 Diabetes Lose Weight\nEstimated primary completion: 23 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-semagluti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7564414
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-306@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0626887
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Investigate the Efficacy and Safety of
  Baxdrostat in Combination With Dapagliflozin on CKD Progression in Partic
 ipants With CKD and High Blood Pressure.\nEstimated primary completion: 24
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268873
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-525@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06268873)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Study to Investigate the Efficacy and Safety of Baxdrostat in Combina
 tion With Dapagliflozin on CKD Progression in Participants With CKD and Hi
 gh Blood Pressure.\nEstimated primary completion: 24 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06268873
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670416-159@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:enicepatide: Phase 3 readout est. (NCT07670416)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Study to Evaluate th
 e Effects of Enicepatide in Participants With Obesity or Overweight\, With
  or Without Type 2 Diabetes\nEstimated primary completion: 24 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07670416
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816382-11363@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Orzeyful (Oveporexton): Phase 2/3 readout est. (NCT05816382)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 2/3\, Narcolepsy.\nStudy: A Stud
 y of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions\
 nEstimated primary completion: 28 February 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/oveporexton#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05816382
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568535-87@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ryoncil (remestemcel-L): Phase 3 readout est. (NCT07568535)
DESCRIPTION:Ryoncil (remestemcel-L)\, phase 3\, Graft-versus-Host Disease.\
 nStudy: A Randomized\, Double-Blind\, Placebo-Controlled\, Multicenter Pha
 se III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV S
 teroid-Refractory Acute Graft-Versus-Host Disease\nEstimated primary compl
 etion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remestemcel-l#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07568535
URL:https://assetmemo.bio/drug/remestemcel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04972760-98@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04972760)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: Baricitinib in Patien
 ts With Relapsing or naïve Dermatomyositis\nEstimated primary completion:
  28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ba
 ricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04972760
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465263-1056@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SYH2053: Phase 3 readout est. (NCT07465263)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the SYH2053 Injection in Patients With Heterozygo
 us Familial Hypercholesterolemia (HeFH)\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 465263
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432854-1339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:CMS-D001: Phase 2/3 readout est. (NCT07432854)
DESCRIPTION:CMS-D001\, phase 2/3\, Psoriasis.\nStudy: A Clinical Study Eval
 uating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adu
 lt Patients With Moderate to Severe Plaque-type Psoriasis\nEstimated prima
 ry completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cms-d001#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07432854
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161025-2696@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Raludotatug Deruxtecan: Phase 2/3 readout est. (NCT06161025)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2/3.\nStudy: A Study of Raludota
 tug Deruxtecan (R-DXd) in Subjects With Platinum-resistant\, High-grade Ov
 arian\, Primary Peritoneal\, or Fallopian Tube Cancer\nEstimated primary c
 ompletion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/raludotatug-deruxtecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06161025
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653477-199@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:UBT251: Phase 3 readout est. (NCT07653477)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic
  Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
 \nEstimated primary completion: 29 February 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07653477
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091254-5820@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091254)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works C
 ompared to Rituximab Combined With Different Types of Chemotherapy for Adu
 lt Participants With Previously Untreated Follicular Lymphoma\nEstimated p
 rimary completion: 29 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06091254
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286331-9165@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07286331)
DESCRIPTION:GSK 5733584\, phase 3.\nStudy: A Study to Investigate Mocertatu
 g Rezetecan Compared With Chemotherapy in Participants With Endometrial Ca
 ncer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometri
 al01)\nEstimated primary completion: 29 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07286331
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416604-11331@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07416604)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: A Clinical Study to Evaluate the E
 ffects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophi
 lia A\nEstimated primary completion: 29 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zemocimig#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07416604
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-2284@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Carfilzomib: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Carfilzomib\, phase 2/3\, Multiple Myeloma.\nStudy: KPD Consoli
 dation After ASCT in NDMM Patients\nEstimated primary completion: March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06879379
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-3123@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pomalidomide: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Pomalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: KPD Consol
 idation After ASCT in NDMM Patients\nEstimated primary completion: March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0687937
 9
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05926505-3446@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Anakinra: Phase 2/3 readout est. (NCT05926505)
DESCRIPTION:Anakinra\, phase 2/3.\nStudy: Safety and Efficacy of Anakinra T
 reatment for Patients With Post Acute Covid Syndrome\nEstimated primary co
 mpletion: March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /anakinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05926505
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dexamethasone: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Dexamethasone\, phase 2/3.\nStudy: KPD Consolidation After ASCT
  in NDMM Patients\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dexamethasone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06879379
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118411-12@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06118411)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study To 
 Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Ad
 ult and Adolescent Participants With Vitiligo\nEstimated primary completio
 n: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06118411
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284979-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284979)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo 
 in Participants Living With Obesity Who Do Not Have Diabetes\nEstimated pr
 imary completion: March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ribupatide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07284979
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219602-401@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT07219602)
DESCRIPTION:Obicetrapib\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Eva
 luate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or 
 Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering The
 rapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07219602
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-3126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Lenalidomide\, phase 3.\nStudy: A Study of Subcutaneously Injec
 ted Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (
 IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplat
 in in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell 
 Lymphoma\nEstimated primary completion: March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06508658
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06508658)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidom
 ide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infus
 ed Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relap
 sed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06508658
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-10986@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tabl
 ets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemci
 tabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 8658
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428838-10396@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT06428838)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: Eptinezumab 
 as an Adjunct to Standard of Care for Migraine in an Acute Emergency Conte
 xt\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06428838
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790861-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07790861)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweig
 ht and Weight-Related Health Problems\nEstimated primary completion: March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07790
 861
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787260-196@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HDM1005: Phase 3 readout est. (NCT07787260)
DESCRIPTION:HDM1005\, phase 3\, Obesity.\nStudy: A Phase III\, Multicenter\
 , Randomized\, Double-Blind\, Placebo-Controlled Clinical Study to Evaluat
 e the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructiv
 e Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PA
 P) Therapy\nEstimated primary completion: March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07787260
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789796-2261@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT06789796)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: a Study of QL17
 06 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After C
 hemoradiotherapy.\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06789796
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-8@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Humira (adalimumab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Humira (adalimumab)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-9@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Remicade (infliximab)\, phase 3\, Rheumatoid Arthritis.\nStudy:
  Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEs
 timated primary completion: March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-10@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cimzia (certolizumab pegol): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase 3\, Rheumatoid Arthritis.\n
 Study: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Respon
 se\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/certolizumab-pegol#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-15@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy:
  Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEs
 timated primary completion: March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-94@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enbrel (etanercept): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Enbrel (etanercept)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/etanercept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-96@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Orencia (Abatacept)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-98@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy
 : Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nE
 stimated primary completion: March 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05723198-98@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT05723198)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Alopecia Areata.\nStudy: A S
 tudy of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Y
 ears of Age With Alopecia Areata\nEstimated primary completion: March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05723198
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202884-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07202884)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Female Participants With Stress Urinary Incontinence Who 
 Have Obesity or Overweight\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07202884
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679270-129@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Myalept (metreleptin): Phase 3 readout est. (NCT06679270)
DESCRIPTION:Myalept (metreleptin)\, phase 3.\nStudy: Open-label Extension S
 tudy to Evaluate Metreleptin in Patients With Partial Lipodystrophy\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metreleptin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06679270
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321886-278@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07321886)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity\, or Overweight Without Type 2
  Diabetes\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07321886
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353931-278@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07353931)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain a
 nd Obesity or Overweight\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07353931
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369011-278@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07369011)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or
  Overweight\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07369011
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225712-857@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07225712)
DESCRIPTION:Ulotaront\, phase 3\, Schizophrenia.\nStudy: A Long-term Admini
 stration Trial of SEP-363856 in Patients With Schizophrenia\nEstimated pri
 mary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ulotaront#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07225712
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05549297)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Tebentafusp Regimen
  Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEB
 E-AM)\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Particip
 ants Receiving Oral Venetoclax in Combination With Intravenously Infused O
 binutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphoc
 ytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-2166@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Clinical Trial of SHR-A1811 in
  the Treatment of Triple-negative Breast Cancer\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adeb
 relimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07111832
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06340568-2448@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06340568)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, Endometrial Cancer.\nStudy: 
 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy 
 or Chemotherapy in Patients With Recurring Uterine Cancer\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06340568
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Partic
 ipants Receiving Oral Venetoclax in Combination With Intravenously Infused
  Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymph
 ocytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-3339@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Parti
 cipants Receiving Oral Venetoclax in Combination With Intravenously Infuse
 d Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymp
 hocytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-3826@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Methotrexate\, phase 3\, Rheumatoid Arthritis.\nStudy: Treatmen
 t of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstimated p
 rimary completion: March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05150704-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT05150704)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: MYTHS - MYocarditis THera
 py With Steroids\nEstimated primary completion: March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05150704
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-5478@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Hydroxychloroquine\, phase 3\, Rheumatoid Arthritis.\nStudy: Tr
 eatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-5897@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sarilumab: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Sarilumab\, phase 3\, Rheumatoid Arthritis.\nStudy: Treatment o
 f Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstimated prim
 ary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03414502
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05840562-8745@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capsaicin (Qutenza): Phase 3 readout est. (NCT05840562)
DESCRIPTION:Capsaicin (Qutenza)\, phase 3.\nStudy: Capsaicin 179 mg Patch V
 ersus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neu
 ropathy\nEstimated primary completion: March 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05840562
URL:https://assetmemo.bio/drug/capsaicin-qutenza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-9096@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Clin
 ical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07111832
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830044-9305@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Milsaperidone (VHX-896): Phase 3 readout est. (NCT06830044)
DESCRIPTION:Milsaperidone (VHX-896)\, phase 3\, Major Depressive Disorder.\
 nStudy: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive T
 herapy in Patients With Major Depressive Disorder\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mi
 lsaperidone-vhx-896#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06830044
URL:https://assetmemo.bio/drug/milsaperidone-vhx-896#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05711394-10367@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05711394)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study to As
 sess the Adverse Events and Change in Disease Activity of Oral Atogepant T
 ablets in Pediatric Participants (6-17 Years of Age) With Episodic Migrain
 e\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/atogepant-qulipta#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05711394
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398417-10867@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07398417)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Fibromyalgia Res
 ponse With Esreboxetine Evaluated Using a Randomized Withdrawal Research D
 esign\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/esreboxetine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07398417
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723248-10910@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinzimetostat: Phase 3 readout est. (NCT07723248)
DESCRIPTION:Rinzimetostat\, phase 3\, Prostate Cancer.\nStudy: A Study to L
 earn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients W
 ith mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-
 1)\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rinzimetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07723248
URL:https://assetmemo.bio/drug/rinzimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-10942@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT05549297)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Melanoma.\nStudy: Teben
 tafusp Regimen Versus Investigator's Choice in Previously Treated Advanced
  Melanoma (TEBE-AM)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793166-2009@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03793166)
DESCRIPTION:Ipilimumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Immunother
 apy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With 
 Cabozantinib for Patients With Advanced Kidney Cancer\, The PDIGREE Study\
 nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03793166
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793166-2031@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT03793166)
DESCRIPTION:Cabozantinib\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Ni
 volumab With Cabozantinib for Patients With Advanced Kidney Cancer\, The P
 DIGREE Study\nEstimated primary completion: 1 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03793166
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-2272@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Utidelone: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Pat
 ients With HER-2 Negative Advanced Breast Cancer\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/u
 tidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07684456
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in 
 Patients With HER-2 Negative Advanced Breast Cancer\nEstimated primary com
 pletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07684456
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520162-1507@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07520162)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Tr
 eatment With Tezepelumab\nEstimated primary completion: 1 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07520162
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05727904)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Study to Investigat
 e Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone 
 in Participants With Untreated Advanced Melanoma.\nEstimated primary compl
 etion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05727904
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904964-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05904964)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Disitamab Vedotin (RC48) in Hormone Receptor Positive\, HER2-lo
 w Metastatic Breast Cancer (the Rosy Trial)\nEstimated primary completion:
  1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disita
 mab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05904964
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-10883@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Amtagvi (lifileucel): Phase 3 readout est. (NCT05727904)
DESCRIPTION:Amtagvi (lifileucel)\, phase 3\, Melanoma.\nStudy: Study to Inv
 estigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab
  Alone in Participants With Untreated Advanced Melanoma.\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/lifileucel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05727904
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642844-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280304
DTEND;VALUE=DATE:20280305
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06642844)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Bevacizumab-
 based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Tre
 atment\nEstimated primary completion: 4 March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06642844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765888-1455@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07765888)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to-
 Severe Eczema\nEstimated primary completion: 10 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07765888
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07144280-2168@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:Fetrastobart vedotin: Phase 3 readout est. (NCT07144280)
DESCRIPTION:Fetrastobart vedotin\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL
 1V Versus Docetaxel in Adult Participants With Previously-Treated Programm
 ed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: 10 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07144280
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926868-2044@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT06926868)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3.\nStudy: A Study of Izalont
 amab Brengitecan Versus Chemotherapy in Participants With Previously Untre
 ated\, Locally Advanced\, Recurrent Inoperable\, or Metastatic Triple-nega
 tive Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)\n
 Estimated primary completion: 13 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06926868
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876714-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT06876714)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: ShortStop-HER2: 1
 2 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ B
 reast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plu
 s Trastuzumab\nEstimated primary completion: 13 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06876714
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792954-179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280314
DTEND;VALUE=DATE:20280315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07792954)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Plac
 ebo in Chinese Adults With Overweight or Obesity\nEstimated primary comple
 tion: 14 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 berobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07792954
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514807-9910@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0651480
 7)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential 
 Thrombocythaemia Patients\nEstimated primary completion: 15 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b
 -besremi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06514807
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908993-2033@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Tepmetko (Tepotinib): Phase 3 readout est. (NCT06908993)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 1
 4 Mutated Non-Small Cell Lung Cancer Previously Treated\nEstimated primary
  completion: 15 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tepotinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06908993
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06722235-3188@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280316
DTEND;VALUE=DATE:20280317
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06722235)
DESCRIPTION:Mezagitamab\, phase 3.\nStudy: A Study of Mezagitamab in Adults
  With Chronic Primary Immune Thrombocytopenia\nEstimated primary completio
 n: 16 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mez
 agitamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06722235
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06873945-5938@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280319
DTEND;VALUE=DATE:20280320
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06873945)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study of 2 Doses of Ritlecitin
 ib in People 12 Years of Age and Older With Alopecia Areata\nEstimated pri
 mary completion: 19 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pf-06651600#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06873945
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04804553-95@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04804553)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: Ap
 remilast Pediatric Study in Children With Active Juvenile Psoriatic Arthri
 tis\nEstimated primary completion: 21 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04804553
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597006-1034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597006)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Safety\, Tolerability and Efficacy of I
 nclisiran in Children With Homozygous Familial Hypercholesterolemia\nEstim
 ated primary completion: 21 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06597006
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597019-1034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597019)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Efficacy and Safety of Inclisiran in Ch
 ildren With Heterozygous Familial Hypercholesterolemia\nEstimated primary 
 completion: 21 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06597019
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350097-1980@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06350097)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label Study of First-line Osimertinib With or Wit
 hout Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-s
 mall Cell Lung Cancer\nEstimated primary completion: 21 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350097
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141486-7194@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141486)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Second
 ary Progressive Multiple Sclerosis\nEstimated primary completion: 24 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614148
 6
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221188-6690@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221188)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Clinical S
 tudy to Investigate the Safety and Tolerability of Efimosfermin Alfa Injec
 tion in Participants With Known or Suspected F2- or F3-stage MASH\nEstimat
 ed primary completion: 24 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/efimosfermin-alfa#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07221188
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284901-185@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284901)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly in Participants Living With Obesity or
  Overweight and Diabetes\nEstimated primary completion: 27 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07284901
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210554-1335@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:stapokibart: Phase 3 readout est. (NCT07210554)
DESCRIPTION:stapokibart\, phase 3.\nStudy: Study of Stapokibart Injection i
 n Subjects With Moderate to Severe Bullous Pemphigoid\nEstimated primary c
 ompletion: 27 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07210554
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221227-6690@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280329
DTEND;VALUE=DATE:20280330
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221227)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-
 confirmed F2- or F3-stage MASH\nEstimated primary completion: 29 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722
 1227
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814664-29@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:ivarmacitinib: Phase 2/3 readout est. (NCT07814664)
DESCRIPTION:ivarmacitinib\, phase 2/3.\nStudy: Ivarmacitinib Versus Glucoco
 rticoids in Mild-to-Moderate Systemic Lupus Erythematosus\nEstimated prima
 ry completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07814664
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941778-29@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:ivarmacitinib: Phase 2/3 readout est. (NCT07941778)
DESCRIPTION:ivarmacitinib\, phase 2/3.\nStudy: Ivarmacitinib Treat PMR\nEst
 imated primary completion: 30 March 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07941778
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718737-2088@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:AMT-116: Phase 2/3 readout est. (NCT07718737)
DESCRIPTION:AMT-116\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Globa
 l\, Multicenter Study of AMT-116 Versus Investigator's Choice in Participa
 nts With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell 
 Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemothera
 py and Anti-PD-1/PD-L1 Immunotherapy\nEstimated primary completion: 30 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amt-116#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07718737
URL:https://assetmemo.bio/drug/amt-116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05316935-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Letrozole: Phase 2/3 readout est. (NCT05316935)
DESCRIPTION:Letrozole\, phase 2/3.\nStudy: GnRHa + Letrozole in Non-obese P
 rogestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients\
 nEstimated primary completion: 30 March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05316935
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06379113-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Letrozole: Phase 2/3 readout est. (NCT06379113)
DESCRIPTION:Letrozole\, phase 2/3.\nStudy: GnRHa + Letrozole in Obese Proge
 stin-insensitive Endometrial Cancer Patients\nEstimated primary completion
 : 30 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letr
 ozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06379113
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091865-5820@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091865)
DESCRIPTION:Odronextamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy:
  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works
  and How Safe it is Against Rituximab Combined With Chemotherapy\, in Adul
 t Patients With Previously Untreated Diffuse Large B-cell Lymphoma\nEstima
 ted primary completion: 30 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06091865
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594158-8851@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Xcopri (Cenobamate): Phase 3 readout est. (NCT07594158)
DESCRIPTION:Xcopri (Cenobamate)\, phase 3\, Epilepsy.\nStudy: A Study to Ev
 aluate the Safety\, Efficacy\, and PK of ONO-2017 in Japanese Patients Wit
 h POS 2 to 17 Year Olds\nEstimated primary completion: 30 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cenobamate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07594158
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06513533-1887@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Dimethyl fumarate (Skilarence): Phase 2/3 readout est. (NCT06513533
 )
DESCRIPTION:Dimethyl fumarate (Skilarence)\, phase 2/3.\nStudy: Dimethyl Fu
 marate in Adrenomyeloneuropathy\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dimethyl-fumarate
 -skilarence#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06513533
URL:https://assetmemo.bio/drug/dimethyl-fumarate-skilarence#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06836973-5633@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06836973)
DESCRIPTION:Blinatumomab\, phase 2/3.\nStudy: Blinatumomab for Treatment of
  Refractory Myasthenia Gravis\nEstimated primary completion: 31 March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06836973
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05581303-1039@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olpasiran: Phase 3 readout est. (NCT05581303)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion (OCEAN(a)) - Outcomes Trial\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olpasiran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05581303
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408638-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT04408638)
DESCRIPTION:Obinutuzumab\, phase 3.\nStudy: A Phase III Study Evaluating Gl
 ofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Com
 bination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refr
 actory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044
 08638
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408638-6083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0440863
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Phase II
 I Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplati
 n vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participan
 ts With Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated prima
 ry completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04408638
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04248452-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04248452)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Testing the Ad
 dition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients 
 With Esophageal and Gastric Cancer That Has Spread to a Limited Number of 
 Other Places in the Body\nEstimated primary completion: 31 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04248452
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679946-10756@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:AMVUTTRA (Vutrisiran): Phase 3 readout est. (NCT06679946)
DESCRIPTION:AMVUTTRA (Vutrisiran)\, phase 3\, Transthyretin Amyloidosis wit
 h Cardiomyopathy.\nStudy: A Study to Evaluate Vutrisiran in Patients With 
 Transthyretin Amyloidosis With Cardiomyopathy\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vut
 risiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06679946
URL:https://assetmemo.bio/drug/vutrisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469046-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07469046)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAH vs V
 A in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07469046
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469046-2832@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07469046)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAH vs 
 VA in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746904
 6
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06702553-551@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:INOmax (nitric oxide): Phase 3 readout est. (NCT06702553)
DESCRIPTION:INOmax (nitric oxide)\, phase 3.\nStudy: Nitric Oxide for Reduc
 ed Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass\nEstim
 ated primary completion: 31 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06702553
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370909-1418@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:LW402: Phase 3 readout est. (NCT07370909)
DESCRIPTION:LW402\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of the 
 Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients Wi
 th Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 31 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lw402#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0737090
 9
URL:https://assetmemo.bio/drug/lw402#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011684-8457@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT03011684)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3.\nStudy: Fertility Preservation 
 Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial\nEstimate
 d primary completion: 31 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03011684
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011684-9035@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Letrozole: Phase 3 readout est. (NCT03011684)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Fertility Preservation Using Tamox
 ifen and Letrozole in Estrogen Sensitive Tumors Trial\nEstimated primary c
 ompletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03011684
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01760005-665@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Leqembi (Lecanemab): Phase 2/3 readout est. (NCT01760005)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2/3\, Alzheimer's Disease.\nStudy: 
 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent De
 mentia. A Study of Potential Disease Modifying Treatments in Individuals a
 t Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a G
 enetic Mutation. Master Protocol DIAN-TU-001\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lecanem
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 1760005
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01760005-686@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Etalanetug: Phase 2/3 readout est. (NCT01760005)
DESCRIPTION:Etalanetug\, phase 2/3\, Alzheimer's Disease.\nStudy: Dominantl
 y Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A
  Study of Potential Disease Modifying Treatments in Individuals at Risk fo
 r or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mu
 tation. Master Protocol DIAN-TU-001\nEstimated primary completion: April 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/etalanetug#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT01760005
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269394-686@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Etalanetug: Phase 2/3 readout est. (NCT05269394)
DESCRIPTION:Etalanetug\, phase 2/3\, Alzheimer's Disease.\nStudy: Dominantl
 y Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A
  Study of Potential Disease Modifying Treatments in Individuals With a Typ
 e of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU
 )\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/etalanetug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05269394
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06276504-1973@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06276504)
DESCRIPTION:Pembrolizumab\, phase 2/3.\nStudy: Pembrolizumab in Progressive
  Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Withou
 t HIV Infection\nEstimated primary completion: April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06276504
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824674-517@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Revatio (sildenafil): Phase 2/3 readout est. (NCT07824674)
DESCRIPTION:Revatio (sildenafil)\, phase 2/3\, Pulmonary Arterial Hypertens
 ion.\nStudy: The Effect of Additive On-Demand Sildenafil vs. Dextrose Cand
 y on Maximum Exercise Capacity in Pulmonary Arterial Hypertension\nEstimat
 ed primary completion: April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sildenafil#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07824674
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862286-3@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04862286)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Psoriasis.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity in Participants Bet
 ween 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With 
 Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participati
 on in Study M19-977\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04862286
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153471-117@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07153471)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and O
 steoarthritis (OA) of the Knee\nEstimated primary completion: April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07153471
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859268-118@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:retatrutide: Phase 3 readout est. (NCT06859268)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in the Maintenance of Weight Reduction in Individuals With Ob
 esity\nEstimated primary completion: April 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06859268
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05840211-1992@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05840211)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Sacituzumab Govitecan Versus Treatment of Physicia
 n's Choice in Patients With Hormone Receptor-positive/Human Epidermal Grow
 th Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Hav
 e Received Endocrine Therapy\nEstimated primary completion: April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05840
 211
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05243797-3124@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Teclistamab: Phase 3 readout est. (NCT05243797)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: Phase 3 Study
  of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Ver
 sus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myelo
 ma as Maintenance Therapy Following Autologous Stem Cell Transplantation\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05243797
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312189-9342@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ingrezza (Valbenazine): Phase 3 readout est. (NCT06312189)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 3\, Huntington's Disease.\nStudy
 : Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Pa
 rticipants With Chorea Associated With Huntington Disease in Canada\nEstim
 ated primary completion: April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/valbenazine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06312189
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450378-1055@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:QLC7401: Phase 3 readout est. (NCT07450378)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in Participants With Heterozygous Familial Hypercholesterolem
 ia (HeFH)\nEstimated primary completion: April 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07450378
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-4@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Omvoh (mirikizumab): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Omvoh (mirikizumab)\, phase 3\, Ulcerative Colitis.\nStudy: Mir
 ikizumab Administered at the Same Time as Tirzepatide in Adult Participant
 s With Moderately to Severely Active Ulcerative Colitis and Obesity or Ove
 rweight: Phase 3b Study\nEstimated primary completion: April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mirikizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/mirikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219953-822@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07219953)
DESCRIPTION:Brenipatide\, phase 3\, Alcohol Use Disorder.\nStudy: A Study o
 f Brenipatide in Participants With Alcohol Use Disorder\nEstimated primary
  completion: April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07219953
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219966-822@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07219966)
DESCRIPTION:Brenipatide\, phase 3\, Alcohol Use Disorder.\nStudy: A Study o
 f Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
 \nEstimated primary completion: April 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07219966
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-1963@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07491445)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Study of Daraxonrasib and Dar
 axonrasib + GnP as First-line Treatment in Patients With Metastatic Pancre
 atic Adenocarcinoma\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767514-2023@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767514)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients With High PD-L1\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06767514
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168200-2166@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07168200)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Clinical Study of Ad
 ebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combin
 ed With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced
  Cervical Cancer\nEstimated primary completion: April 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07168200
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-2216@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07491445)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib and Daraxonrasib + GnP as First-line 
 Treatment in Patients With Metastatic Pancreatic Adenocarcinoma\nEstimated
  primary completion: April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132827-3551@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07132827)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: Efficacy and Safety of SHR-190
 5 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps\nEst
 imated primary completion: April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07132827
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371572-4661@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07371572)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: The Efficacy and Safety o
 f Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis\nE
 stimated primary completion: April 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07371572
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582835-6104@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT07582835)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Study of the Long-term Effects of P2Y12 Inhibitor Monot
 herapy and Coagulation Markers After Percutaneous Coronary Angioplasty.\nE
 stimated primary completion: April 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07582835
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011719-10820@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Casdatifan: Phase 3 readout est. (NCT07011719)
DESCRIPTION:Casdatifan\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStudy:
  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in P
 atients With Advanced Clear Cell Renal Cell Carcinoma\nEstimated primary c
 ompletion: April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/casdatifan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07011719
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480356-10925@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:TARA-002: Phase 3 readout est. (NCT07480356)
DESCRIPTION:TARA-002\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Efficacy and Safety of Intravesical TARA-002 Compared With Investigator'
 s Choice of Intravesical Chemotherapy in Participants With BCG-naïve High
 -grade Non-muscle Invasive Bladder Cancer\nEstimated primary completion: A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tara-002#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07480
 356
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-11052@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Mirikizumab
  Administered at the Same Time as Tirzepatide in Adult Participants With M
 oderately to Severely Active Ulcerative Colitis and Obesity or Overweight:
  Phase 3b Study\nEstimated primary completion: April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163611-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Obinutuzumab: Phase 2/3 readout est. (NCT07163611)
DESCRIPTION:Obinutuzumab\, phase 2/3.\nStudy: Obinutuzumab Induced Decrease
 s of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study\nEstimated 
 primary completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07163611
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733038-1962@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06733038)
DESCRIPTION:Atezolizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFOXIRI P
 lus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR
  and IS IC-High Metastatic Colorectal Cancer Patients.\nEstimated primary 
 completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06733038
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733038-2008@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06733038)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFOXIRI Pl
 us Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR 
 and IS IC-High Metastatic Colorectal Cancer Patients.\nEstimated primary c
 ompletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06733038
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793917-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06793917)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Tislelizumab P
 lus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter\
 , Open-label\, Randomized Phase III Studyunresectable or Metastatic Gastri
 c/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 
 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06793917
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519070-1385@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280405
DTEND;VALUE=DATE:20280406
SUMMARY:HSK44459: Phase 3 readout est. (NCT07519070)
DESCRIPTION:HSK44459\, phase 3\, Idiopathic Pulmonary Fibrosis.\nStudy: A M
 ulticenter\, Randomized\, Double-Blind\, Placebo-Controlled Phase III Stud
 y to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With
  Idiopathic Pulmonary Fibrosis\nEstimated primary completion: 5 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hsk44459#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07519070
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775404-148@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07775404)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Study to Investigat
 e the Efficacy and Safety of Elecoglipron in Asian Participants With Obesi
 ty or Overweight With or Without Type 2 Diabetes Mellitus\nEstimated prima
 ry completion: 6 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elecoglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07775404
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919965-11225@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:TAR-210: Phase 3 readout est. (NCT06919965)
DESCRIPTION:TAR-210\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy:
  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in
  Participants With High Risk Non-Muscle-Invasive Bladder Cancer\nEstimated
  primary completion: 6 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tar-210#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06919965
URL:https://assetmemo.bio/drug/tar-210#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360132-2128@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07360132)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Non-Small Cell Lung Cancer.\nStud
 y: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pe
 mbrolizumab Combined With Chemotherapy for the First-Line Treatment of Adv
 anced Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 1
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotibur
 afusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07360132
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383116-2128@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07383116)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Non-Small Cell Lung Cancer.\nStud
 y: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Ti
 slelizumab Combined With Chemotherapy as First-Line Treatment for Advanced
  Nonsquamous Non-Small Cell Lung Cancer\nEstimated primary completion: 10 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotiburaf
 usp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07383116
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383116-2232@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07383116)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus 
 Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanc
 ed Nonsquamous Non-Small Cell Lung Cancer\nEstimated primary completion: 1
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetre
 xed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07383116
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668181-92@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06668181)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekiz
 umab in Pediatric Study Participants With Active Juvenile Idiopathic Arthr
 itis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankyl
 osing Spondylitis) and Juvenile Psoriatic Arthritis\nEstimated primary com
 pletion: 12 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bimekizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06668181
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-330@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT04573478)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Atra
 sentan in Patients With IgA Nephropathy\nEstimated primary completion: 14 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasenta
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 573478
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-909@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Zigakibart: Phase 3 readout est. (NCT04573478)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Atrasent
 an in Patients With IgA Nephropathy\nEstimated primary completion: 14 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zigakibart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045734
 78
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988386-11047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT04988386)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Open-Label Safety Study
  of Acoramidis (AG10) in Symptomatic ATTR Participants\nEstimated primary 
 completion: 15 April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/acoramidis#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04988386
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06407401-7141@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280418
DTEND;VALUE=DATE:20280419
SUMMARY:Cymbalta (Duloxetine): Phase 3 readout est. (NCT06407401)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 3.\nStudy: Improvement of Quality
  of Life Through Supportive Treatments for Hormone Therapy - Related Sympt
 oms in Patients With Early Breast Cancer\nEstimated primary completion: 18
  April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxeti
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6407401
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349329-1795@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280419
DTEND;VALUE=DATE:20280420
SUMMARY:Amdokitug (Yisaituo): Phase 3 readout est. (NCT07349329)
DESCRIPTION:Amdokitug (Yisaituo)\, phase 3.\nStudy: A Study to Evaluate the
  Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondy
 loarthritis (Nr-axSpA)\nEstimated primary completion: 19 April 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/amdokitug-yisaituo#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07349329
URL:https://assetmemo.bio/drug/amdokitug-yisaituo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-2159@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06065748)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Evaluate Efficacy and Safety of Giredestrant Co
 mpared With Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With E
 R-Positive\, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant En
 docrine Therapy (pionERA Breast Cancer)\nEstimated primary completion: 20 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemacicl
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6065748
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-2228@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Ribociclib: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Ribociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With 
 Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive\,
  HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Ther
 apy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9034@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06065748)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study to Evaluate Efficacy and Safety of Giredestrant Com
 pared With Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER
 -Positive\, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant End
 ocrine Therapy (pionERA Breast Cancer)\nEstimated primary completion: 20 A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbocicli
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 065748
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9126@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Giredestrant: Phase 3 readout est. (NCT06065748)
DESCRIPTION:Giredestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Giredestrant Compared Wit
 h Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER-Positive
 \, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Th
 erapy (pionERA Breast Cancer)\nEstimated primary completion: 20 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/giredestrant#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06065748
URL:https://assetmemo.bio/drug/giredestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05946564-291@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Actos (Pioglitazone): Phase 3 readout est. (NCT05946564)
DESCRIPTION:Actos (Pioglitazone)\, phase 3.\nStudy: A Trial to Evaluate the
  Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Va
 sculitis - RENATO Trial\nEstimated primary completion: 24 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05946564
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911502-4915@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06911502)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: A 
 Study to Compare the Efficacy and Safety of Golcadomide in Combination Wit
 h Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela
 psed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Lin
 e of Systemic Therapy (GOLSEEK-4)\nEstimated primary completion: 24 April 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06911502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911502-11182@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06911502)
DESCRIPTION:Golcadomide\, phase 3.\nStudy: A Study to Compare the Efficacy 
 and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Inv
 estigator's Choice in Participants With Relapsed/Refractory Follicular Lym
 phoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK
 -4)\nEstimated primary completion: 24 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06911502
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733765-5938@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07733765)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study in Young People and Adul
 ts to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair L
 oss\, Known by the Medical Term as Moderate Alopecia Areata\nEstimated pri
 mary completion: 26 April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pf-06651600#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07733765
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916480-1479@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Roflumilast (Zoryve): Phase 3 readout est. (NCT07916480)
DESCRIPTION:Roflumilast (Zoryve)\, phase 3\, Atopic Dermatitis.\nStudy: Rof
 lumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis\nEstimated pr
 imary completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/roflumilast-zoryve#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07916480
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-2201@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Zanidatamab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A 
 Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Ea
 ch in Combination With Physician's Choice Chemotherapy\, for the Treatment
  of Participants With Metastatic HER2-positive Breast Cancer\nEstimated pr
 imary completion: 28 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377643-2241@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07377643)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: IBI
 354 With or Without Pertuzumab Versus Taxane\, Trastuzumab and Pertuzumab 
 in HER2-positive Metastatic Breast Cancer\nEstimated primary completion: 2
 8 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07377643
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-7635@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Eribulin mesylate: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Eribulin mesylate\, phase 3\, Breast Cancer.\nStudy: A Study Co
 mparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Each in Co
 mbination With Physician's Choice Chemotherapy\, for the Treatment of Part
 icipants With Metastatic HER2-positive Breast Cancer\nEstimated primary co
 mpletion: 28 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/eribulin-mesylate#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study Comparing the Efficacy 
 and Safety of Zanidatamab to Trastuzumab\, Each in Combination With Physic
 ian's Choice Chemotherapy\, for the Treatment of Participants With Metasta
 tic HER2-positive Breast Cancer\nEstimated primary completion: 28 April 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07236606-10822@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Clemidsogene lanparvovec: Phase 3 readout est. (NCT07236606)
DESCRIPTION:Clemidsogene lanparvovec\, phase 3\, Mucopolysaccharidosis Type
  II.\nStudy: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter
  Syndrome)\nEstimated primary completion: 30 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/clemidsogene-lanparvovec#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07236606
URL:https://assetmemo.bio/drug/clemidsogene-lanparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614387-7@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06614387)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: V
 edolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06614387
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614387-9@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT06614387)
DESCRIPTION:Remicade (infliximab)\, phase 3\, Ulcerative Colitis.\nStudy: V
 edolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06614387
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373990-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07373990)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Shor
 t-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal C
 arcinoma\nEstimated primary completion: 30 April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07373990
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823608-179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07823608)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Use a Breathing
  Machine (PAP) (VESPER-OSA 1)\nEstimated primary completion: 30 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07823608
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041776-2235@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Befotertinib: Phase 3 readout est. (NCT06041776)
DESCRIPTION:Befotertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Posit
 ive EGFR Sensitive Mutations\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06041776
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487896-2817@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07487896)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of YL201 Versus Investigator's Choice of Chemotherap
 y in Participants With Locally Advanced or Metastatic Esophageal Squamous 
 Cell Carcinoma After Failure of First-Line Therapy\nEstimated primary comp
 letion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07487896
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982521-9030@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06982521)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + 
 Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant 
 HR+/HER2- Breast Cancer\nEstimated primary completion: 30 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06982521
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982521-9083@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Zovegalisib: Phase 3 readout est. (NCT06982521)
DESCRIPTION:Zovegalisib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant
  as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- B
 reast Cancer\nEstimated primary completion: 30 April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zovegalisib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06982521
URL:https://assetmemo.bio/drug/zovegalisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05164172-10396@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05164172)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or E
 pisodic Migraine\nEstimated primary completion: 30 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05164172
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824986-2803@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:VT3989: Phase 3 readout est. (NCT07824986)
DESCRIPTION:VT3989\, phase 3.\nStudy: A Phase 3 Trial in Advanced Epithelio
 id Mesothelioma\nEstimated primary completion: 1 May 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vt3989#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07824986
URL:https://assetmemo.bio/drug/vt3989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06472245-2663@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:OSE2101: Phase 3 readout est. (NCT06472245)
DESCRIPTION:OSE2101\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Trial o
 f Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung 
 Cancer and Secondary Resistance to Immune Checkpoint Inhibitor\nEstimated 
 primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ose2101#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06472245
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-1356@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07919899)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: Pha
 rmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupilumab and Be
 rahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary completion:
  2 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupiluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 919899
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-2259@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07919899)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3.
 \nStudy: Pharmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupi
 lumab and Berahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary
  completion: 2 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab-berahyaluronidase-alfa#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07919899
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595549-179@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280504
DTEND;VALUE=DATE:20280505
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07595549)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called Berobenatide (PF-08653944) in People With Over
 weight or Obesity\nEstimated primary completion: 4 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07595549
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05841381-2207@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280506
DTEND;VALUE=DATE:20280507
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT05841381)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Adjuvant Study of Pyrotinib in Com
 bination With Trastuzumab in HER2 Positive Invasive Breast Cancer\nEstimat
 ed primary completion: 6 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05841381
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2041@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Ibrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: Ass
 essing the Ability of Combination Treatment With Venetoclax to Permit Time
  Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary comple
 tion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03701282
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2078@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: As
 sessing the Ability of Combination Treatment With Venetoclax to Permit Tim
 e Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary compl
 etion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03701282
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2649@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Obinutuzumab\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Assessing the Ability of Combination Treatment With Venetoclax to Permit T
 ime Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary com
 pletion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03701282
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06331312-91@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280508
DTEND;VALUE=DATE:20280509
SUMMARY:Cosentyx (secukinumab): Phase 3 readout est. (NCT06331312)
DESCRIPTION:Cosentyx (secukinumab)\, phase 3.\nStudy: Open-label\, Long-ter
 m Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)\nEstimated p
 rimary completion: 8 May 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/secukinumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06331312
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184996-1@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184996)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: An Induction 
 Study to Investigate the Efficacy and Safety of Duvakitug in Participants 
 With Moderately to Severely Active Ulcerative Colitis\nEstimated primary c
 ompletion: 9 May 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07184996
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136650-8936@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Dexamethasone: Phase 3 readout est. (NCT06136650)
DESCRIPTION:Dexamethasone\, phase 3.\nStudy: A Study of Opevesostat (MK-568
 4) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic C
 astration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)\nEs
 timated primary completion: 10 May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dexamethasone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06136650
URL:https://assetmemo.bio/drug/dexamethasone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136650-11235@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Opevesostat: Phase 3 readout est. (NCT06136650)
DESCRIPTION:Opevesostat\, phase 3\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Opevesostat (MK-5684) Versus Alternative Next
 -generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prosta
 te Cancer (mCRPC) Post One NHA (MK-5684-004)\nEstimated primary completion
 : 10 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/opeves
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06136650
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267821-3446@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Anakinra: Phase 2/3 readout est. (NCT05267821)
DESCRIPTION:Anakinra\, phase 2/3.\nStudy: Targeted Reversal of Inflammation
  in Pediatric Sepsis-induced MODS\nEstimated primary completion: 15 May 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05267821
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-2010@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study of Disitamab Vedotin Co
 mbined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined Wit
 h Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction A
 denocarcinoma\nEstimated primary completion: 15 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-2454@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combine
 d With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junct
 ion Adenocarcinoma\nEstimated primary completion: 15 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-9047@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study of Disitamab Vedotin Co
 mbined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined Wit
 h Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction A
 denocarcinoma\nEstimated primary completion: 15 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917247-91@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Cosentyx (secukinumab): Phase 3 readout est. (NCT07917247)
DESCRIPTION:Cosentyx (secukinumab)\, phase 3.\nStudy: Safety and Efficacy o
 f Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendro
 cyte Glycoprotein Antibody-associated Disease\nEstimated primary completio
 n: 15 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/secuk
 inumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07917247
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06346197-2380@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Balstilimab: Phase 3 readout est. (NCT06346197)
DESCRIPTION:Balstilimab\, phase 3.\nStudy: Combination of Immune Checkpoint
  in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas\nEs
 timated primary completion: 15 May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06346197
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06346197-2415@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Botensilimab: Phase 3 readout est. (NCT06346197)
DESCRIPTION:Botensilimab\, phase 3.\nStudy: Combination of Immune Checkpoin
 t in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas\nE
 stimated primary completion: 15 May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06346197
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06076642-11365@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:TAK-881: Phase 3 readout est. (NCT06076642)
DESCRIPTION:TAK-881\, phase 3\, Primary Immunodeficiency.\nStudy: A Study A
 bout the Long-Term Safety of TAK-881 in People With Primary Immunodeficien
 cy Diseases\nEstimated primary completion: 16 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tak-881#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06076642
URL:https://assetmemo.bio/drug/tak-881#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100289-7@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06100289)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or
  Crohn's Disease\nEstimated primary completion: 16 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06100289
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220785-147@assetmemo.bio
DTSTAMP:20261121T002638Z
DTSTART;VALUE=DATE:20280519
DTEND;VALUE=DATE:20280520
SUMMARY:mibavademab: Phase 3 readout est. (NCT07220785)
DESCRIPTION:mibavademab\, phase 3\, Generalized Lipodystrophy.\nStudy: Effi
 cacy and Safety of Mibavademab in Adult and Pediatric Patients With Genera
 lized Lipodystrophy\nEstimated primary completion: 19 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/mibavademab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220785
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
